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Introduction:  Van Gogh-Like 2 (VANGL2) is a scaffolding planar cell polarity protein 
involved in non-canonical Wnt signalling.  It has been shown to have crucial roles in 
regulating epithelial development and homeostasis.  Moreover, VANGL2 has been 
implicated in human cancers, with increased expression and copy number 
amplification seen in several cancer contexts.  Many related components 
within this pathway have also been linked to cancer development, 
with VANGL2 expression known to regulate factors involved in cell migration and 
extracellular matrix (ECM) remodelling in cell lines.  These cellular processes tend to 
be erroneously activated in cancer.  VANGL2 is known to inhibit the classical driver 
pathway of colorectal cancer (CRC), canonical, or β-
catenin dependant, Wnt signalling, in CRC cell lines.  The aim of this thesis is to 
determine the expression of VANGL2 in CRC, and to investigate how VANGL2 may act 
to regulate intestinal homeostasis and disease. 
Methods: Transcriptional verification of VANGL2 expression in the mouse intestine 
was carried out by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR), and 
transcripts localised within the murine colon using RNA-In Situ Hybridisation (RNA-




Wnt signalling components was confirmed using immunohistochemistry 
(IHC). Furthermore, using a combination of human Tissue Micro-Array (TMA), 
transcriptional data and genomic data, we determined an association between 
VANGL2 on tumour grade and disease-free survival.   
To functionally validate the effects of VANGL2 on colorectal biology, we 
used a model in which VANGL2 is selectively deleted from the colonic 
epithelium using Villin-CreERT Vangl2flox mouse lines.  Using a combination of 
molecular biology methods, we identified the ECM as differentially regulated 
following VANGL2 modulation.   
To test the role of VANGL2 in colorectal cancer, we used a murine colorectal 
cancer model in which adenomatous polyposis coli (APC) is deleted from colonic 
epithelium resulting in the formation of cancer concurrently with deletion of Vangl2.  
We evaluated survival of these mice as well as tumour number and size.  Tumour 
tissue was analysed using IHC, qRT-PCR and 3-Dimensional organoid culture. 
Results: Within this thesis I have illustrated that the murine colonic epithelium 
expresses Vangl2, and other components known to interact with VANGL2 including 




is expressed within the human colonic epithelium.  I go on to show that 9.2% of 
human CRC possesses VANGL2 transcriptional alterations which correlates with a 
worsened disease-free survival (DFS) rate among patients.  Using IHC, I also 
show that higher grade CRC is associated with increased VANGL2 expression.   
In our murine cancer model, mice with single or dual-copy loss 
of VANGL2 were found to have a reduced number of colonic tumours, 
while maintaining similar tumour size.  Investigations to identify how VANGL2 may 
have control of tumour initiation were carried out focussing on the ECM.  I found 
that, contrary to what I have discovered in the healthy murine colon, tumours from 
VANGL2-deficient mice had increased transcription of the ECM markers Secreted 
protein acidic and rich in cysteine (Sparc) and Decorin (Dcn), as well as increased 
expression of the ECM regulators Matrix Metallopeptidase 9 (Mmp9) and Tissue 
Inhibitor of Metalloproteinases 1 (Timp1).  Changes in the ECM was also seen at the 
protein level, with increases in staining for the ECM components Col1 (Collagen, type 
I), and Laminin in VANGL2-deficient tissue.  The ECM modulator Connective Tissue 
Growth Factor (Ctgf), is implicated in multiple cancers including CRC and is increased 
within VANGL2-deficient tumours at both the transcript and protein level, 





VANGL2 is expressed within the human colonic epithelium and its transcriptional or 
genomic alteration is associated with poorer DFS in human CRC, while higher grade 
tumours show increased VANGL2 marker staining.  The murine colon epithelium 
expresses VANGL2 and related non-canonical Wnt signalling components.  Loss of 
VANGL2 in the colonic epithelium leads to alteration of downstream Wnt target 
expression, and of ECM component expression.  Loss of VANGL2 reduces the number 
of tumours developed in our intestinal cancer model while not altering tumour 
size.  VANGL2-deficient tumours have increased ECM component expression and 








Although many patients survive bowel cancer, the chances of survival remain 
relatively low should the disease be diagnosed at an advanced stage, or occur in an 
aggressive form.  One of the main ways bowel cancer forms is through changes in a 
signal which controls how bowel cells behave, known as Wnt signalling, which causes 
cells to grow more quickly.   
While there are parts of this Wnt signalling that we understand, there are 
other aspects that remain a ‘black box’.  In this thesis, I have studied this black box, 
concentrating on a Wnt gene known as VANGL2.  It has been suggested that changes 
in this gene play a part in bowel cancer and I wanted to better understand how 
VANGL2 functions in colonic health and disease.  
I show that VANGL2 is present in human bowel cells, and I have found 
that if you have more VANGL2 in tumours there is increased risk of cancer 
recurrence following treatment.  Using mouse models to change how VANGL2 
functions, I found that the Wnt signalling pathway that VANGL2 regulates was 
altered.  Importantly, this pathway regulates the ECM, a net of proteins that holds 




that VANGL2 can change how cells in the colon interact with this net we will be able 
to design drugs that regulate this process and have the potential to help improve 
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Chapter 1: Introduction 
Colorectal cancers (CRC) are the third most prevalent cancer in Scotland, with 3,671 
cases diagnosed in 2015.  This represents a 6% lifetime risk that a person will develop 
CRC.  As well as being a cancer with a high rate-of-incidence, it is one of the deadliest, 
being the second-highest in terms of cancer-related mortality, with 1,565 deaths 
from CRC per year in Scotland (10% of all cancer mortality).  CRC mortality is only 
surpassed by lung cancer  (ISD, 2016). 
In the period of 2005-2015, there have been improvements in survival.  During 
this time, CRC-related mortality had decreased an average of 16% (21% for men and 
8% in women).  Survival rates of patients with CRC have also seen considerable 
improvement.  Patients diagnosed between 1987-1991 had a five-year survival rate 
of 35.9%, however patients diagnosed between 2007-2011 have a 59.5% five-year 
survival rate.  This is due to earlier diagnosis and to improvements in treatment 
(Bujanda et al., 2010).  This said, improving patient CRC survival with small-molecule 
or biological therapies, targeted at specific cell signalling pathways, has yet to be 
realised.  One of the most important cellular pathways in CRC development is the 
Wnt signalling pathway. 
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The Wnt signalling network is composed of signal transduction pathways that 
are dependent on the Wnt ligand, a small glycoprotein which is secreted from cells 
and initiates a number of signalling cascades.  The Wnt signalling network consists of 
canonical and non-canonical Wnt pathways.  Together these signals control several 
critical physiological functions such as self-renewal, cell fate determination, 
proliferation, polarity, and organogenesis.  It has been demonstrated to be critical in 
adult tissue homeostasis as well as in the establishment of proximal-distal (or planar) 
polarity in drosophila organ development (Baena-López, Baonza, & García-Bellido, 
2005; Fevr, Robine, Louvard, & Huelsken, 2007), highlighting this pathway as a highly 
conserved signalling cascade, central to multicellular life.  As well as this role in adult 
tissue maintenance and development, loss of control of Wnt signalling in adult 
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1.1 Colorectal Cancer 
Colorectal cancer, also commonly known as bowel cancer or colon cancer, falls under 
the ICD-10 (international classification of diseases) C18-C20.  It is cancer of the colon 
or rectum in the large intestine (or large bowel).  CRC originates from epithelial cells, 
which line the lumen of the colon or rectum.  Uncontrolled growth of these cells can 
result in a polyp, or an adenoma.  These are usually protrusions of tissue into the 
lumen of the gut.  
Aberrant crypt foci (ACF) have been proposed as the initial stage of colorectal 
adenoma development, and the precursor to the development of an adenoma.  
These were first identified in 1987 by Bird et al in rodent models of carcinoma, and 
later shown in the human colonic epithelium.  ACF normally appear with a ‘slit’-like 
crypt lumen shape, increased crypt size, increased epithelial proliferation, and these 
lesions are associated with K-ras mutations (Bird, 1987, 1995; Pretlow, Brasitus, 
Fulton, Cheyer, & Kaplan, 1993; Pretlow, O’Riordan, Spancake, & Pretlow, 1993; 
Stellato et al., 1991) 
 Adenomas, or adenomatous polyps, are frequently found in humans over 50 
years of age, with ~40% of patients having ≥1 adenoma (Winawer et al., 1993).  
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Adenomas are typically described as being tubular, tubulovillous, or villous, with the 
majority occurring as tubular.  Adenomas that grow to larger than 2 cm in diameter 
are associated with containing malignant cells, as this size of tumour requires 
vascularisation to survive.  Adenomas tend to grow slowly, often over a period of 
years.  As the adenoma grows, the risk of the adenoma acquiring malignant 
characteristics and becoming an adenocarcinoma, increases.  Adenocarcinomas 
possess the ability to invade into the adjacent colonic tissue and breach the 
submucosa (wall of the colon), which is known as invasion.  Many adenomas can be 
removed via colonoscopy very easily, however, if allowed to become an 
adenocarcinoma and invade into the submucosa, treatment becomes much more 
difficult.  For this reason, during a colonoscopy all discovered polyps will be removed 
if possible. 
 If an adenocarcinoma is permitted to develop further, it may invade 
adjacent organs or the visceral peritoneum.  Further progression may lead to 
metastasis by spread of malignant cells to regional lymph nodes or distant 
organs/lymph nodes.  This often occurs through the shedding of cells into the 
circulatory system.  Multiple genetic alterations, discussed below, are necessary for 
normal colorectal epithelium to become cancerous.  The most common organs to 
find metastasis in CRC are the liver and lung. Also, metastasis can be found in the 
peritoneum. 
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1.1.1 Risk Factors for CRC 
Increasing age is the highest risk factor for colorectal cancer.  This is mainly because, 
due to imperfect DNA replication, cells accumulate mutations with age, and an 
increasing number of mutations increases the likelihood that a tumour-regulating 
pathway disturbed, this is particularly problematic in tissues with a high rate of 
turnover, where constant replication of genetic material is required in order to 
maintain homeostasis (Tomasetti & Vogelstein, 2015).  Other risk factors include a 
family history of colorectal cancer, personal history of colorectal adenomas/cancer 
or ovarian cancer, hereditary conditions such as familial adenomatous polyposis 
(FAP) and Lynch syndrome (hereditary nonpolyposis colorectal cancer [HNPCC]) and 
personal history of chronic ulcerative colitis or Crohn’s.  Environmental factors such 
as excessive alcohol use, cigarette smoke and obesity also lead to increased risk of 
colorectal cancer disease (Fedirko et al., 2011; Imperiale et al., 2014; Johns & 
Houlston, 2001; Laukoetter et al., 2011; P. S. Liang, Chen, & Giovannucci, 2009; Ma 
et al., 2013; Mork et al., 2015; PDQ Adult Treatment Editorial Board, 2002; Singh, 
Nugent, Demers, Czaykowski, & Mahmud, 2013; Srinivasan, Yang, Rubin, Morgan, & 
Lewis, 2007).  Both the biological factors and epidemiology for each major risk factor 
is described in more detail below. 
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1.1.1.1 History of Colorectal cancer or intestinal diseases 
Patients who have a history of adenomas also have an increased risk of developing 
CRC (De Jong et al., 2005).  Similarly, patients with a family history of CRC or 
adenomas have a significantly increased risk of developing CRC over those patients 
without such family history.  This risk is greater for those with relatives diagnosed 
before the age of 45 or with 2 or more affected relatives (Johns & Houlston, 2001), 
suggesting that there are potential poorly defined genetic susceptibilities which have 
not been elucidated, or that there are local environmental factors which confer this 
increased risk. Whilst risk of CRC development is certainly transmitted through 
families, there are several hereditary colorectal cancer conditions which have been 
linked to causative variants being passed longitudinally from parents to their 
probands.  Lynch syndrome, FAP, MUTYH-associated polyposis (MAP) and attenuated 
FAP (AFAP) are all inherited and carry a lifetime risk of colorectal cancer of between 
50-100% (Leoz, Carballal, Moreira, Ocaña, & Balaguer, 2015).  Conditions which 
confer a high CRC risk are summarised in Table 1.1.  Inflammatory bowel disease 
(IBD), which includes both Crohn’s disease and ulcerative colitis, may cause patients 
to have an increased risk of colorectal cancer.  However, evidence in this area is 
conflicting around the actual level of increased risk.  This is possibly due to patients 
with IBDs receiving greater endoscopic surveillance, colectomies, and therapies 
which reduce the incidence of CRC (Triantafillidis, Nasioulas, & Kosmidis, 2009). 




Table 1.1 Characteristics of high-risk colorectal cancer conditions.  Adapted from 
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1.1.1.2 Environmental risk factors 
A meta-analysis by Fedirko et al found that moderate (2-3 drinks/day) and heavy (≥4 
drinks/day) consumption of alcohol had an increased risk of colorectal cancer of 21% 
and 52%, respectively.  Males and Asian participants were found to particularly 
susceptible to this association.  These correlations were found to be dose dependent, 
as doses of alcohol at 10, 50 and 100 g/day were found to increase the chance of 
colorectal cancer at 7%, 38% and 82%, respectively (Fedirko et al., 2011). 
In addition, Liang, Chen and Giovannuci found that current and former 
smokers had a significantly increased risk of CRC incidence and mortality relative to 
non-smokers.  Specifically, an increase of 40 cigarettes per day causes a 38% increase 
in risk of developing CRC.  Over a 40-year period of smoking there is a 20% increase 
in risk.  The same study also found that 60 pack years led to a 51% increase in CRC 
risk (a pack year is defined as twenty cigarettes smoked every day for one year) (P. S. 
Liang et al., 2009).  
As well as alcohol and cigarette smoke, obesity has been implicated in 
increasing the lifetime risk of CRC.  Ma and colleagues found through meta-analysis, 
that individuals within the obese category of body mass index (BMI) have a 33% 
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higher chance of CRC than those within the normal category.  Those within the 
highest category of waist circumference were found to have a 46% higher risk than 
those within the lowest category (Ma et al., 2013).  In support of this, another analysis 
found for every 5 kg of weight gain, the risk of CRC increased by 4% (Schlesinger et 
al., 2015). Furthermore, dietary composition could have an impact on the likelihood 
of developing CRC, with red meat being a controversial risk factor in CRC 
development.  The potential impact of red meat consumption on CRC risk is widely 
contested.  A study by Xu et al found that a 50 g/day increase in processed meat 
consumption resulted in a 28% increased risk, and that a 100 g/day increase in red 
meat intake increased the risk of colorectal adenomas by 36% (Xu et al. 2013).  In a 
meta-analysis, it was found that high red meat consumption was associated with an 
11% increased risk of CRC.  However, this risk reduced when the meta-analysis was 
restricted to studies that considered only fresh red meat specifically.  As well as this, 
no clear dose-response emerged from red meat intake and CRC (Alexander, Weed, 
Miller, & Mohamed, 2015). 
Conversely, Terry and colleagues, using data from a Swedish female cohort, 
found an inverse correlation between total fruit and vegetable consumption and CRC.  
Individuals who consumed less than 1.5 servings of fruit and vegetables per day had 
an increased risk of 65% compared to those who consumed more than 2.5 servings.  
They also found that higher consumption of cereal fibre did not lower the risk of 
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colorectal cancer (Terry et al., 2001).  A meta-analysis performed in 2002 specifically 
looked at dietary fibre, and found no statistically or clinically significant association 
with incidence or recurrence of adenomatous polyps (Asano & McLeod, 2002). 
While diet has been closely studied as a causative factor in CRC, use of non-
steroidal anti-inflammatory drugs (NSAIDs) has also been inversely correlated with 
CRC.  Din and colleagues found that low-dose aspirin use (75 mg daily) associated 
with a decreased CRC risk of 22% in a Scottish cohort.  Similarly, non-aspirin NSAIDs 
were also found to have a protective effect against CRC.  No effect on CRC survival 
was found as a result of aspirin/NSAID intake (Din et al., 2010).  Furthermore, Rostom 
et al found CRC incidence was reduced by 30-39% with use of non-aspirin NSAIDs, but 
no association with CRC survival was found (Rostom et al., 2007).  Using a large cohort 
(301,240 individuals), Ruder et al demonstrated that the use of aspirin and non-
aspirin NSAIDs lowered CRC risk by 9% and 18%, respectively, when compared to non-
users of these drugs (Ruder et al., 2011).  These data show that aspirin and other 
NSAIDs can be protective against CRC incidence when taken in the right contexts, 
however whether NSAIDS should be used prophylactically remains to be seen given 
the potential off-target effects of these drugs. 
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Finally, the link between physical activity and colorectal cancer risk has also 
been investigated.  A meta-analysis by Shaw and colleagues found that the 
association between physical activity and colorectal cancer risk for those with a 
family history of colorectal cancer and those without was 0.72 and 0.56, respectively 
(Shaw et al., 2018).  This inverse correlation of physical activity with colorectal cancer 
risk indicates that it may be useful as a cancer prevention strategy. 
Studies have gone some way to showing genetic-environmental interactions 
in CRC risk.  For example, Hutters et al examined potential effect-modification of 
previously identified CRC susceptibility loci and major CRC environmental risk factors 
(sex, body mass index, height, smoking status, aspirin/NSAID use, alcohol use, as well 
as calcium, folate, red meat, processed meat, vegetables, fruit, and fibre intake) 
(Hutter et al., 2012).  The strongest positive interaction was found between vegetable 
consumption and the SNP rs16892766 (chromosome 8q23.3; near the EIF3H and 
UTP23 genes).  In a genome-wide investigation of the genetic interaction with 
obesity, smoking, and alcohol consumption in CRC risk, obesity was found to have a 
statistically significant negative interaction with the SNP rs1944511 (Siegert et al., 
2013). 
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1.1.2 CRC Prognostic Markers 
Prognosis for patients with CRC is based on several factors: 1) the extent of invasion 
of tumour into the wall of the colon, 2) the presence or absence of cancerous cells in 
lymph nodes, and 3) the presence or absence of distant metastases.  The TNM 
classification of malignant tumours, the most widely used cancer staging system 
worldwide, is used to reflect the features that characterise a patient’s cancer.  ‘T’ 
represents the primary tumour.  A score of 0-4 is assigned to represent the size and 
extent of the invasion by the tumour.  ‘N’ represents lymph node involvement.  A 
score is given representing the number of lymph nodes that contain cancer.  Distant 
metastases are represented by ‘M’.  A score of zero means there are no metastases 
detectable and a score of one indicates a metastasis is present (National cancer 
institute, 2017).  The TNM classification can be more broadly represented by the AJCC 
(American Joint Committee on Cancer) stage (AJCC, 2018).  This progresses from 
stage 0 to Stage IV.  Stage 0 represents a T0 stage cancer (cancer confined to mucosa), 
stage I represents invasive T1/T2 tumours.  Stage II cancers are typically T3/T4, with 
the tumour invading adjacent tissues.  Stage III cancers involve metastasis to regional 
lymph nodes, and are often N1/N2.  Stage IV cancers possess distant metastases, 
which are M1 by TNM definition. 
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Additionally colonic tumours can be graded histologically using a score of G1-
G4, with G1 meaning that the tumour is well-differentiated (i.e. the tumour has 
normal tissue structure) and with G4 meaning the tumour is undifferentiated 
(tumour has high architectural abnormality, meaning the cells do not look like the 
cells from which the tumour arose) (National Cancer Institute, 2013). 
Other pathological prognostic features include the presence of signet ring-cell 
carcinoma.  This is defined by most tumour cells possessing prominent 
intracytoplasmic mucin, which occurs with nuclear displacement within the cell.  
Patients with signet-ring cell carcinoma (around 1% of CRCs) have reduced five-year 
survival when compared to other subsets of colorectal carcinoma (Kang, O’Connell, 
Maggard, Sack, & Ko, 2005).  Mucinous adenocarcinoma, which is defined as the 
majority of the tumour is composed of extracellular mucin represents 12% of CRCs 
(Langner et al., 2012).  While survival between all stages of mucinous and non-
mucinous adenocarcinomas are not significantly different, when stage III carcinomas 
are considered patients with mucinous adenocarcinomas have worsened survival 
(Xie, Villeneuve, & Shaw, 2009).  As well as this, Betge and colleagues identified both 
venous and lymphatic invasion as significant prognostic variables in patients with 
CRC, associating with tumour classification, lymph node status, and CRC stage (AJCC) 
(Betge et al., 2012). 
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Several other factors can be used as prognostic markers for CRC, such as the 
presence of a bowel obstruction or perforation (Steinberg, Barkin, Kaplan, & Stablein, 
1986).  Novel, circulating biomarkers are also being identified to help detect CRC in a 
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1.1.3 CRC Management 
DIAGNOSIS: Symptoms suggestive of CRC include changes in bowel habits, 
rectal bleeding, and bloody stool.  The primary method of colorectal cancer 
investigation is via colonoscopy, however small lesions can be missed (Leslie & Steele, 
2002). 
SCREENING: Patients considered to have high-risk for CRC are given regular 
colonoscopic surveillance.  High-risk patients include those with a family history of 
CRC (including those with hereditary CRC conditions), those with a personal history 
of adenomatous polyps and/or colorectal cancer, and those with inflammatory bowel 
disease (IBD).  For the general population, faecal occult blood testing is used for those 
over 60 years of age.  A meta-analysis of this type of screening by Bernie et al found 
it led to a reduction in mortality by 23% (relative risk 0.77 (0.57 to 0.89) for those 
who undertake the screening (Towler et al., 1998).  The same study found that one-
third of those invited did not participate, thereby limiting the effectiveness of this 
type of screening. 
TREATMENT: Current standards of care for CRC are as follows:  stage 0 
colorectal cancer is usually treated with polyp removal during a colonoscopy.  Stage 
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I is treated with surgical removal of the tumour.  Stage II colorectal cancer is usually 
treated with surgical resection of the tumour, with optional adjuvant chemotherapy.  
Stage III colorectal cancer is treated with surgical tumour and associated lymph node 
removal, combined with adjuvant chemotherapy.  Stage IV colorectal cancer 
treatment is often more variable, depending on which tissues the cancer has spread 
to.  Often the treatment plan would include a combination of surgical resection, 
chemotherapy, and radiotherapy.  Recurrent CRC is often given a treatment plan 
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1.1.4 The Intestine 
The mammalian intestine is made up of a mesenchymal smooth muscle lumen, and 
a luminal lining of a single layer of epithelial cells.  There are several distinct 
anatomical areas within the small intestine (duodenum, jejunum, and the ileum), and 
large intestine (caecum and the colon).  The epithelial surface is invaginated through 
the mesenchyme to give the morphological structures of the crypts and villi (in the 
large intestine the invaginations have less depth, and do not form villi).  The 
epithelium of the intestine represents one of the most important barriers in the body.  
It must be selectively permeable, allowing in nutrients while staying resilient to 
toxins, foreign antigens, and gut microbiota.  A series of protein-protein interactions 
across cellular junctions in the epithelium, and physical barriers such as mucus allow 
this barrier to exclude such insults, such as bacteria (Johansson, Sjövall, & Hansson, 
2013).   
The cells in the intestinal epithelium are continually replaced throughout life, 
with the entire epithelium is replaced every 3-5 days in the small intestine, and every 
5-7 days in the colon (Barker, 2013).  This persistent proliferation takes place within 
the crypt compartments (Figure 1.1).  There are two models for the precise identity 
of the intestinal stem cells (SCs).  The SC zone model postulates that crypt base 
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columnar (CBC) cells present at the bottom of crypts provide the SC pool for epithelial 
regeneration.  In support of this hypothesis, cloning marking techniques show these 
cells’ ability to give rise to multiple cell types in the small intestinal crypt (M. Bjerknes 
& Cheng, 1999; Matthew Bjerknes & Cheng, 1981).  The +4-position model 
hypothesises that a ‘band’ of proliferating cells sit in the crypt above non-cycling 
Paneth cells present in the base.  The intestinal SCs are +4 cells from the crypt bottom.  
Again in the small intestine, Potten et al found that these +4 SCs retain DNA labels 
for extended periods of time, suggesting limited cycling activity (Potten, Kovacs, & 
Hamilton, 1974).  Barker et al, in pioneering murine lineage tracing work 
demonstrated that Lgr5+ CBCs can generate all epithelial lineages over a 60-day 
period in both the small intestine and colon (Barker et al., 2007).   
While cycling, label retaining, stem cells have been shown to act as a key 
progenitor pool for the epithelium, research by Buczacki et al found that intestinal 
quiescent cells are precursors to multiple epithelial cell types too, and that in 
intestinal regeneration following injury they can proliferate and provide the main 
epithelial cell types (Buczacki et al., 2013).  Therefore, there are potentially multiple 
pools of progenitors within the intestine that can repopulate the epithelium following 
injury and some may have context-dependent activation.  At the bottom of the small 
intestinal crypts stem cells (identified by the presence of Lgr5) are interspaced by 
larger, Paneth cells.  These long-lived cells contribute to the intestinal barrier by 
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secretion of anti-microbial products such as defensins.  These Paneth cells also supply 
the epithelial niche for the intestinal stem cells with Wnt3, EGF and Notch ligand 
(Sato, van Es, et al., 2011).  While there are no Paneth cells in the colon, it has recently 
been reported that Reg4+ expressing CBC cells are the Paneth-equivalent cell-type 
and function as the epithelial niche in the colon (Sasaki et al., 2016) 
Wnt signalling plays a crucial role in the maintenance and activation of SC 
pools, and it is no different in the intestinal stem cell context.  For example, Clevers 
and colleagues found that depletion of one of the main effector molecules of the Wnt 
signalling cascade, TCF-4 (Transcription factor-4), leads to the loss of proliferative 
compartments in the murine small intestine.  This impairment leads to death shortly 
after birth.  It has also been shown that the intracellular signal transducer, β-catenin, 
accumulates in the nucleus of intestinal crypt progenitors, which indicates active Wnt 
signalling. 
β-catenin, the defining molecule of canonical Wnt signalling, is accumulated 
in progenitors in the intestinal crypt.  Disruption of β-catenin activity in CRC cells leads 
to a G1 arrest, and a switch in cellular programming from proliferation to 
differentiation (Van de Wetering et al., 2002).  When β-catenin is deleted from the 
intestinal epithelium in mice, crypt structures are ablated and transit-amplifying cells 
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are lost, showing that Wnt/β-catenin signalling is essential for intestinal homeostasis 
(Fevr et al., 2007).  Dickkopf1 (Dkk1) is a secreted Wnt inhibitor that binds the Wnt 
co-receptor, LRP5/6.  The crucial role of Dkk1 was shown in the development of 
knockout mice, in which the deletion was embryonic lethal and led to cranial defects, 
highlighting the importance of Dkk1 in development.  Conversely, overexpression of 
Dkk1 in the mouse intestine leads to the cessation of proliferation, complete with the 
absence of nuclear β-catenin in the crypts (Pinto, Gregorieff, Begthel, & Clevers, 
2003).  While a significant body of research exists showing the importance for Wnt 
signalling in the small intestine, Dkk1 antagonism of Wnt signalling has also been used 
to show that Wnt signalling is essential in colon proliferation as well as in the small 
intestine (Kuhnert et al., 2004).  These data, plus the activation of the Wnt pathway 
in the initiation of colorectal cancer, indicates that Wnt signalling is the overarching 
factor that drives proliferation within intestinal crypts. 
While the factors that drive intestinal homeostasis are well established, 
understanding how the canonical Wnt signalling pathway interacts with and 
regulates the intestinal stem cell pool has been the focus of recent efforts.  Van der 
Flier et al, using gene-expression analysis, identified ~80 Wnt/TC4 target genes in the 
intestine.  One of the genes most restricted in crypt expression is Lgr5 (Gpr49) (Van 
der Flier et al., 2007).  Lgr5+ stem cells reside within the crypt base of the intestine in 
a pattern like the SC zone model mentioned earlier.  Supporting the theory that Lgr5+ 
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cells comprise the SC pool of the intestinal epithelium, they have been shown to form 
self-organising proliferating crypt-villus units in vitro (Sato et al., 2009).  Lineage 
tracing analysis using a LacZ reporter has shown that Lgr5+ cell progeny can generate  
all of the epithelial cell types (Barker et al., 2007).  LacZ lineage tracing means that 
progeny from a progenitor cell can be tracked by observation of the ‘blue ribbon’ 
propagating up intestinal crypts.  All of the differentiated epithelial cell types, such as 
enterocytes, goblet cells, enteroendocrine cells and Paneth cells can be found within 
the ‘blue ribbons’ produced by LacZ-Lgr5+ cells in the intestine.  Moreover, these 
Lgr5+ lineages remain within the intestinal epithelium up to 14 months after reporter 
induction.  These data suggest that Lgr5+ have long-term self-renewal and 
multipotency and are therefore bona fide adult stem cells.  
It has been proposed that these Lgr5+ stem cells represent one of the cancer 
SC pools present during colorectal cancer.  Lineage tracing mouse models have shown 
that Lgr5+ cells can function as the cells-of-origin for intestinal tumours, and that 
ablation of the gene led to tumour regression in murine xenograft models (Sato et 
al., 2009; Schepers et al., 2012; Shimokawa et al., 2017; Yanai et al., 2017).  
Interestingly, tumour regrowth in this model occurred through the re-emergence of 
Lgr5+ cancer SCs, highlighting their importance in intestinal tumour development, but 
also demonstrating again the cellular plasticity within the intestinal epithelium, 
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where following stem cell ablation, other epithelial cells can dedifferentiate to 










Figure 1.1 Structure of the crypt unit of the large intestine. Inset: The intestinal 
crypt-villus unit.  The intestinal epithelial stem cells are thought to reside at the base 
of the crypt either as rapidly cycling CBC cells (brown), which are marked by Lgr5, or 
+4 cells (blue).  Either SC pool may provide the stem cell population for the 
proliferating epithelium.  CBCs are interdigitated between Paneth-like cells (green) 
which provide the epithelial niche for rapidly cycling SCs, are marked by Reg4.  Transit 
Amplifying (TA) cells (yellow) migrate along crypt axis to form differentiated cells 
(white) in the epithelium: including Paneth-like cells, enteroendocrine cells, goblet 
cells, and enterocytes. 
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1.1.5 The genetic contribution to CRC 
Genetics contribute to susceptibility to CRC, the progression of the disease and 
resistance of the disease to treatments.  Therefore understanding the genetic basis 
of colorectal cancers can both help inform patients and help tailor prophylactic and 
reactive treatments (S. D. Markowitz & Bertagnolli, 2009). 
Most often, mutations occur that increase the activity of the Wnt signalling, a 
group of signal transduction pathways essential to the proper functioning of multiple 
tissues, contributing to aberrant growth of the epithelial tissue.  For example, 
mutations occur in key Wnt regulatory proteins APC, β-catenin, and AXIN2 (Wanguo 
Liu et al., 2000; Mori et al., 1992). 
1.1.5.1 Mendelian CRC syndromes 
Less than 5% of CRCs are caused by the inheritance of a single faulty gene (Lynch & 
de la Chapelle, 2003).  These diseases are known as Mendelian CRC syndromes.  Most 
of these diseases lead to the predisposition to colorectal adenomas.  For example, 
FAP is caused by a mutation in the Wnt signalling pathway gene APC, while MAP is a 
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result of a mutation in the base-excision repair gene MUTYH.  Lynch Syndrome, or 
HNPCC, can be as a result of mutations to DNA mismatch repair genes, such as MSH2, 
or MLH1.  Other Mendelian CRC syndromes include Juvenile polyposis, which can be 
as a result of a mutation to BMP pathway gene SMAD4 (Tomlinson, 2015). 
1.1.5.2 Familial CRC 
While less than 5% of the total burden of CRC is as a result of Mendelian syndromes, 
it has been suggested that around 30% of CRC is heritable (Lichtenstein et al., 2000).  
Therefore, there is a significant portion of heritable CRC burden that is not accounted 
for.  It is thought that these non-syndromic familial CRCs are made up of a mixture of 
low risk susceptibility variants/SNPs with environmental factors (discussed 
previously) (Hahn et al., 2016). 
1.1.5.3 Sporadic CRC 
Many of the genes mutated in heritable CRC are often somatically inactivated in 
sporadic CRC (that is cancers that occur in people without a genetic predisposition 
towards or family history of cancer), so are of interest.  Making up 70% of all CRC 
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cases, sporadic CRC occurrence is commonly thought of as a ‘pathway’ of genetic 
alterations, with an example of a traditional pathway involving mutation of 
APC/KRAS, followed by TP53, and finally TGF-β mutation (Yamagishi, Kuroda, Imai, & 
Hiraishi, 2016).  However alternative pathways involving rarer sequences of 
alterations have also been postulated, such as the pathway resulting in sporadic 
serrated CRC, which may initiate with a mutation in BRAF (Pancione, Remo, & 
Colantuoni, 2012). 
 
1.1.5.4 Inactivating mutations in tumour-suppressing genes & activating mutations 
in oncogenes 
The most common initial gene mutated in both inherited and sporadic colon cancer 
is APC, and this gene’s mutational inactivation represents the initiating event in 
colorectal cancer.  Both alleles of APC are inactivated in colonic tumours through 
mutations which cause the loss of the full-length protein (Goss & Groden, 2000).  This 
alteration has wide-ranging consequences in the colonic epithelial cell, affecting cell 
cycle progression, migration, differentiation, and apoptosis.  In homeostasis, Wnt 
signalling, in which APC acts as an essential component mediates these pathways.  
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Wnt signalling results in β-catenin translocation to the nucleus resulting in cellular 
activation of Wnt transcriptional programming.  APC holds β-catenin in complex, in 
the cytoplasm and targets it for degradation by the destruction complex, thereby 
inhibiting its nuclear localisation and blocking the activation of signalling 
programmes.  Upon activation of the pathway by specific Wnt ligands (e.g. Wnt1), β-
catenin is released from APC and the inhibition is removed. 
Mutational inactivation of the gene that encodes APC leads to β-catenin being 
aberrantly translocated to the nucleus, and consequently, constitutive activation of 
the canonical Wnt signalling pathway. The consequence of hereditary APC-
inactivating mutations is the development of Familial Adenomatous Polyposis (FAP), 
a CRC predisposition syndrome that occurs in humans and demonstrates a direct, 
causal link between canonical Wnt signalling levels and the subsequent development 
of CRC.  FAP patients also develop colonic adenomas (numbering in the hundreds to 
thousands) at an early age and 95% of patients with FAP will be diagnosed with CRC 
by 50 years of age.  FAP occurs with mutations in APC between codons 1250 and 
1464, with mutations at codon 1309 particularly common (Bertario et al., 2003; Mori 
et al., 1992; Nagase et al., 1992).  Attenuated FAP (AFAP) is an ameliorated form of 
FAP, which Burt and colleagues found a lifetime risk of 69% of CRC and a median 
polyp number of 25 (Burt et al., 2004).  Patients with AFAP also develop polyp/CRC 
development at an older age compared to FAP counterparts.  Mutations between 
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codons 1445 and 1578 of the APC gene are particularly associated with AFAP (Caspari 
et al., 1995). 
As well as representing a significant risk factor in developing CRC in family 
groups, most sporadic colorectal adenomas and cancers contain somatic inactivation 
of APC (at 50% and 80% respectively) (Goss & Groden, 2000).  Some CRC cell lines 
have mutations in β-catenin, rendering the protein resistant to degradation by the 
APC inhibiting complex and constitutively activating Wnt signalling (Morin, 1997).  In 
serrated CRC, where APC is not normally found mutated but BRAF is, the ubiquitin 
ligases RNF43 and ZNRF3 (which negatively regulate canonical Wnt signalling) are 
found to be commonly mutated in 24% and 30% of BRAF mutant/MSI cancers, 
respectively (Bond et al., 2016).  The consequence of RNF43 mutations is that the FzD 
receptor, which binds Wnt ligand cannot be ubiquitinated and therefore is no longer 
targeted for degradation following stimulation.  Treatment with a porcupine inhibitor 
(which inhibits the palmitolaytion of Wnt ligand and therefore prevents their 
secretion) reduces growth of RNF43/ZNRF3 mutant cells in vitro and therefore a 
potential therapeutic for serrated CRC, where RNF43/ZNRF3 is mutated.  R-spondin 
family members are modulators of canonical Wnt signalling and are also implicated 
in CRC development.  Seshagiri et al showed that RSPO2 and RSPO3 are together 
involved in recurrent gene fusions in 10% of colonic tumours.  These events were 
mutually exclusive with APC mutations, suggesting that they may have a role in Wnt 
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hyperactivation and tumour initiation.  It was then later shown that these fusion 
events are sufficient to initiate tumourigenesis in vivo (T. Han et al., 2017; Seshagiri 
et al., 2012).  As this alteration makes the tumours entirely Wnt-dependent, 
treatment with the Wnt secretion inhibitor LGK974 resolved tumourigenesis entirely.  
This represents another therapeutic opportunity in treating CRC sub-types by using 
Wnt-modulating drugs. 
The p53 signalling pathway also exerts tumour suppressive effects within the 
colon.  P53 mediates cell-cycle arrest and also has a cell-death checkpoint, which are 
normally triggered by cellular stresses (S. D. Markowitz & Bertagnolli, 2009).  
Mutational inactivation of the gene TP53 (tumour protein p53) is a formative step in 
the development of CRC, often denoting the transition from adenoma into invasive 
carcinomas (S. J. Baker et al., 1990).  Baker et al found that most tumours with 
inactive TP53 had a combination of the loss of one copy of chromosome 17p and a 
mutation in the remaining copy of p53.  In this work they postulate that the mutation 
is the rate limiting step of p53 inactivation (S. J. Baker et al., 1990).  Using conditional 
deletion of APC in the p53-deficient adult murine intestine, Reed et al showed that 
loss of p53 did not alter the APC-null phenotype (Reed et al., 2008).  It is suggested 
that any potential changes in Wnt regulation carried out by p53 are overwhelmed by 
the constitutive Wnt activation brought about by loss of APC.  Nakayama et al, using 
conditional mutant of p53 in loss-of-function APC mouse model, showed that the 
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mutation in p53 accelerated submucosal invasion.  The mutation also conferred 
morphological changes in organoids created from the mice, with features associated 
with invasiveness.  Allografts using these organoids displayed malignant histology, 
including increased mesenchymal marker expression and increased numbers of 
myofibroblasts (Nakayama et al., 2017). 
Another key tumour suppressor pathway turned off in the development of 
CRC is Transforming Growth Factor-β (TGF-β) signalling.  TGF-β is a pleiotropic 
cytokine which plays roles in immunosuppression, cellular differentiation and in 
maintaining homeostasis.  A third of human colorectal cancer cell lines possess 
somatic mutations in the receptor TGFBR2 leading to inactivation (S. Markowitz et 
al., 1995).   Grady et al found that this gene harboured inactivating mutations in 90% 
of MSI CRC.  It was found that, like mutations of the p53 pathway, inactivation of 
TGFBR2 in MSI tumours tightly correlated with the progression from adenoma to 
carcinoma.  They also estimated half of MSS cancers have either mutations in TGFBR2 
or inactivating mutations or deletion of the downstream TGF-β components SMAD2 
or SMAD3 (W M Grady et al., 1999; William M. Grady et al., 1998).   
Oncogenic mutations of MAPK signalling components RAS and BRAF occur in 
37% and 13% of CRCs, respectively (Bos et al., 1987; Nosho et al., 2008).  One member 
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of the RAS gene family, KRAS, is mutated to cause constitutive GTPase activity that 
activates RAF, thereby driving the MAPK signalling cascade.  This pathway regulates 
transcription of genes important for the cell cycle such as cyclin-dependent kinase 2 
(CDK2) (Dogan et al., 2017).  A member of the RAF family, BRAF, is commonly found 
in CRC to have oncogenic mutations which drive its own serine-threonine kinase 
activity which again causes aberrant MAPK signalling (Rajagopalan et al., 2002; Siena, 
Sartore-Bianchi, Di Nicolantonio, Balfour, & Bardelli, 2009). 
 
 
1.1.5.5 Growth factor pathways 
Growth factor pathways are often activated in CRC.  Epidermal Growth Factor 
(EGF) is a key protein for intestinal epithelial homeostasis, stimulating cell growth, 
proliferation, and differentiation.  It signals via activation of the mitogen-activated 
protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) oncogenic pathways 
(Amado et al., 2008; Jhawer et al., 2008).  Clinical data has shown that certain 
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colorectal cancers with oncogenic mutations in these pathways are resistant to anti-
EGFR CRC therapy.  For example, the monoclonal antibody panitumumab, which 
targets EGFR (EGF-Receptor), is shown to be effective in slowing progression of CRC 
in patients with WT KRAS, but in not patients with KRAS mutations (Amado et al., 
2008).  Therefore, KRAS mutational status screening can help improve efficacy of anti-
EGF therapies in CRC. 
A common early step involves aberrant activation of the prostaglandin 
signalling cascade (Cha & DuBois, 2007).  It has been found that this signalling can be 
activated by upregulation of cyclooxygenase-2 (COX-2), seen in 67% of colorectal 
cancers, and by the loss of 15-prostaglandin dehydrogenase (15-PGDH) expression, 
seen in in 80% of colorectal cancers (Fink et al., 2014; Yan et al., 2004).  The use of 
NSAIDs in clinical trials have been shown to prevent new adenoma formation via 
inhibition of COX-2.  For example, aspirin has been shown to moderately reduce 
adenoma formation in a randomised trial with 1121 patients with recent history of 
adenomas (Baron et al., 2003).  Celecoxib, a specific COX-2 inhibitor, was also found 
to reduce adenoma formation in a similar trial (Bertagnolli et al., 2006). 
PI3K is a lipid kinase, which operates in pathways important in neoplasia such 
as motility, proliferation, and adhesion via PI3K/AKT signalling.  Samuels et al found 
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that PI3KCA, encoding the catalytic subunit of PI3K, contains somatic mutations in 
32% of colorectal cancers (Samuels, 2004).  It was also found that PI3KCA mutations 
correlate with invasive cancers, suggesting that this type of signalling is important for 
CRC progression (Samuels, 2004).  Similarly, PTEN, a negative regulator of PI3K/AKT 
signalling, was reported to be mutated in 19.5% of primary sporadic colorectal 
cancers, while the loss-of-heterozygosity was observed in 17% of cancers (Nassif et 
al., 2004). 
Vascular endothelial growth factor (VEGF) is normally produced during 
periods of tissue growth or injury, promoting angiogenesis.  Angiogenic pathways 
have recently been highlighted as having a role in colorectal cancer.  For example, 
VEGF expression at the deepest invasive site of tumour is the most statistically 
significant prognostic indicator in advanced colorectal carcinoma (Ellis, 2007).  A 
clinical study in 2004 used an anti-VEGF antibody in CRC therapy, resulting in a 5 
month improvement in median survival over standard therapy (Hurwitz et al., 2004).  
More recently work in CRC cells has shown that VEGF signalling mediates migration 
and invasion (Bhattacharya et al., 2017) 
1.1.5.6 Genomic Instability 
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Numerous oncogenic mutations can be acquired through the loss of genomic 
stability.  The most common way this happens is through chromosomal instability 
(CIN), which can alter chromosomal copy number and structure.  Wild-type copies of 
tumour-suppressor genes, such as APC and P53, can be lost in this way (S. Baker et 
al., 1989; Morin, 1997; Samowitz et al., 1999).   
Barber et al systematically identified somatic mutations of potential CIN 
genes in colorectal cancers.  It was found that most of mutations were in putative 
genes that regulate sister chromatid cohesion.  The same group further 
demonstrated that the down regulation of these genes in human cells leads to CIN 
and defects in chromatid cohesion (Barber et al., 2008).  This indicates that much of 
the CIN in colorectal cancer is due to mutations of genes that normally maintain 
stability of the chromosomes during replication. 
Another form of genomic instability is found during defective DNA-repair.  
This occurs when genes which are normally responsible for repairing base-base 
mismatches are inactivated.  In Lynch syndrome (HNPCC or hereditary nonpolyposis 
colorectal cancer), the heritable inactivation of these genes (e.g. hMLH1), leads to an 
autosomal dominant condition that predisposes to CRC.  However, the inactivation 
of these genes can also be acquired non-heritably, through methylation-associated 
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silencing.  Approximately 2-4% of all CRCs are as a result of Lynch syndrome, making 
it the most common inherited CRC syndrome (Hampel et al., 2008).  Lifetime risk of 
colorectal cancer for those with Lynch syndrome is 50-80% (Stoffel et al., 2009).  
Patients with Lynch syndrome typically experience colonic adenomas and cancer at a 
younger age than patients with sporadic forms of these neoplasms.  These cancers 
often occur more proximally in the colon than most others.  A key characteristic of 
Lynch syndrome associated CRC is the elevated level of microsatellite instability (MSI-
H), which is typical of cancers which have defective DNA mismatch repair (MMR) 
genes.  Patients are also particularly susceptible to endometrial cancers, and to a 
lesser extent, cancers of the stomach and ovary (Lynch & de la Chapelle, 2003).   
Mismatch-repair defects can be identified by the presence of microsatellite instability 
(S. D. Markowitz & Bertagnolli, 2009). A meta-analysis in 2015 found that MSI status 
was not predictive of survival in CRC patients undergoing conventional 5FU-based 
chemotherapy (Webber, Kauffman, O’Connor, & Goddard, 2015).  In fact, CRC 
patients with MSI-H cancer have better survival rates than their microsatellite stable 
(MSS) counterparts (Ribic et al., 2003).  Sporadic MSI-H cancers are seen much more 
commonly (approximately 12% of CRC) than heritable MSI-H cancers such as Lynch 
syndrome (3%) (Gatalica, Vranic, Xiu, Swensen, & Reddy, 2016). 
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1.2 Wnt Signalling 
Wnt signalling is one of the major pathways in development and homeostasis.  The 
importance of this signalling is stressed by the presence of many Wnt-related 
pathologies (for example, in idiopathic pulmonary fibrosis in the lung and in wound 
healing in the skin) (Cheon et al., 2002; Chilosi et al., 2003).  Wnt signalling is essential 
for intestinal epithelial homeostasis and loss of it leads to loss of crypt structures and 
epithelial progenitors (Fevr et al., 2007).  As well as this mutation of the downstream 
Wnt signalling regulator APC results in CRC initiation, highlighting the importance of 
Wnt in cancer development (Groden et al., 1991).   
Wnt signalling can be broadly split into the Wnt/β-catenin dependent (or 
canonical) and the less-well defined β-catenin independent (or non-canonical) 
pathways (figure 1.2).  Within the non-canonical pathway two further subtypes exist, 
the Wnt/Ca2+ pathway and the Planar Cell Polarity (PCP) pathway.  All of the Wnt 
signalling pathways can be activated by members of the Wnt ligand family 
(Wallingford, Vogeli, & Harland, 2001).   Wnt homologues are associated with the 
activation of specific pathways.  For example, Wnt4, Wnt5a and Wnt11 are thought 
to have the ability to drive non-canonical signalling in different tissues (for example 
in bone or in adipose tissue), while Wnt1, Wnt3a and Wnt8 have been known to 
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activate the canonical β-catenin-dependent pathway (Catalán et al., 2014; Chang et 
al., 2007; Niehrs, 2012).  However, increasingly, there are examples where ligands 
can activate both pathways depending on context, for example in 
osteoblastogenesis, where the typically non-canonical ligand Wnt5a enhances 
Wnt/β-catenin signalling (Okamoto et al., 2015).  Suggesting that these delineations 
require some refinement.  
It is well known that canonical Wnt signalling is important in regulating the 
proliferation and differentiation of the intestinal epithelium (Samowitz et al., 1999).  
As previously discussed, Lgr5+ cells within the intestinal crypt represent the stem cell 
for the intestinal epithelium, capable of differentiating into all epithelial cell types.  
The epithelial SC niche is comprised of different cell types depending on the location 
in the intestine where, in the small bowel Paneth cells act as a stem cell niche, 
whereas in the colon Reg4+ cells provide the stem cell niche. 
Wnt signalling is a conserved pathway and is central for embryonic 
development, tissue homeostasis and disease (Biechele, Cox, & Rossant, 2011; Fevr 
et al., 2007; Groden et al., 1991)  Wnts are secreted glycoproteins which are ligands 
to the Frizzled (Fzd) transmembrane receptor family, which are found on the surface 
of Wnt-responsive cells (Kikuchi, Yamamoto, Sato, & Matsumoto, 2011).  In addition 
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to this, the Wnt co-receptors Low-density lipoprotein receptor-related protein-5 
(LRP5) and -6 (LRP6) are important in mediating Wnt signals.  LRP5 can bind to Axin, 
in response to Wnt ligand, in order to stabilise β-catenin, while LRP6 can initiate 
Wnt/β-catenin signalling in response to its phosphorylation (Mao et al., 2001; X. Zeng 
et al., 2007).  Janda et al demonstrated that FZD-LRP6/LRP6 heterodimers can form 
and can elicit Wnt/β-catenin signalling, like Wnt agonist action, independent of 
ligand.  Moreover, it was shown that this heterodimer exhibits Wnt activity in vivo in 
the liver in order to promote Wnt signalling and metabolic resonation in hepatocytes 
(Janda et al., 2017). However, it is unlikely that these dimers occur in vivo, but this 
study does demonstrate that activation of the canonical Wnt signalling pathway can 
be manipulated for regenerative medicine.  
The Wnt ligand-receptor interaction is complex and following stimulation a number 
of signal transduction cascades can be activated. These are detailed below.  One 
explanation of the high levels of pathway complexity is the numerous possible Wnt 
ligand, Fzd and co-receptor combinations that can be achieved.  In addition to the 
canonical Fzd/Lrp interaction, Wnt is also known to act with non-canonical Fzd and a 
wide range of co-receptors including ROR1, ROR2, RYK and PTK7.  ROR2, a Tyrosine-
protein kinase transmembrane receptor, contains an extracellular cysteine-rich 
domain (CRD) which resembles the Fzd Wnt binding site, and has been show to act 
as a receptor for Wnt5a to activate non-canonical Wnt signalling (Oishi et al., 2003).  
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In a similar fashion to FZD/LRP interactions, PTK7 and ROR2 were shown to form 
heterodimers in mammalian cells, while WNT5A directly interacted with both 








Figure 1.2 The Wnt signalling pathways.  Schematic of the main Wnt pathways 
involving Wnt, Fzd and co-receptor interactions.  (A) Wnt/PCP signalling.  Non-
canonical Wnt ligand forms a complex with Frizzled (Fzd) and a co-receptor.  Fzd 
recruits Dvl to the receptor complex which activates downstream effects DAAM and 
RAC1.  DAAM activates RhoA which enacts actin reorganisation through ROCK.  RAC1 
phosphorylates JNK which is an activator of Jun, part of the AP-1 transcription factor 
complex.  This action can inhibit canonical Wnt signalling. (B) Wnt/β-catenin 
signalling.  Canonical Wnt ligands induce a receptor complex involving Fzd, LRP5/6 
and a co-receptor.  Dvl is recruited to the complex which binds Axin and GSK3, 
thereby disrupting the β-catenin destruction complex, leaving β-catenin free to 
accumulate in the cytoplasm and translocate to the nucleus, where it interacts with 
TCF/LEF transcription co-factors to enact canonical Wnt target gene transcription.  (C) 
Wnt/Ca2+ signalling.  Non-canonical Wnt ligand forms a complex with Fzd and a co-
receptor.  Fzd recruits Dvl to the receptor complex leading to cytoplasmic Ca2+ 
accumulation.  This results in transcriptional activation and cytoskeletal 
rearrangement. (D) Various Wnt receptor configurations and associated signalling 
outputs.  Taken from Niehrs, 2012 (Niehrs, 2012). 
(B) Wnt/β-catenin (C) Wnt/Ca2
+
 (A) Wnt/PCP  
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1.2.1 Regulation of Wnt signalling 
The Wnt signalling pathway is regulated at multiple points.  In Wnt secretion, the ER-
associated protein PORCN (Porcupine) palmitoylates Wnt ligands, which 
subsequently prevents accumulation of the ligand (Hausmann, Bänziger, & Basler, 
2007; Takada et al., 2006) in the cell by promoting its transit though the golgi, via 
Wingless where it is secreted.  Conditional deletion of PORCN in the skin of mouse 
embryos phenocopied β-catenin conditional mutants where both lacked hair follicles, 
suggesting that PORCN is essential for proper Wnt signalling (Wei Liu et al., 2012).  
PORCN inhibition has been used to block secretion of all Wnts in CRC-derived 
xenografts, leading to the inhibition of Wnt autocrine signalling and inhibiting the 
growth of colon cancers with RSPO translocations (Madan et al., 2016).  Additionally, 
a phase I clinical study is currently underway in patients with solid malignancies using 
the PORCN inhibitor WNT974 (or LKG974) (Janku et al., 2015). 
At the extracellular level, there are two classes of secreted Wnt antagonists.  
Secreted Frizzled-related proteins (sFRPs) were first identified in xenopus embryos.  
The have been found to bind directly to Wnts and act as a decoy receptor for the 
ligand, thereby inhibiting Wnt ligand from engaging the receptor complex (Salic, Kroll, 
Evans, & Kirschner, 1997).  Deletion of (sFRP)-1 activates canonical Wnt signalling in 
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bone and increases trabecular bone formation in aged animals (Bodine et al., 2009)  
Another negative regulator that directly binds Wnt ligands is Wnt inhibitory factor 1 
(WIF-1) (Malinauskas, Aricescu, Lu, Siebold, & Jones, 2011).  The Dickkopf class of 
antagonists (such as Dkk1) inhibit Wnt signalling by binding the LRP5/6 components 
of the Wnt receptor complex.  Deletion of a single allele of Dkk1 has been shown to 
lead to increased bone formation and bone mass, while the loss-of-heterozygosity of 
Dkk3 is associated with carcinogenesis yet reduced lymph node metastasis and better 
overall survival in head and neck squamous cell carcinoma (Katase et al., 2008), 
indicating that Dkk1 could have divergent and tissue specific roles.  As LRP5/6 is 
recruited to the Wnt receptor complex for canonical Wnt signalling, theoretically only 
sFRPs can inhibit non-canonical Wnt signalling, and Dkk1 inhibitors have been 
restricted to the canonical pathway (Kawano, 2003)  However, recent evidence 
indicates that Dkk1 might also function in the non-canonical pathway through 
regulating availability of non-canonical ligands (Caneparo et al., 2007; Tao, Liu, & Liu, 
2013) 
Wnt signalling can also be regulated through the composition of the Wnt 
receptor complex that is presented to the ligand.  Frizzled is known to be present in 
the receptor complex in both canonical and non-canonical pathways.  However, there 
are instances of Fzd-independent activation of the non-canonical pathway, whereby 
Wnt ligand can induce VANGL2 phosphorylation through ROR2 (Wei Liu et al., 2012).  
   
43 
 
The previously mentioned LRP5/6 receptors are thought to be required in Wnt 
receptor complexes that can activate the canonical pathway (X. He, 2004).  
Interestingly, Bryja and colleagues found that the non-canonical Wnt ligand Wnt5a 
can interact with LRP6 but this does not activate the Wnt/β-catenin pathway.  They 
also found that extracellular domains of LRP5/6 could inhibit the downstream target 
of Wnt5a, Rac1, suggesting that LRP5/6 can inhibit non-canonical Wnt signalling in 
vivo, and that this is achieved through the LRP5/6 receptor competing for Wnt ligands 
(Bryja et al., 2008).  Another example of an intracellular regulator of the canonical 
Wnt pathway is DACT1 (Dishevelled Binding Antagonist Of Beta Catenin 1), which 
antagonises signalling through interaction with Dvl in hepatocellular carcinoma (Yau 
et al., 2005) 
Known agonists for Wnt signalling include R-spondin and Norrin, both of 
which are thought to activate only Wnt/β-catenin signalling.  Kazanskaya et al 
showed first that R-spondin2 could act synergistically with canonical Wnt ligands to 
activate the Wnt/β-catenin pathway.  They also found R-spondins were often co-
expressed with Wnts, and that R-spondin expression was dependant on Wnts, 
suggesting that R-spondin acts as a positive feedback mediator in canonical Wnt 
signalling (Kazanskaya et al., 2004).  Using colorectal models, it was elucidated that 
RSPO functions as a ligand for the intestinal stem cell marker and orphan receptor 
LGR5 (Carmon, Gong, Lin, Thomas, & Liu, 2011).  While this RSPO-LGR5 is important 
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for canonical control of intestinal homeostasis, it may be that similar mechanisms are 
in place in non-canonical signalling too.  Later, it was shown that injection of human 
R-spondin1 into mice led to intestinal crypt proliferation, driven by activation of 
canonical Wnt signalling (K.-A. Kim, 2005).  Norrin is an agonist for Fzd4, which 






   
45 
 
1.3 Wnt/β-catenin signalling 
1.3.1 Wnt/β-catenin signalling in the absence of Wnt 
 
β-catenin and its regulation in the cytosol represents the crux of canonical Wnt 
signalling (figure 1.3).  The β-catenin destruction complex is well characterised, with 
the scaffolding protein Axin providing structural stability for the complex 
components GSK3, CK1α and β-catenin to come together.  This complex allows the 
formation of the β-catenin destruction complex through sequential phosphorylation 
of β-catenin at serine 33, serine 37, serine 45 and threonine 41 performed by CK1α 
and GSK3 (Kimelman & Xu, 2006).  Phosphorylation of the serine 33 and 37 residues 
creates a binding site for β-TrCP, an E3 ubiquitin ligase.  The ubiquitination by β-TrCP 
results in β-catenin’s degradation.   
 
Axin also binds to another the scaffolding protein, APC, which itself binds to 
β-catenin.  This complement ensures β-catenin is phosphorylated and subsequently 
degraded in the absence of Wnt (Stamos & Weis, 2013).  Su et al showed that APC 
helps protect the β-TrCP binding sites in β-catenin from de-phosphorylation, thereby 
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Figure 1.3 Canonical Wnt signalling in the absence and presence of Wnt 
(a) In the absence of Wnt, cytoplasmic β-catenin is bound in a destruction complex 
formed by GSK3, APC, AXIN, and CK1.  β-catenin is phosphorylated by CK1 and GSK3 
which creates a binding site for β-TrCP, an E3 ubiquitin ligase.  Subsequent 
ubiquitination targets β-catenin for degradationby the proteosome.  (b) Wnt ligand 
forms a complex with the receptors LRP5/6 and Fzd.  Fzd binds Dvl which leads to 
LRP5/6 phosphorylation through recruitment of Axin-GSK3-CK1 to the receptor 
complex.  This disrupts the destruction complex-mediated phosphorylation and 
proteosomal degradation of β-catenin, allowing saturation in the cytoplasm.  
Subsequently β-catenin accumulates in the nucleus where it recruits TCF/LEF for 
activation of the Wnt transcriptional programme.    Taken from Macdonald et al, 2009 
(MacDonald, Tamai, & He, 2009). 
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1.3.2 Wnt/β-catenin (canonical) signalling in the presence of Wnt 
 
The essential receptors Fzd and LRP5/6 are complexed in the presence of Wnt (figure 
1.3).  It has been shown that Wnt-induced phosphorylation of LRP5/6 is essential for 
Wnt/β-catenin signalling and the docking of the scaffolding protein Axin to the 
receptor complex at the membrane (Mao et al., 2001; Tamai et al., 2004).  This key 
phosphorylation is carried by Axin-bound GSK3β and CK1α from the destruction 
complex (Xin Zeng et al., 2005).   
Fzd is essential for this phosphorylation of LRP6 by Wnt ligands and it has been 
shown that Fzd interaction with Dvl is also required.  Dishevelled (Dvl) is a cytoplasmic 
phosphoprotein that acts in the multiple Wnt signalling pathways directly 
downstream of Frizzled.  Since it has been shown that Dvl interacts with Axin, it may 
be that recruitment of Axin-GSK3-CK1 for LRP6 phosphorylation is carried out by Fzd-
Dvl (Bilic et al., 2007; Wallingford & Habas, 2005; X. Zeng et al., 2007), particularly as 
Dvl is known to form a polymer in the cytoplasmic side of the plasma membrane 
following Wnt ligand stimulation.  It has been suggested that differential regulation 
of Dvl may represent the ‘switch’ between downstream canonical or non-canonical 
Wnt signalling (Simons et al., 2005).  Grumaloto et al showed that the canonical Wnt 
ligand Wnt3a and non-canonical ligand Wnt5a specifically trigger unrelated co-
receptors (LRP5/6 and ROR1/2, respectively).  This triggering is achieved through a 
common mechanism of Wnt-Fzd interaction and recruitment of Dvl and GSK3.  It was 
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also shown that GSK3 has the ability to phosphorylate both the canonical or non-
canonical co-receptors (Grumolato et al., 2010).  This shows that canonical and non-
canonical Wnt compete at the cell surface for Fzd binding, and binding reciprocally 
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1.4 Non-canonical Wnt signalling 
Non-canonical Wnt signalling, often referred to as β-Catenin-independent Wnt 
pathway, is classically divided into two branches: the Wnt/Planar Cell Polarity 
(Wnt/PCP) and the Wnt/Ca2+ pathways.  Interactions between Wnt-Fzd (in a related 
way to canonical Wnt signalling) have been known to evoke non-canonical responses, 
as have Fzd independent interactions.  These pathways diverge from the canonical 
signalling, as signalling does not directly control cytoplasmic β-catenin saturation to 
evoke transcriptional responses.  
 In 1982, Moon and colleagues first identified the ligand WNT5A in Xenopus 
when working to identify homologues of the Wnt ligand WNT1 (Christian, Gavin, 
McMahon, & Moon, 1991).  Later, they found that injection of this ligand into 
Xenopus embryos led to developmental defects resulting from disruption of cellular 
movements, in contrast to WNT1 treatment which duplicated the embryonic axis 
(Moon, 1993).  This data was the first suggestion that certain WNTs may act non-
canonically.  Since then, further Wnt ligands have been identified as initiating a non-
canonical response.  Jordan et al identified WNT4 as a key factor in female gonadal 
development, where the ligand attenuates recruitment of β-Catenin recruitment to 
steroidogenic factor 1 (SF1) binding sites (Jordan, Shen, Olaso, Ingraham, & Vilain, 
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2003).   Heisenberg et al identified WNT11 as a requirement for proper convergent 
extension movements in zebrafish gastrulation (Tada & Smith, 2000).  They 
consequently showed that WNT11 acts non-canonically as a dominant-negative 
Wnt11 mutant phenotype can be rescued by a truncated Dvl protein that fails to 
signal through the canonical pathway.  These discoveries have led researchers to 
investigate components involved in non-canonical Wnt signalling other than ligands, 
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1.5 Planar Cell Polarity Signalling  
Simple epithelial cells are polarised within tissue.  This polarity is instrumental in the 
function of complex epithelial structures, by providing directionality to the 
epithelium.  Planar Cell Polarity is a conserved pathway that establishes the anterior-
posterior (also known as proximal-distal) axis of epithelial cells during 
morphogenesis.   This is achieved through asymmetric localisation of the membrane-
associated PCP components and intercellular communication to co-ordinate this 
localisation, and therefore polarity, between neighbouring cells. 
 
1.5.1 Wnt/PCP signalling and the establishment of polarity in 
development  
There is only a basic understanding of the PCP pathway, as opposed to the β-catenin 
dependent pathway, which has been studied extensively in several model species.  It 
is known, however, that Wnt/PCP signalling plays a crucial role in tissue patterning in 
development. 
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PCP is established through the mutually exclusive localisation of core PCP 
proteins at opposing sides of the cell, which forms a pattern which is propagated 
across a plane of tissue.  In Drosophila, Van-Gogh (Vang) forms a complex with Prickle 
and Fmi (mammalian homologue Celsr1) on the proximal side of the cell, whereas Fzd 
(mammalian homologues Fzd1-10), Dvl (Dvl1-3), Diego and Fmi form a complex on 
the distal side of the cell.  In mammals, the VANGL2 (Vang-like 2, homologue of Vang) 
complex prevents the Fzd complex from forming on the proximal side, whereas the 
Fzd complex prevents the VANGL2 complex from forming on the distal side (Tree, 
Shulman, Scott, Gubb, & Axelrod, 2002).  This effect propagates among cells in the 
same plane by interaction between proximal VANGL2 and distal Fzd in adjacent cells 
(J. Wu & Mlodzik, 2008).   
Proper polarisation of tissues by establishment of PCP is crucial in the 
development of many tissues.  Convergent extension movements in Xenopus are 
controlled by Wnt11 which activates the non-canonical pathway via Dvl (Tada & 
Smith, 2000).  Moreover, Wnt11 was also shown to mediate convergent extension 
movements in zebrafish (Heisenberg et al., 2000).  Planar cell polarity was again 
implicated in the control of convergent extension by Lienkamp et al, who showed 
that PCP signalling is required for control over orientation during zebrafish kidney 
tubule elongation (Lienkamp et al., 2012).  A lack of proper convergent extension in 
neuroepithelial development is one of the major reasons for neural tube defects 
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(NTDs).  The homozygous loss-of-function (LOF) mutant VANGL2 mouse, Looptail, Lp 
displays frequent NTDs as this has a mutation in the C-terminal domain of Vangl2 
(S464N) which interferes with activation of downstream, non-canonical Wnt 
cascades.  As well as this, additional PCP genes have been identified has being 
important in neural tube closure (Murdoch et al., 2014) and many phenocopy the 
Vangl2 Lp mutation.   
PCP is also critical for proper orientation of cilia within cells.  One of the most 
classical examples of PCP is within the mouse inner ear, where the asymmetric PCP 
patterning controls cilia orientation (Ehrenhofer-Murray, Rivier, & Rine, 1997).  
Multiciliated cells (MCCs) contain dozens of directionally beating cilia that act in 
concert to direct fluid flow across the tissue, and are crucial for development and 
homeostasis of the airway, the central nervous system, and the reproductive tracts.  
PCP signalling controls concerted cilia beating in all MCCs (Boutin et al., 2014; Guirao 
et al., 2010; Mitchell et al., 2009; T. J. Park, Mitchell, Abitua, Kintner, & Wallingford, 
2008; Shi et al., 2014; Tissir et al., 2010; Vladar, Bayly, Sangoram, Scott, & Axelrod, 
2012). 
Other non-canonical Wnt pathway components have been implicated in a 
range of developmental and early life processes. Cervantes et al showed that Wnt5a 
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is essential for murine intestinal elongation in morphogenesis, and it was found 
cellular proliferation was reduced in this model, where Wnt5a is lost (Cervantes, 
Yamaguchi, & Hebrok, 2009).  Further evidence of the importance of Wnt/PCP 
signalling in the intestine was found in 2015 when Jung colleagues identified the co-
receptor PTK7 as a colonic SC marker in humans.  Higher surface abundance of PTK7 
correlated with self-renewal capacity, while a subset of PTK7+ colonic SCs display 
label-retaining ability in differentiation towards enteroendocrine lineage (Jung et al., 
2015).  
While these core PCP components propagate polarity in this way between 
cells, they also play a crucial role in intracellular Wnt/PCP signalling.  Upon activation 
of Fzd by a non-canonical Wnt ligand, Dishevelled (Dvl) is recruited to Fzd and co-
receptor Ror2, which results in the activation of the GTPases RhoA, Rac1 and Cdc42 
(figure 1.5) (Kirjavainen, Laos, Anttonen, & Pirvola, 2015; Niehrs, 2012).  VANGL2 
plays an integral role here in regulating where the Fzd/Dvl/Ror2 complex forms.  
Several studies have shown that VANGL2 can promote the internalisation of Fzd3, 
and this is done via VANGL2 antagonism of Dvl1 phosphorylation of Fzd3 (M. 
Montcouquiol, 2006; Shafer, Onishi, Lo, Colakoglu, & Zou, 2011).  This Fzd/Dvl/Ror2 
complex promotes the polymerisation of actin and activation of the JNK-dependent 
transcription factors (e.g. AP-1, which includes cJun and cFos).  More recently, this 
complex was implicated again in actin assembly where Gombos et al showed that 
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Wnt5a, Fzd, Dvl and VANGL2 act in concert to activate the formin, dDAAM, a specific 
actin regulator (Gombos et al., 2015). These processes are thought to lead to changes 








Figure 1.4 VANGL2 in Wnt/PCP signalling 
VANGL2 can form a non-canonical Wnt (e.g. Wnt5a) induced receptor complex with 
Ptk7/Ror2.  The VANGL2 cytoplasmic C-terminal PDZ binding domain can activate JNK 
signalling which leads to activation of the AP-1 transcription co-factors Jun/Fos.  
VANGL2 cytoplasmic N-terminal tail contains Ser and Thr and are sites of 
phosphorylation and can activate Rho and Rac signalling which mediate cytoskeletal 
rearrangements.  VANGL2 can also act antagonistically towards the canonical Wnt 
signalling pathway via Dvl. 
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1.5.2 Wnt/PCP signalling in cancer 
Significantly less is known about Wnt/PCP signalling within adult tissues.  Most 
research looking at PCP in adult tissues has been centred on its dysregulation in 
cancers.  In breast cancer VANGL2 has been shown to interact with VANGL1, as well 
as the scaffold protein p62/SQSTM1.  It was shown that the VANGL2-p62/SQSTM1-
JNK signalling is upregulated in breast cancer patients with shorter survival 
(Puvirajesinghe et al., 2016). 
There has been some recent work on the proteins downstream of VANGL2 in 
cancer.  For example, Prickle1 knockdown reduces metastasis of breast cancer cells, 
and is one of the many PCP components (including VANGL2) increased in CLL (Kaucká 
et al., 2013; Luga et al., 2012).  Another downstream component, Scribble (Scrib1), 
has been shown to function as a tumour suppressor in liver cancer in vivo (Kapil et 
al., 2017).  Scrib1 is required for the establishment of epithelial polarity and interacts 
with VANGL2 via its PDZ-binding domain (Kallay, McNickle, Brennwald, Hubbard, & 
Braiterman, 2006).  High expression of Scribble is correlated with worsened risk of 
relapse in breast cancer patients.  However, other work has demonstrated that 
Scribble is an suppressor of tumour initiation in mice (Navarro et al., 2005; Zhan et 
al., 2008). 
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1.6 Wnt/Ca2+ Signalling  
Another branch of the non-canonical Wnt pathway is Wnt/Ca2+ signalling.  Like PCP 
signalling, it functions through Wnt/Fzd interaction and is crucial in development.  It 
has been found that Wnt5a, Wnt11 and Fzd proteins are sufficient for intracellular 
Ca2+ release from endoplasmic reticulum (ER), while not affecting β-catenin 
stabilisation (Slusarski & Pelegri, 2007).  In regions of the gastrulating embryo, 
‘waves’ of Ca2+ are found suggesting it plays an essential role in pattern formation.  
Like the other Wnt pathways, this response is mediated by Fzd and Dsh proteins 
(Kühl, Sheldahl, Malbon, & Moon, 2000; Mudher et al., 2001; Sheldahl, Park, Malbon, 
& Moon, 1999).  Ca2+ responsive proteins are subsequently activated by this 
signalling, including protein kinase C (PKC) and calcium/calmodulin-dependent kinase 
II (CAMKII).  PKC can activate the small GTPase CDC42, a critical mediator of 
gastrulation.  CAMKII has been shown to antagonise Wnt/β-catenin signalling via a 
pair of kinases (TAK1 and NLK) (Malinauskas et al., 2011; Sheldahl et al., 2003; 
Slusarski & Pelegri, 2007).   
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1.7 VANGL Planar Cell Polarity Protein 2 (VANGL2) 
The Vangl, or Strabismus, protein family are Wnt/PCP pathway scaffolding proteins 
targeted to the cellular membrane.  The two human members of the family, VANGL1 
and VANGL2, are membrane-spanning proteins with 73% amino-acid identity.  
VANGL1 and VANGL2 display genetic interaction in murine models, while VANGL2 has 
been shown to have the ability to homodimerize with itself, as well as heterodimerise 
with VANGL1 (Belotti et al., 2012; E. Torban et al., 2008). 
1.7.1 Vangl structure 
The Vangl proteins are the mammalian homologues of the Drosophila melanogaster 
protein Van Gogh (Vang/Strabismus).  VANGL2 and VANGL1 possess four 
transmembrane domains and intracellular N- and C-termini, and are thought to 
interact with other proteins through their C-terminal coiled-coil domain or their PDZ-
binding motif (figure 1.4) (Murdoch, Doudney, Paternotte, Copp, & Stanier, 2001).  
Their function is carried out entirely by protein-protein interactions as they lack 
inherent enzymatic activity.  Human and murine VANGL2 share 99% amino-acid 
identity.  Belotti et al found evidence of endogenous VANGL2-VANGL1 
heterodimerisation in mice, of which N- and C- termini were not required (Belotti et 
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al., 2012).  Furthermore, Torban et al found that VANGL1 heterozygotes and VANGL2 
heterozygotes were viable and fertile, with subtle defects, while double VANGL1 and 
VANGL2 heterozygotes displayed severe developmental defects, including neural 
tube defects (NTDs), defects of the inner ear, and cardiac abnormality (E. Torban et 
al., 2008).  These results show genetic interaction between the mammalian VANGL 
homologues, and a lack of redundancy between these genes.  As VANGL2 
homozygotic loss-of-function (LOF) mutants display severe developmental defects, 
while VANGL1 homozygotic LOF mutants do not, it has been proposed that VANGL2 
is dominant over VANGL1.  It may be that the homodimerisation ability of VANGL2 
may be able to compensate for loss of VANGL1 in development. 
There is evidence that VANGL2 acts in a signalling complex with Fzd to 
promote non-canonical Wnt signalling (Shafer et al., 2011; Treat et al., 2016).  
Dishevelled1 (Dvl1) can inhibit PCP signalling by hyper-phosphorylating Frizzled3 
(Fzd3), whereas VANGL2 antagonises the phosphorylation of Fzd3, causing its 
internalisation and thereby releasing inhibition of PCP signalling.  Supporting this, 
Gao et al showed that Wnt5a mediates the phosphorylation of the VANGL2 N-
terminal cytoplasmic units in a VANGL2-ROR2 receptor complex, thereby controlling 
establishing PCP in chondrocytes (B. Gao et al., 2011).  




Figure 1.5 VANGL2 structure 
Vangls are membrane-associated proteins with four transmembrane domains.  A 
cytoplasmic N-terminal tail possesses phosphorylation clusters at Ser and Thr 
residues.  The cytoplasmic c-terminal tail contains a coiled-coil region and a PDZ 
binding-domain, both of which allow protein-protein interactions.  The conserved 
membrane targeting motif allows transport from the trans-Golgi network.  Looptail 
mutations on the c-terminal tail disrupt the membrane targeting ability of the 
protein.  Taken from Hatakeyama et al, 2014 (Hatakeyama, Wald, Printsev, Ho, & 
Carraway, 2014). 
 
N-terminal phosphorylation clusters 
Looptail mutations in the mouse (S464N, D255E, R259L) 
Conserved plasma membrane-targeting motif 
Coiled-coil region 
PDZ-binding motif 
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1.7.2 VANGL2 in development  
In 1949, the Looptail (Lp) mouse was identified from inbreeding in a forward genetic 
screen (Strong & Hollander, 1949).  Adult heterozygote (Lp/+) mice were 
characterised as having a variably kinked tail and unsteady or ‘wobbly’ head 
movements (Yin, Copley, Goodrich, & Deans, 2012).   This is caused by disruption of 
the cilia within the cochlea, causing balance instability.  
Having the correct PCP signalling in the epithelium is essential for the correct 
cell function and affects the morphology of that tissue.  For example, in vertebrate 
development, a homozygous point mutation in the key signalling protein VANGL2 
causes a lack of convergent extension in the neuro-epithelium, leading to the failure 
of the neural tube to close (craniorachischisis, a severe neural tube defect) (Kit 
Doudney & Stanier, 2005).  This is likely caused by a failure in growth cone guidance, 
shown by Shafer et al in the Looptail mouse (Shafer et al., 2011).  In fact, human PCP 
genes are some of the most well-defined risk factors for NTDs (Wallingford, 
Niswander, Shaw, & Finnell, 2013).  In patients with NTDs, mutations in many of the 
core PCP genes have been identified (Juriloff & Harris, 2012).  Around 20% of patients 
with the NTD craniorachischisis contain putative mutations in VANGL2, Scrib, Dact1 
(Dishevelled Binding Antagonist Of Beta Catenin 1), or Celsr1.  In the heterozygote 
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form of the same mutation, the sensory hair cells in the mouse cochlea lose 
polarisation and have random orientation of cilia/stereocilia (Mireille Montcouquiol 
et al., 2003; Simons & Mlodzik, 2008).  Mutations in other important non-canonical 
components Celsr and Scribble give the same phenotypes (Curtin et al., 2003; Mireille 
Montcouquiol et al., 2003).  This literature indicates there is a global dependence on 
correct cellular orientation for epithelial tissues to function in the vertebrate. 
 Furthermore, embryonic lethal homozygotic (Lp/Lp) mutants were identified 
with cranioschisis, a neural tube defect.  Kibar et al localised the Lp mouse mutation 
in VANGL2, and identified mutations within the gene which cause the Looptail 
phenotype (Kibar, Underhill, et al., 2001; Kibar, Vogan, et al., 2001).  In addition to 
this, a study sequencing stillborn or mis-carried Han Chinese foetuses with severe 
NTDs found novel mutations within VANGL2 (Y.-P. Lei et al., 2010).  Identified 
mutations from this study were in similar positions to ones already shown to affect 
VANGL2 function, and likely disrupt VANGL2 interaction with Dvl (K. Doudney et al., 
2005; Elena Torban, Wang, Groulx, & Gros, 2004).  These mutations were exclusive 
to patients with NTDs and the lack of these mutations in healthy controls suggests 
that they have a lethal effect in utero which precludes their presence in living 
persons. 
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Mutations which cause the Lp phenotype are present within the C-terminal 
cytoplasmic domain, which contains a membrane targeting motif (Guo, Zanetti, & 
Schekman, 2013).  It is was shown that the Lp mutation affects the membrane 
localisation of VANGL2, and results in its degradation by the proteasome (Iliescu, 
Gravel, Horth, Kibar, & Gros, 2011).  However, another study suggested that the Lp 
mutation impaired the binding of VANGL2 to Dvl proteins (Elena Torban et al., 2004).  
The same mutation in the lung also impairs organisation of the alveolar epithelium 
and causes a more constricted luminal space.  These abnormalities are phenocopied 
by inhibition of Rho kinase, indicating that this Wnt/PCP factor downstream of 
VANGL2 plays a role in lung epithelial organisation (Yates, Schnatwinkel, et al., 2010).  
There is also evidence that this mutation causes defects in the developing heart and 
in hair follicle patterning (Cetera, Leybova, Woo, Deans, & Devenport, 2017; 
Devenport & Fuchs, 2008; Phillips et al., 2008; Tatin et al., 2013).  As well as this, 
VANGL2 has been shown to be necessary for normal heart, lung and kidney 
development in vertebrates.  In the cardiac outflow tract development of Lp mice, 
the extension of polarised membrane protrusions and the reorganisation of the actin 
cytoskeleton are inhibited in myocardial cells, indicating that this is a result of a defect 
in cellular polarity or migration (Deborah J. Henderson, Phillips, & Chaudhry, 2006).  
VANGL2 has previously been shown to act via RhoA, which along with ROCK1 carries 
out cytoskeletal rearrangement and cellular movements, to regulate polarised cell 
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movements during the developing proximal outflow tract myocardium (Phillips, 
Murdoch, Chaudhry, Copp, & Henderson, 2005).  
1.7.3 VANGL2 has a developing role in cancer 
As shown, VANGL2 has been well characterised in mammalian development, but its 
effect in adult tissue homeostasis is still not known. 
The tumour sample database The Cancer Genome Atlas (TCGA) found 
VANGL2 was consistently upregulated or amplified in breast, ovarian and uterine 
carcinomas (Table 1).  It has been shown that 24% of breast invasive carcinoma 
samples show upregulation VANGL2 expression alongside 13% of samples containing 
VANGL2 copy number amplification.  VANGL1 shows less strong trends in correlation 
with cancers, however it has been found in a separate analysis by Anastas et al to be 
a predictor in tumour recurrence in breast cancer patients (Hatakeyama et al., 2014).   
This suggests that the Vangl proteins may be important regulators of cancer 
development in certain contexts.  Kho et al, in 2009, showed that VANGL1 is required 
for the invasiveness of CRC cells, and that VANGL1 expression positively correlated 
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with human CRC stage.  They also found that VANGL1 promotes cell migration and 
invasion in colorectal cancer by forming a complex with Dvl and PKCδ to change cell 
motility (Kho et al., 2009).  Similarly, Lee et al found that short-interfering RNA 
(siRNA)-mediated knockdown of VANGL1 suppressed the progression and metastasis 
in colonic tumours in mice.  It was found that VANGL1 interacts with a PKC inhibitor 
(PKCI), which promotes invasiveness, and it was proposed that VANGL1 interacts with 
PKCI to promote invasiveness/metastasis (Lee et al., 2005). 
While we can find implications of VANGL2’s importance in cancer 
development using large-scale gene expression and copy number analyses, 
mechanistic insight into how it functions remains sparse.  VANGL2, in recreating a 
similar role it plays in zebrafish gastrulation, inhibits cellular motility and cell surface 
expression of MMP2/MMP14 levels in fibrosarcoma cells.  This implicates VANGL2 in 
cell migration and extracellular matrix remodelling (Cantrell & Jessen, 2010; B. 
Blairanne Williams, Mundell, Dunlap, & Jessen, 2012).   
PCP signalling may play a role in suppressing canonical Wnt signalling, which 
is the classical tumour-initiating stimulus.  Mikels and Nusse found Wnt5a ligand can 
inhibit Wnt/β-catenin signalling, depending on the receptor context (Mikels & Nusse, 
2006).  This effect was mediated by the orphan tyrosine kinase ROR2, and did not 
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influence cellular calcium levels, suggesting that PCP signalling carries out this 
inhibition.  Park and Moon found VANGL2 has been shown to abrogate canonical Wnt 
signalling upstream of β-catenin via recruitment of Dvl1 to the plasma membrane, 
while promoting activation of the PCP pathways via phosphorylation of the c-Jun as 
part of the AP-1 transcriptional complex (which also includes Fos) (M. Park & Moon, 
2002).  Piazzi et al found that VANGL2 promoter methylation is associated with higher 
tumour grade and BRAF mutation in human colon cancer.  They also found that 
VANGL2 overexpression inhibits Wnt/β-catenin signalling in CRC cell lines (Piazzi et 
al., 2013).  This evidence suggests that VANGL2 and PCP signalling functions as a 




   
68 
 
1.8 Hypothesis & Aims 
I hypothesise that VANGL2 acts to regulate mammalian intestinal homeostasis and 
colorectal cancer. 
 
The aims of the thesis are as follows:  
1. Determine if VANGL2 is expressed within the healthy adult intestine and in 
colorectal cancers.   
2. Evaluate whether alteration of VANGL2 expression plays a role in human 
colorectal cancer pathology.   
3. Establish the role VANGL2 plays in mammalian intestinal homeostasis and 
in cancer, using murine LOF and intestinal cancer models.   
4. Determine the mechanisms through which VANGL2 is acting in the 
intestinal epithelium and establish how signalling through VANGL2 




Chapter 2: Materials & Methods  
2.1 Buffers and Solutions 
2.1.1 Methacarn Fixative 
60% Methanol 
30% Chloroform 
10% Glacial Acetic Acid 
 
2.1.2 TE antigen retrieval Buffer (1 L) 
Tris 1.21 g 
EDTA 0.37 g 
Distilled water 1 L 
Mix to dissolve. Adjust pH to 9.0 then add 0.5 mL of Tween 20 (Sigma). 
 
2.1.3 Sodium Citrate antigen retrieval Buffer (1 L) 
Tri-sodium citrate (dihydrate) 2.94 g 
Distilled water 1 L 
Mix to dissolve.  Adjust pH to 6.0 then add 0.5 mL of Tween 20 (Sigma).  
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2.1.4 3% Hydrogen Peroxide (10 mL) 
Hydrogen Peroxide 30% solution (Sigma) 1 mL 
Distilled water 9 mL 
 
2.1.5 Trypsin-Versene Solution 
0.025% Trypsin and 0.01% Versene (EDTA) solution in PBS  
 
2.1.6 Flow Cytometry Buffer 
PBS 
0.05% Sodium Azide (Sigma) 
0.5%
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2.2 Mouse models 
Mice were maintained and bred at University of Edinburgh facilities according to UK 
Home Office guidelines.  Wild type C57BL/6 mice were bred in-house. Mice were 
maintained in 12h light-dark cycles and had access to food and water ad libitum.  
 
2.2.1 VillinCreERT VANGL2flox/flox mice 
VillinCreERT mice, which contain an inducible Cre recombinase gene under control of 
the Villin1 promoter, were crossed with VANGL2flox/flox mice, which have loxP 
recombination target sites flanking exon 4 (the transmembrane component) of the 
gene (Madison et al., 2002).  VANGL2flox mice were provided by Professor Deborah 
Henderson (Newcastle University) (Ramsbottom et al., 2014).  Mice were culled 5 
days after induction were tamoxifen. 
To assess long-term loss of VANGL2 and tumourigenesis, mice were induced and aged 
for 6 months.  Survival and tumour number was quantified as shown in section 2.2.3. 
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2.2.2 Villin-CreERT VANGL2flox/flox RosamT/mG mice 
VillinCreERT VANGL2flox/flox mice were crossed with RosamT/mG mice (Jackson 
Laboratory) (Muzumdar, Tasic, Miyamichi, Li, & Luo, 2007). tdTomato (RFP) 
expression is found in all tissues, while Cre-expression tissue (in this case in Villin-
expressing cells) undergo recombination resulting in EGFP expression.  Mice were 
culled 5 days after induction with tamoxifen. 
 
2.2.3 VillinCreERT VANGL2flox/flox APCflox/WT mice 
VillinCreERT VANGL2flox/flox mice were crossed with APCflox/WT animals.  These mice had 
loxP recombination target sites flanking exon 14 in one allele of the APC gene (Colnot 
et al., 2004).  Symptom surveillance was carried out over the duration of the 
experiment specifically noting hunching, rectal bleeding, anaemia, and weight loss.  
Mice were sacrificed when disease severity reached endpoint status (up to 300 days 
following induction). 




For tumour quantification, mice intestines were flushed with PBS and opened 
longitudinally.  Intestines were pinned and submerged in methacarn to allow 
detection of all intestinal polyps.  Number of tumours was counted in the small 
intestine and in the colon.  Diameter of all tumours was also measured.  Cumulative 
tumour burden was calculated as the sum of all tumour diameters within each 
mouse.  Average tumour diameter was calculated as the sum of all diameters divided 
by number of polyps. 
 
2.2.4 Tamoxifen induction 
Cre expression was induced with intravenous injections of tamoxifen (reconstituted 
in Ethanol, then diluted in corn oil at 40°C, both Sigma) at 80 mg/kg of bodyweight 
on two consecutive days. 
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2.3 Epithelial Isolation 
The dissected mouse colon was isolated and washed with cold PBS.  The colon was 
opened longitudinally and rinsed again with cold PBS before tissue was cut into small 
(2-3 mm) pieces.  Tissue was washed with PBS before incubation with agitation in 25 
mM EDTA in PBS at 40C for 30 minutes.  EDTA solution was removed and tissue 
washed with PBS, using a motorized pipette, displacing the tissue 10 times.  Tissue 
was allowed to settle and supernatant taken as one epithelial fraction.  This process 
was repeated until four fractions were collected.   
2.3.1 RNA extraction of epithelial cells 
Following this, all fractions were combined and RNA extraction protocol was followed 
(Section 2.6.2).  
2.3.2 Flow cytometry analysis of epithelial cells 
Alternatively, for flow cytometry analysis of Villin-CreERT VANGL2flox/flox RosamT/mG 
mice, epithelial cells were digested into single cells using TrypLE Express (Gibco) for 
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15 minutes at 370C.  Cells were re-suspended in flow cytometry buffer.  Cells were 
analysed via flow cytometry for GFP (excitation peak 488 nm) and tdTomato (554 nm) 
expression (after gating for single cells).  Samples were acquired on a FACSJazz 
benchtop flow cytometer (BDBiosciences).  All flow cytometry data was analysed 
using FlowJo software (BDBiosciences).  The %GFP+ cells between VANGL2WT/WT and 
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2.4 Human tissue 
2.4.1 Human CRC tissue sections 
Slide sections comprised of colorectal cancer (CRC) and non-cancer human tissue 
were obtained from the Division of Pathology Laboratories at the Western General 
Hospital (tissue approval number: TGU-LAB-587). 
2.4.2 Tissue microarray (TMA) 
Pantomics TMAs COC1261 and COC1262 used, comprising 42 CRC patient cores 
paired with normal colonic tissue (www.pantomics.com). 
2.5 Human CRC Database 
Colorectal Adenocarcinoma (TCGA, Provisional) study used.  Patient overall survival 
and disease-free survival data segregated into high-expression and unaltered-
expression of VANGL2 was downloaded from the Colorectal Adenocarcinoma (TCGA 
Research Network, Provisional) dataset through cBioPortal (www.cbioportal.org) on 
10.08.17 (J. Gao et al., 2013).  High and unaltered patient survival times were plotted, 
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median survival times were calculated.  Differences in survival was tested for 
statistical significance using a Log-rank test (p < 0.05). 
2.6 Molecular biology techniques 
2.6.1 RNA Isolation & Quantification 
A small piece of tissue (small intestinal or colonic whole tissue; or extracted colonic 
epithelial cells) was placed in 1 mL of TRIzol reagent (Invitrogen).  Tissue was first 
homogenized using a steel bead and a TissueLyser LT machine (Qiagen) for 4 minutes 
at 50 Hz, with an additional 1 minute at 50 Hz as required.  Samples were then 
centrifuged at 10,000 g for 3 minutes at 4C to remove tissue debris and supernatants 
decanted into fresh eppendorf tubes. 
Chloroform was added (200 μl per 1 mL TRIzol), samples inverted 10 times and 
incubated at room temperature (RT) for 3 minutes.  Samples were centrifuged at 
12,000 g for 10 minutes at 40C.  The clear aqueous phase (containing total RNA) was 
removed and transferred to a new 1.5 mL eppendorf tube (carefully avoiding the 
white-coloured interphase containing genomic DNA, and the pink-coloured organic 
phase containing cellular debris).  Isopropanol (500 μl per 1 mL TRIzol) was added, 
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samples inverted 10 times and left for 10 minutes at RT. Samples were then purified 
using the RNeasy Mini Kit (Qiagen).  Purifications were performed according to 
manufacturer’s instructions, with RNA eluted in a final volume of 30 μl of RNase-free 
water (Qiagen). RNA concentration and purity was analysed on a Nanodrop ND-1000 
spectrophotometer (Thermo Fisher Scientific).  UV absorption was measured at 230, 
260, and 280 nm.  1.5 μl of each RNA sample was used for measurements, with 1.5 
μl of RNase-free water used to blank the machine.  RNA measurement was calculated 
using absorbance at 260 nm.  Optimally, RNA samples had an A260:A280 ratio of > 1.8 
(lower indicating DNA contamination) and an A260:A230 ratio of > 1.4 (lower indicating 
phenol contamination) 
2.6.2 Synthesis of cDNA and gene expression quantification via qRT-PCR 
A fixed amount of 1 μg of RNA was used for the reverse transcription synthesis of 
cDNA from cellular RNA.  Reverse transcription reactions were performed using 
QuantiTect Reverse Transcription Kit (Qiagen) using manufacturer’s instructions. 
SYBR Green I-based real-time PCR assays were performed on the LightCycler 480 
instrument within 384-Well Reaction Plates (all Roche).  Primers (QuantiTect Primer 
Assays, Qiagen) were purchased from Qiagen’s Primer Assay library 
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(www.qiagen.com) and are shown in Table 2.6.  Reactions were performed using 
SYBR Green System (Roche) according to manufacturer’s instructions.  cDNA samples 
were diluted 1:5 with nuclease-free water (Qiagen), and 5 μl of diluted cDNA was 
used per sample in a total reaction volume of 12.5 μl.  Cycle conditions: 5 min pre-
denaturation at 95°C, followed by 45 cycles of 10 s denaturation at 95°C, 20 s 
annealing at 60°C, and 20 s elongation at 72°C.  All samples were performed in 
technical triplicate.  A no-transcriptase control was used to assess DNA 
contamination and nuclease-free water was used as a non-template control.  PPIA 
(Peptidylprolyl Isomerase A) was used as housekeeping gene for normalisation in all 
qRT-PCR analyses.  This was chosen on recommendation from Dr Kevin Myant (CRUK, 
Edinburgh) as the optimal intestinal transcript to normalise against (with low 
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Table 2.6 Quantitative PCR primer assays 
Gene Entrez Gene ID QuantiTect Primer Assay 
AXIN2 12006 Mm_Axin2_1_SG 
BMP4 12159 Mm_Bmp4_1_SG 
β-CATENIN 12443 Mm_Ccnd1_1_SG 
CMYC 17869 Mm_Myc_1_SG 
CTGF 14219 Mm_Ctgf_1_SG 
CYR61 16007 Mm_Cyr61_1_SG 
DCN 13179 Mm_Dcn_1_SG 
DVL1 13542 Mm_Dvl1_1_SG 
DVL2 13543 Mm_Dvl2_1_SG 
DVL3 13544 Mm_Dvl3_1_SG 
FOS1 14281 Mm_Fos_1_SG 
IGFBP4 16010 Mm_Igfbp4_1_SG 
KRT19 16669 Mm_Krt19_1_SG 
LEF1 16842 Mm_Lef1_1_SG 
LGR5 14160 Mm_Gpr49_1_SG  
MMP2 17390 Mm_Mmp2_1_SG 
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MMP7 17393 Mm_Mmp7_1_SG 
MMP9 17395 Mm_Mmp9_1_SG 
PKCθ 18761 Mm_Prkcq_1_SG 
PPIA 268373 Mm_Ppia_1_SG 
PRICKLE1 106042 Mm_Prickle1_1_SG 
PRICKLE2 243548 Mm_Prickle2_2_SG 
PRICKLE3 54630 Mm_Prickle3_1_SG 
PRICKLE4 381104 Mm_Prickle4_2_SG 
ROR2 26564 Mm_Ror2_1_SG 
SCRIB1 105782 Mm_Scrib_1_SG 
SOX9 20682 Mm_Sox9_1_SG 
SPARC 20692 Mm_Sparc_1_SG 
TIMP1 21857 Mm_Timp1_1_SG 
TIMP3 21859 Mm_Timp3_1_SG 
VANGL1 229658 Mm_Vangl1_1_SG 
VANGL2 93840 Mm_Vangl2_1_SG 
WNT4 22417 Mm_Wnt4_1_SG 
WNT5A 22418 Mm_Wnt5a_1_SG 
WNT5B 22419 Mm_Wnt5b_1_SG 
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WNT11 22411 Mm_Wnt11_1_SG 
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2.6.3 RIN scores, RNAseq, and Transcriptome pathway analysis 
RNA quality assessment for RNA sequencing was performed by Agnes Gallacher 
(Medical Research Centre Human Genetics Unit (MRC HGU), University of Edinburgh) 
using the Agilent 2100 Bioanalyser.  An RNA integrity number (RIN) of ≥7 was deemed 
appropriate for sequencing. 
RNA samples were provided to GATC Biotech for Illumina RNA sequencing 
(www.gatc-biotech.com).  Dr. Stuart Aitken of the MRC HGU performed quality 
control and mapping of the source data, followed by calculation of FPKM (fragments 
per kilobase of exon per million reads mapped) for differential expression analysis 
between genotypes, and finally identification of differentially expressed genes and 
transcripts (q < 0.05). 
Overexpression analysis on ConsensusPathDB (CPDB) was performed on the gene list 
of significantly upregulated genes and on the list of significantly downregulated genes 
in the VANGL2Flox/Flox tissue compared to control.  Genes are mapped to pathway-
based gene sets (only pathways with two or more matched genes included).  Pathway 
sources used include Reactome, KEGG, PID, Wikipathways, and NetPath. Significantly 
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(q < 0.05) over-represented pathways are selected for and top 10 from each gene list 
shown in Table 4.2.5B (Kamburov et al., 2011) (http://cpdb.molgen.mpg.de/CPDB).  
2.6.4 RNA ISH (RNAScope) 
RNA in situ hybridization (was performed by Aquila Histoplex using RNAScope probes 
(ACDBio) against VANGL2, VANGL1, WNT5A, PTK7, PPIB (positive control), and a non-
targeting negative control (nt-control) (www.histoplex.co.uk).  Staining was 
visualised using Diaminobenzidine (DAB) chromogen. 
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2.7 Histology & Immunohistochemistry 
2.7.1 Intestinal histology 
Mice were sacrificed and intestine removed.  Dissected intestinal tissue (small 
intestine or colon) was washed with PBS, opened longitudinally before being rolled 
into a ‘swiss-roll’ as previously published (Moolenbeek & Ruitenberg, 1981).  Tissue 
was fixed in methacarn for 24 hours then washed in Methanol for 24 hours 
(alternatively for immunofluorescent staining, tissue was fixed in 4% 
paraformaldehyde, PFA, solution for 24 hours). Tissue was then washed in fresh 
methanol for 1 hour, followed by incubation in ethanol, xylene, and paraffin (3 x 30 
minutes each).  All steps for tissue processing performed in Tissue-Tek VIP Infiltration 
Processor (Sakura).  Processed tissue was embedded in paraffin and tissue sections 
cut at 4 μm thickness.  Tissue sections were baked in an oven overnight at 50°C.  
Sections were deparaffinized in 3 x 5 min washes of xylene followed by rehydration 
in a graduated ethanol series.  
For histological evaluation of RosamT/mG mice, colons were dissected and flash frozen 
in O.C.T. compound (Tissue-Tek) using a 2-methylbutane/dry ice bath.  Sections were 
cut at 10 μm thickness.  Cryosections were fixed in a 1:1 acetone:methanol mixture 
before mounting with with Vectashield containing DAPI (Vector Laboratories). 




Deparaffinised sections were stained in Harris haematoxylin for 5 minutes and 
washed in running tap water for 5 minutes.  Staining was differentiated in 1% acid 
alcohol for 30 seconds before washing again for 1 minute.  Developing the stain was 
performed in saturated lithium carbonate solution for 30 seconds followed by 
washing in tap water for 5 minutes.  Tissue was counterstained in eosin for 1 minute 
and tissue dehydrated in ethanol before clearing tissue in xylene and mounting slides 
with DPX mounting medium (Sigma). 
Tumour histopathology assessment was carried out by Dr. Tim Kendall (MRC Centre 
for Inflammation Research, University of Edinburgh) using H&E-stained sections from 
induced VillinCreERT VANGL2flox/flox APCflox/WT and VillinCreERT VANGL2WT/WT APCflox/WT 
mice. 
2.7.3 IHC: Chromogenic staining 
Antigen retrieval (if required) was performed using pre-warmed TE or Sodium Citrate 
buffer.  Slides treated with 3% Hydrogen Peroxide for 15 minutes at RT to block 
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endogenous peroxidase.  Slides blocked with Avidin and Biotin block solution each 
for 15 minutes at RT.  Protein block (Spring Bioscience) was added for 30 minutes at 
RT.  Primary antibodies (Table 2.7) in antibody diluent reagent solution (Invitrogen) 
were incubated overnight at 4°C.  Tissue incubated in -biotinylated secondary 
antibody at RT for 30 minutes, followed by treatment with VECTASTAIN Elite ABC-
HRP (Vector Laboratories) treatment for 30 minutes at RT.  Slides are incubated in 
DAB substrate (Abcam, made according to manufacturer’s instructions) for 5 minutes 
at RT.  Slides counterstained with haematoxylin, dehydrated in alcohol, and washed 
in xylene before mounting with DPX mounting medium (Sigma).  PBS washes used in 
between all antibody incubation steps. 
 
2.7.4 IHC: Immunofluorescent staining 
Antigen retrieval (if needed) was performed using pre-warmed TE or Sodium Citrate 
buffer.  Retrieval was performed in a conventional microwave oven for the time 
indicated in table 2.7.  Protein block (0.5% BSA, 0.5% casein in PBS, Spring Bioscience) 
was added for 30 minutes at RT.  Primary antibodies (Table 2.7) in antibody diluent 
reagent solution (Invitrogen) were incubated overnight at 4°C and washed in PBS 3 
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times for 5 minutes each.  Tissue incubated in fluorescently conjugated secondary 
antibody in the dark at RT for 30 minutes and subsequently washed in PBS 3 times 
for 5 minutes each.  Slides were mounted with Vectashield containing DAPI (Vector 
Laboratories).  
2.7.5 Definiens IHC Quantification 
Quantitative IHC analyses were performed using Definiens Tissue Studio (Definiens, 
Carlsbad, CA) image analysis software.  Whole-scans of intestinal sections were 
imported for analysis.  User-guided machine learning is employed to generate an 
analysis that defines positive areas of expression.  Regions of interest (ROIs, for 
example epithelium or adenomas) were identified for analysis using manually drawn 
areas.  Nuclei are detected from haematoxylin counter-staining, while DAB 
chromogenic staining is recognized as positive areas of expression.  Images were then 
batch processed to define and quantify areas of expression along with intensity of 
expression.  Proliferative stains were quantified as a percentage of positive nuclei, 
while all other stains were quantified using a quickscore (QS).  QS = average intensity 
of expression x % area of expression.  Three or more sections were quantified per 
genotype. 
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2.7.6 VillinCreERT RosamT/mG crypt recombination counting 
Sections were prepared as described in section 2.7.1 from colons from two induced 
VillinCreERT RosamT/mG mice.  Ten fields-of-view (FOV) from each colon was captured 
using a confocal microscope at 10x magnification.  Total number of crypts and 
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Table 2.7 List of antibodies for immunohistochemistry (IHC) 
Specificity Host Dilution  Source 
Antigen Retrieval 
(PFA-fixed tissue) 
VANGL2 Rabbit 1:100 Sigma/Atlas 10 min in TE buffer 
WNT5A Rabbit 1:100 LS Bio 10 min in TE buffer 
PTK7 Rabbit 1:100 Proteintech 10 min in TE buffer 
KI67 Rabbit 1:2000 Abcam 
PCNA (PC10) Mouse 1:4000 Cell Signalling  
DCN Goat 1:50 R&D Systems 
SPARC Goat 1:100 R&D Systems 
COL1 Goat 1:1000 SouthernBiotech 
LAMININ Rabbit 1:500 Abcam 
CTGF Rabbit 1:500 Abcam 
C-JUN (60A8) Rabbit 1:300 Cell Signalling 
PHOSPHO-C-JUN 
(SER73) 
Rabbit 1:100 Cell Signalling 
Specificity Host   Dilution Source 
Anti-Rabbit 
Biotinylated 
Goat 1:500 Vector Labs 
Anti-Mouse 
Biotinylated 
Goat 1:500 Vector Labs 
Anti-Goat Biotinylated Rabbit 1:500 Vector Labs 
Specificity Host   Dilution Source 
Anti-Rabbit Alexa Fluor 
488 
Donkey 1:500 Life Technologies 
Anti-Rabbit Alexa Fluor 
594 
Donkey 1:500 Life Technologies 
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2.8 Intestinal and Colonic Organoids 
 
2.8.1 Colonic organoid culture 
The dissected murine colon was flushed with cold PBS and cut longitudinally to 
expose the lumen.  Exposed lumen was washed again with PBS and cut into 1-2 mm 
pieces.  Tissue was washed 3-4 times with cold PBS before incubation in 25 mM EDTA 
in PBS for 30 minutes with agitation at 4°C.  After EDTA aspiration, tissue was washed 
with 10 mL of cold PBS and vigorous pipetting.  The supernatant (containing crypts) 
was collected as one fraction.  This PBS washing was repeated until four fractions 
were collected, and each fraction was analysed under a light microscope for crypt 
enrichment.  Fractions most enriched for crypts were combined and filtered through 
a 70 µM cell filter (Fisher Scientific) and washed with ADF media.  Crypts were then 
centrifuged at 100G to remove single epithelial cells.  Crypts were then spun at 300G 
and the resultant pellet resuspended in Matrigel (Corning).  500 μl of Matrigel was 
used per colon used for culture, and 20 μl was plated per well in a 24-well tissue 
culture plate.  ADF-based organoid growth media was added, featuring EGF, Noggin, 
and R-Spondin1 growth factors.  Organoids were incubated at 37°C, 5% CO2 and 
culture media renewed every 2-3 days. 
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2.8.2 Colonic adenoma organoid culture 
Dissected murine colonic adenoma was rinsed with PBS before being cut into 1 mm 
pieces.  Adenoma tissue was then incubated with agitation in 25 mM EDTA in PBS for 
15 minutes at 4°C.  Tissue was then incubated with Trypsin-Versene solution for 15 
minutes at 37°C.  Tissue was washed by centrifugation at 300 g for 5 minutes and 
passed through a 70 µM cell filter (Fisher Scientific) and washed with ADF media.  
Cells are spun down at 300 g and pellet re-suspended with Matrigel (Corning), with 
around 500 µL Matrigel used per 24-well tissue culture plate.  ADF-based organoid 
growth media was added without recombinant R-Spondin1 or Wnt3a ligand to select 
for neoplastic epithelial cells (featuring Wnt hyper-activation).  Organoids were 
incubated at 37°C, 5% CO2 and culture media renewed every 2-3 days. 
 
Complete ADF for organoid culture: 
Advanced DMEM/F12 medium (Gibco) 
100 U/ml penicillin & 100 μg/ml Streptomycin (MRC HGU) 
2 mM L-glutamine (MRC HGU) 
10mM HEPES Buffer 
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1x N2 Supplement (Thermo Fisher Scientific) 
1x B27 Supplement (Thermo Fisher Scientific) 
50 ng/mL EGF (Invitrogen) 
100 ng/mL Noggin (Peprotech) 
500 ng/mL R-Spondin1 (R&D) * 
100 ng/mL Wnt3a (Peprotech) * 
*not used for adenoma organoid culture 
 
2.8.3 RNA extraction 
For organoid RNA extraction, TRIzol (Invitrogen) was added directly to Matrigel 
droplets following removal of culture medium.  RNA was subsequently extracted 
from the organoids using the RNA extraction protocol (Section 2.4.2). 
2.9 Statistical analysis 
All statistical analyses were performed using Graphpad Prism 7 (Graphpad Software 
Inc.).  Unless otherwise indicated in figure legends, data analysis was performed as 
follows;  
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For comparisons of two groups, a parametric student’s t-test, unpaired, and two-
tailed was used. When three or more groups were analysed by one-way ANOVA, with 
a Tukey’s multiple comparisons post-test.  *** = P < 0.001, ** = P < 0.01, * P < 0.05, 




Chapter 3: Characterisation of VANGL2 & non-canonical 
Wnt Signalling components in the intestinal epithelium 
3.1 Introduction 
Loss-of function (LOF) mutations in VANGL2 have been identified in humans with 
neural tube defects (NTDs), however it has been difficult to define whether these 
mutations are causative, as they have generally been identified using targeted 
sequencing.  Therefore, there could be other causative variants that interact with 
mutations in VANGL2 or are able to cause NTDs independent of VANGL2.  To address 
the limitations of site directed sequencing, the core Wnt/Planar Cell Polarity (PCP) 
gene, VANGL2, has long been studied for its role in vertebrate development using 
mice (Kibar, Vogan, et al., 2001; van Abeelen & Raven, 1968).  Mice used include 
knock-outs using VANGL2 floxed alleles and point mutations in VANGL2 such as the 
LOF Looptail model, which has a VANGL2S464N point mutation (D. J. Henderson et al., 
2001; Y.-P. Lei et al., 2010; E. Torban et al., 2008).  While similar phenotypes are found 
in mice and patients with VANGL1 mutations, homozygous mutants do not display 
the severe developmental conditions compared to the VANGL2, suggesting VANGL2 
plays the predominant role in regulating development.  While VANGL2 has shown the 
ability to homodimerize, VANGL1 can only form heterodimers with VANGL2 (Belotti 
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et al., 2012; E. Torban et al., 2008).  It may be that the ability for VANGL2 to bind itself 
may compensate for any loss of functional VANGL1 in development. 
While it has been shown that VANGL2 is expressed in the stomach epithelium 
in development and is required for proper fore-stomach morphogenesis, the role of 
VANGL2 in intestinal development has yet to be fully elucidated (Satoh, Matsuyama, 
Takemura, Aizawa, & Shimono, 2008; Elena Torban et al., 2007).  It has been 
reported, however, that VANGL2 is expressed in the intestinal tube during 
organogenesis from E9.5 and increases over time, while Wnt/PCP ligand WNT5A is 
essential for the elongation and development of the small intestine in mice 
(Cervantes et al., 2009).  Given the compelling evidence for VANGL2’s critical role in 
epithelial morphogenesis, it must be considered that Vangl2 may have a role in the 
homeostasis and/or disease of epithelial tissues, such as the intestinal epithelium. 
To date, there has been no research carried out examining the role of VANGL2 
in intestinal epithelium.  Given this and given VANGL2 has previously been shown to 
inhibit canonical Wnt signalling, an essential driver of intestinal epithelial renewal, 
researching of VANGL2 and related non-canonical signalling genes would be 
beneficial (Hayes, Naito, Daulat, Angers, & Ciruna, 2013) to define the role of Vangl2 
in intestinal epithelial homeostasis. 
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VANGL2 has been implicated in several cancers, including in breast cancer 
where transcriptional upregulation and genomic amplification of the gene leads to 
the promotion of epithelial proliferation through JNK signalling, and ultimately 
poorer prognosis in patients (Puvirajesinghe et al., 2016).  However, there is little 
analysis of the role of VANGL2 in colorectal cancer.  Piazzi et al found that VANGL2 is 
frequently silenced by methylation in microsatellite instable (MSI) colorectal cancer 
cell lines (Piazzi et al., 2013).  It was also shown that methylated VANGL2 associated 
with CRCs that are MSI, higher grade, BRAF mutant and have proximal colon location.  
Moreover, in the colorectal cancer cell line SW480 overexpressing VANGL2, it was 
found that β-catenin levels were decreased concurrently with proliferation, 
indicating that VANGL2 expression may be able to inhibit canonical Wnt signalling.  
Similarly, fellow Wnt/PCP signalling components WNT5A and ROR2 are also 
frequently repressed due to promoter hyper-methylation, and overexpression of 
these genes resulted in tumour suppressive behaviour in vitro (Lara et al., 2010; Ying 
et al., 2008).    These data are in agreement with previous data showing VANGL2 acts 
as a suppressor of invasion in fibrosarcoma cells (Cantrell & Jessen, 2010).  Here cells 
with suppressed VANGL2 expression have augmented migratory ability, and have 
increased invasiveness through improved matrix metalloproteinase (MMP) activity.  
Therefore, VANGL2 may play a role in regulating human CRC, and it is of interest to 
explore further. 




3.2.1 Quantification and localisation VANGL2 transcript within the 
murine intestine 
Given that there is little definitive information about VANGL2 expression in the colon, 
I wanted to determine the presence or absence of VANGL2 within the murine 
intestine, and to define the expression of VANGL2 longitudinally along the intestine.  
As well as this, investigating the expression pattern of other PCP components in the 
intestine was also of interest, as VANGL2 functions in tandem with several other 
proteins to orchestrate the PCP signal.  The murine intestine serves well as a model 
of human intestinal homeostasis, with similar gross architecture, epithelial structure, 
and cell types, as well as similar pathways governing the epithelium (as evidenced by 
the conserved Wnt signalling pathway).  Therefore, the mouse intestine used here 
for characterising of the expression of VANGL2.  Adult C57BL/6J mice had the full 
length of their intestines (comprising the small intestine starting from the duodenum, 
the caecum, and the colon up to the anal canal) harvested.  Intestines were divided 
into 3cm pieces, RNA extracted and cDNA synthesised.  Each 3cm piece of tissue was 
assigned to each of the intestinal segments (duodenum, jejunum, ileum, caecum, and 
colon) and qRT-PCR analysis was carried out looking at PCP component expression 
(Figure 3.2.1A).   
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I found that VANGL2 transcript is detectable in all sections of the whole mouse 
intestine (using a cut-off Ct of 40 for detection), along with several other genes which 
are components of the PCP signalling pathway (Figure 3.2.1A).  This includes the 
VANGL2 homologue VANGL1 (shown to be dysregulated in some human cancers), the 
Dishevelled (Dvl) gene family (crucial for PCP signalling during development), and the 
Prickle family (a key PCP regulatory factor).  The Wnt family ligands shown to activate 
the non-canonical pathway (including WNT5A shown to be a key prognostic marker 
in other epithelial cancer), ROR2 (known to interact with WNT5A to activate PCP 
signalling) and Scrib1 (established to be mutated in the neural tube defect spina 
bifida) are also included (Andre, Song, Kim, Kispert, & Yang, 2015; Etheridge et al., 
2008; Gibbs et al., 2016; Hatakeyama et al., 2014; Heinonen, Vanegas, Lew, Krosl, & 
Perreault, 2011; Jenny, Reynolds-Kenneally, Das, Burnett, & Mlodzik, 2005; Y. Lei et 
al., 2013; Martinez et al., 2015; Saling et al., 2017; Shafer et al., 2011; Wang, 2006).  
Expression levels, relative to those of the duodenum, vary across the intestine for 
each gene.  
While I have shown that there is transcript expression of these PCP 
components in the colon, this analysis includes transcripts from the whole intestine 
and not just epithelium.  Given the prominent role PCP and VANGL2 play within 
epithelial tissue organisation, I narrowed my investigation to epithelial tissue.  To 
analyse component expression specifically within the colonic epithelium, and to 
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localise individual transcripts, I performed RNA in situ hybridisation (ISH).  Mouse 
colonic tissue was probed for VANGL2, VANGL1, WNT5A, or PTK7 mRNA in a 
chromogenic assay that is sensitive enough to detect single transcripts (Figure 
3.2.1B).  Using this method of defining mRNA positivity I found that transcripts of 
each of these genes were found in the murine colonic epithelium, validating the qRT-
PCR data by showing these are expressed and localising expression to the epithelium.  
Transcripts of each of these genes were found broadly along the crypt axis.  The 
presence of VANGL2 and its homologue VANGL1, the non-canonical ligand WNT5A, 
and the Wnt/PCP signalling co-receptor PTK7 support further investigation into the 
function of VANGL2 signalling in the intestine. 
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3.2.2 Localisation of VANGL2 protein within the murine colon 
With the pattern of VANGL2 transcription within the colon defined, I proceeded to 
investigate VANGL2 expression at the protein level.  This would define the presence 
and localisation of VANGL2 protein within the mouse colonic epithelium.  Fixed 
mouse colon was stained using an anti-VANGL2 antibody, and I visualised VANGL2 
protein in the murine colon using DAB (Figure 3.2.2A).  VANGL2 was found to be 
expressed broadly across the crypt axis (similar to what  I have defined with VANGL2 
transcripts using ISH), however, the protein was found to generally have cytoplasmic 
or membranous cellular localisation.  It is thought that VANGL2 needs to be localised 
to the membrane for activity in PCP signalling (S. Li et al., 2011).  I also assessed the 
Wnt/PCP ligand WNT5A for expression in the colon (Figure 3.2.2A).  It has previously 
been shown that this protein functions in PCP signalling in mice (Qian et al., 2007).  
WNT5A is localised at the base of the colonic crypts and surrounding stromal cells.  
Given the presence of the core PCP proteins VANGL2 and WNT5A (one of the Wnt 
ligands that conventionally activate PCP signalling), I investigated if both proteins can 
be found in the same location, which could suggest interaction (direct or otherwise.  
I conducted immunofluorescent stains on both proteins and found that they co-
localised in the murine colonic epithelium (Figure 3.2.2B).  Another transmembrane 
protein, PTK7, has been shown to promote PCP signalling and has been shown to 
interact genetically with VANGL2 (Hayes et al., 2013; Lu et al., 2004).  PTK7 has also 
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been identified as a colonic SC marker with lineage tracing ability (Jung et al., 2015). 
Immunofluorescence analysis in the mouse colon shows co-localisation of both 
VANGL2 and PTK7 within the base of the colonic crypts (Figure 3.2.2C).  Interestingly, 
this co-localisation was not seen within the small intestine (Figure 3.2.2D).  My data 
illustrates the presence of a Wnt/PCP ‘signalling hub’ within the murine colon, 
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3.2.3 Localisation of VANGL2 in the human colon 
Given that VANGL2 is expressed at the transcript and protein level in the murine 
colonic epithelium, I then sought to establish if VANGL2 is present in an analogous 
manner in the human colonic epithelium, to validate the murine colon as a suitable 
model for looking at the role of VANGL2 in human colorectal disease.  Fixed human 
non-cancerous colonic tissue was stained using the same VANGL2 antibody that we 
used in the murine stains (Figure 3.2.3A).  Representing the first characterisation of 
VANGL2 in the human colon, I found that VANGL2 protein is localised to the colonic 
epithelium and is broadly expressed along the crypt axis.  Recapitulating part of the 
PCP ‘signalling hub’ seen in the mouse.  VANGL2 and PTK7 were also seen to be co-
localised within the human colon (Figure 3.2.3B).  More specifically, PTK7 staining 
was restricted to the crypt base, which is important given the reports on PTK7 acting 
as a colonic stem cell marker (Jung et al., 2015).  This supports the data seen in the 
mouse and I therefore decided to characterise the expression of VANGL2 in human 
CRC. 
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3.2.4 VANGL2 in human CRC: expression segregation and structural 
variation 
Certain subtypes of colorectal cancer (CRC) such as those with MSI are associated 
with VANGL2 promotor methylation, which can suppress transcription of VANGL2 
(Piazzi et al., 2013).  However, there is no analysis looking directly at transcriptional 
variation of VANGL2 within human CRC.  Given that we have characterised the 
expression of VANGL2 within the human and mouse colon, we then sought to 
examine dysregulation of VANGL2 expression in disease, in this case CRC.  
Transcriptional variation within canonical Wnt signalling components has already 
been shown to have prognostic significance, with Wnt-1, β-catenin and E-cadherin all 
implicated in CRC (Stanczak et al., 2011).  In breast cancer, VANGL2 transcriptional 
upregulation correlates with poorer metastasis-free survival (MFS) (Puvirajesinghe et 
al., 2016).  Using The Cancer Genome Atlas (TCGA) dataset, it was found that VANGL2 
mRNA is upregulated in 35 (9.2%) of 379 of colorectal adenocarcinoma patient 
tumours (Articles, 2012; J. Gao et al., 2013).  By stratifying patients based on VANGL2 
mRNA expression I found that these patients with high VANGL2 expression have 
similar overall survival (OS) to those with unaltered VANGL2 expression (median of 
43.1 months OS versus 48.2 months) (Figure 3.2.4).  However, by stratifying disease 
free survival (DFS) based on mRNA upregulation, it was found that the patients with 
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upregulated VANGL2 expression had significantly worsened median DFS (median of 
34 months DFS) than those with unaltered expression (84 months). 
 Given the interesting findings from looking at this ‘VANGL2-high’ subset of 
patients, I also searched for changes in expression of tumour-regulating genes within 
this subset.  I found that the prevalence of MAPK1 (also known as ERK2) 
downregulation in the ‘VANGL2-high’ patients is increased over ‘VANGL2-normal’ 
patients.  Therefore, VANGL2-high CRC patients have a significant association with 
downregulation of MAPK1 (OR = 2.616, 95% CI 1.155-6.12).  MAPK1 is associated with 
promotion of cell growth and inhibition of apoptosis in vitro in CRC cells, while a 
similar effect has been shown in prostate cancer in vivo (Q. guang Chen et al., 2016; 
N. Zhang, Lu, & Chen, 2016).  While this research showing MAPK1 promotes tumour 
malignancy does not fit with VANGL2-high patients showing MAPK1 downregulation, 
there is evidence to show that activation of MAPK1 in certain contexts can cause cell 
cycle arrest through induction of p21 and inhibition of Cyclin-dependent kinase 2 
(Cdk2) (J. Han, Tsukada, Hara, Kitamura, & Tanaka, 2005; Malumbres et al., 2000).  It 
could be speculated that this represents a mechanism through which downregulation 
of MAPK1 may promote CRC development, which may explain why we see decreased 
MAPK1 expression in patients with reduced DFS.  However, as no direct link can be 
made, this association may be a result of a secondary effect from increased VANGL2 
expression. 
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3.2.5 VANGL2 protein localisation and quantification in human CRC 
Given that high expression of VANGL2 is associated with worsened disease-free 
survival in colorectal cancer, further investigation into the role VANGL2 plays in CRC 
is warranted.  Using sections of human adenocarcinoma and non-cancerous tissue, I 
performed immunohistochemical staining for VANGL2.  Intensity of expression of 
VANGL2 is highly varied between patient tumour samples, illustrating that there is an 
opportunity to define patient subsets based on VANGL2 expression levels (Figure 
3.2.5A). 
I then repeated this staining on tissue microarrays (TMAs) featuring cores 
taken from human colon cancers with matched healthy tissue cores, totalling 84 
cases (Figure 3.2.5B).  Overall core protein expression of VANGL2 was quantified and 
cores stratified based on non-cancer or cancer tissue, patient age, sex, tumour 
grading and TNM staging data.  No significant difference in VANGL2 expression was 
found between non-cancer and cancerous tissue, nor was VANGL2 expression 
different between CRC patients aged under 60 and those 60 and over.  In assessing 
differences in gender, VANGL2 expression was increased in females over males.  We 
also see that VANGL2 expression differs between tumour sub-types.  Patients with 
tumours that are histologically grade II are found to have higher expression of 
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VANGL2 than those with grade I tumours, showing an association of higher VANGL2 
expression with tumour abnormality.  While VANGL2 expression was increased in 
Grade III tumours over grade I, this was not to a significant extent.  No significant 
difference in expression was found between grade II and III tumours.  While grading 
assesses the normality and differentiation of a growth, AJCC tumour staging defines 
a tumour’s invasiveness into the surrounding tissue.  Interestingly, T1 clinical stage 
cancers have significantly higher VANGL2 expression than those patients with T2 
stage cancers, indicating an association of higher VANGL2 expression with tumours 
that are smaller in size or spread into the colon.    While a decrease in VANGL2 
expression was also found when comparing T1 v T3 and T1 v T4 tumours, these were 
not to a significant extent.  No association was found with VANGL2 expression and 
lymph node spread.  It is surprising that VANGL2 is found higher in earlier stages given 
that it is associated with grade II tumours over grade I.  However, these measures are 
assessing two different phenotypes of a tumour so it is possible that high VANGL2 
expression may confer higher tumour abnormality without increasing invasiveness. 
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Many studies have supported a role for VANGL2 in epithelial development.  For 
example, VANGL2 is required for directing migration and proper alignment of mouse 
corneal epithelial cells (Findlay et al., 2016).  In other work, VANGL2 is shown to be 
essential for cardiac morphogenesis (Ramsbottom et al., 2014) .  Yates et al showed 
that VANGL2 and fellow PCP gene Celsr1 are critical for foetal lung development 
(Yates, Schnatwinkel, et al., 2010) .  However, there is also a growing field on the role 
of VANGL2 and related PCP genes in homeostasis and disease (Poobalasingam et al., 
2017; Vladar, Nayak, Milla, & Axelrod, 2016).  
 Transcriptional analysis found that VANGL2 and several other PCP genes, such 
as WNT5A, are expressed within the adult mouse intestine, including the colon 
suggesting that non-canonical Wnt signalling could play a role here.  It has previously 
been demonstrated that VANGL2 is expressed during intestinal morphogenesis, while 
WNT5A has been shown to be essential for intestinal elongation during development 
(Cervantes et al., 2009; Elena Torban et al., 2007).  My analysis shows that these 
genes and other ‘core’ PCP genes are also expressed in the healthy adult gut.  Further 
to this, VANGL2 protein is present within the adult mouse colonic epithelium, and is 
expressed in a broad manner across the crypt axis.  Moreover, VANGL2 is also 
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expressed within the cytosol and at cell-cell junctions.  This shows that VANGL2 is 
present in its typical functional location within the membrane of epithelial cells, as is 
seen during development (Ramsbottom et al., 2014; Seo, Habas, Chang, & Wang, 
2017).  We also see that WNT5A is expressed in the mouse colon, providing evidence 
of a sufficient ligand for PCP signalling, however in this study we have not directly 
demonstrated that Wnt5a is important for colonic non-canonical Wnt signalling in 
vivo.  Additionally, PTK7 is seen expressed within the mouse colon, and seen co-
localising with VANGL2 within colonic crypts at cell-cell junctions.  Interestingly, in 
the small intestine we do not see this co-localisation of VANGL2 and PTK7, suggesting 
PCP components are not organised in the same way across the gut.  The expression 
of several ‘core’ PCP components is shown transcriptionally and histologically 
indicating the presence of a ‘signalling-hub’ in the murine colon.  This suggests that 
PCP signalling in the colon is possible and therefore may be important in maintaining 
epithelial homeostasis in the epithelium. 
 For the first time, it has been shown that VANGL2 is also expressed in the 
human colon, in a similar broadly epithelial manner to the mouse.  I also show that 
the human colon expresses PTK7 and the two proteins are seen to co-localise again 
at cellular junctions within the crypts, where the intestinal and colonic stem cells 
reside.  This demonstrates that the murine colon is comparable to the human in PCP 
component expression and is a suitable model for analysing VANGL2’s role in 
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intestinal homeostasis and disease.  As well as this, proof of VANGL2’s presence 
within the human colon raises the question of its importance in human disease.  This 
is a question I address in this thesis.  Further investigation of VANGL2 and PTK7 ability 
to bind in the colon would be of interest, as PTK7 has been shown previously to bind 
another PCP component, ROR2, in vertebrate Wnt signalling (Martinez et al., 2015). 
 Deregulation of several Wnt/PCP signalling components have already been 
shown to modulate CRC development.  Overexpression of PTK7 and ROR2 both result 
in increased tumourigenesis (Lhoumeau et al., 2015; Mei et al., 2014).  WNT5A has 
evidence also linking it to increased tumourigenesis, while other data indicates 
WNT5A acts as a tumour suppressor (Bakker et al., 2013; Cheng et al., 2014).  
Although VANGL2 has been previously identified as a marker of poor prognosis in 
other cancers (such as breast cancer),  the only previous analysis looking at VANGL2 
expression in CRC has been in cell lines, where it was found overexpression led to 
decreased proliferation, colony formation and β-catenin levels (Piazzi et al., 2013; 
Puvirajesinghe et al., 2016).  This data suggests that VANGL2 may act as a tumour 
suppressor in CRC.  However, it must be acknowledged that there is only limited 
scope for extrapolation of cell line data to in vivo systems.  As such, I present 
contrasting evidence in this chapter where elevated levels of VANGL2 are associated 
with shortened time to recurrence in CRC following primary treatment, suggesting 
that VANGL2 may not act as a tumour suppressor in vivo but may act like an oncogene 
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or possibly compound the oncogenic phenotype.  No difference in overall survival 
was found between altered and unaltered patients.  Therefore, high VANGL2 tumour 
expression is associated with an increased risk of CRC recurrence without significantly 
lowering survival.  I also find that high VANGL2 tumour expression is associated with 
MAPK1 downregulation in in CRC patients.  This finding would be consistent with 
research showing VANGL2 downregulation via methylation associates with 
overactivation of the MAPK pathway (via oncogenic mutation in BRAF) (Piazzi et al., 
2013).  MAPK1 is commonly thought of as an oncogene, with research showing 
downregulation of MAPK1 can suppress cancer cell growth in colorectal and prostate 
cancer (Blaj et al., 2017; Q. guang Chen et al., 2016).  However, there is also data 
indicating MAPK signalling can confer tumour-suppressive behaviour, including in 
colorectal cancer (Deschênes-Simard et al., 2013; Gulmann et al., 2009), as such, it 
remains unclear whether MAPK1 contributes to tumour growth or repression of such 
in vivo.   
VANGL2 expression in human tumours could be linked with disease severity, 
and I found that in a cohort of CRCs there was a prominent level of VANGL2 protein 
variability between tumours, which allows histological stratification to be performed.  
No association is seen between VANGL2 protein expression and cancer and non-
cancer tissue, showing that VANGL2 levels cannot be used as a marker of cancer and 
suggesting that higher levels of VANGL2 are not sufficient for predicting CRC 
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initiation.  Evidence from VANGL2 stratification shows that VANGL2 expression is 
significantly higher in Grade II tumours over Grade I, suggesting that higher 
expression of VANGL2 is associated this step up in architectural dysregulation in 
tumours, where the cells do not look like the epithelial cells from which the tumour 
arose.  This association could be as a result of higher VANGL2 expression causing a 
propensity for tumours be grade II rather than grade I, or this effect could be a 
consequence from tumours that are grade II having a higher VANGL2 expression as a 
result.  Interestingly, we see that higher VANGL2 expression is associated with 
tumours of the smallest size and/or spread in human CRC.   
Overall, these data provide an initial characterisation of the expression of 
VANGL2 and non-canonical components in the human, and in the mouse to allow 
further investigation into the role of VANGL2 in the intestine
 
 
Chapter 4: VANGL2-mediated signalling is implicated in 
the regulation of the ECM 
4.1 Introduction 
The data discussed in chapter 3 focused on the primary characterisation of VANGL2 
expression in the mouse and human intestine, as well as in human colorectal cancer.  
This revealed that VANGL2 and other WNT/PCP components are expressed in the 
intestinal epithelium, and that a VANGL2-overexpressing subset of patients 
experience worsened disease-free survival (DFS).   
The presence of VANGL2 in the adult intestinal epithelium is in addition to its 
presence in the developing intestinal tube and other epithelial tissues (Cervantes et 
al., 2009; Iliescu et al., 2011).  VANGL2 has previously been identified as a 
requirement for normal lung architecture, while later it was implicated in 
maintenance adult lung homeostasis (Poobalasingam et al., 2017; Yates, 
Schnatwinkel, et al., 2010).  It was shown that the heterozygous Looptail mutation 
(creating mislocalised VANGL2 protein) created enlarged alveolar airspace decreased 
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lung function, possibly caused by altered distribution of actin microfilaments.  In vitro 
assays identified reduced cellular migration in VANGL2-knockdown alveolar epithelial 
cells.  Interestingly, the VANGL2-deficient lungs display markers of tissue damage in 
the form extracellular matrix remodelling components, with an altered macrophage 
population (enriched in large, highly vacuolar cells), significant increase in MMP12 
expression, and abnormal elastin (which is a MMP12 substrate) deposition.  VANGL2 
polymorphisms interact with lung function in response to insult (smoking), indicating 
that VANGL2 plays a role in wound healing in the lung epithelium.  Many of the 
studies that have defined the role of VANGL2 have been defined in development. 
VANGL2-knockdown in Xenopus, in both development and in tail regeneration in the 
adult, leads to aberrant neuronal length through loss of control of neural tissue 
proliferation.  It is suggested that VANGL2 and PCP signalling plays a role in signalling 
to terminate proliferation in neuroepithelium following tissue patterning.  (Beane, 
Tseng, Morokuma, Lemire, & Levin, 2012).  These data provide evidence that tissues 
where VANGL2 is shown to be important developmentally often are also reliant on 
VANGL2 for homeostatic mechanisms in the adult. 
It is not known how VANGL2 may be regulating homeostasis in the intestinal 
epithelium.  Piazzi et al found VANGL2 overexpression in CRC cells reduced 
proliferation concurrently with β-catenin activation (Piazzi et al., 2013).  VANGL2 has 
also been implicated in proliferative VANGL2-JNK signalling in breast cancer 
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(Puvirajesinghe et al., 2016).  Given this evidence, and given VANGL2 has been 
implicated in antagonising proliferative-driver canonical Wnt signalling, VANGL2 may 
be mediating epithelial proliferation in the intestine (Shafer et al., 2011). 
 
  




4.2.1 VANGL2-deficient colonic epithelium is histologically normal  
To assess VANGL2-signalling and its effect on the intestinal epithelium, I wanted to 
examine the adult intestine when VANGL2 is lost.  To do this I created an inducible, 
intestinal epithelial specific knockout of VANGL2.  Villin-CreERT transgenic mice have 
a tamoxifen inducible Cre recombinase downstream of the Villin1 promoter, which is 
expressed specifically in the intestinal epithelium.  VANGL2flox/flox (provided by 
Professor Deborah Henderson at Newcastle University) transgenic mice have LoxP 
recombination target sites flanking exon 4 (which includes the transmembrane 
domains) of both copies of VANGL2 (Figure 4.2.1D) (Ramsbottom et al., 2014).  Cre 
activation in cells containing VANGL2flox/flox leads to Cre-induced excision of exon 4 
and leads to a premature stop codon, giving rise to a truncated VANGL2 protein of 8 
KDa, lacking its four transmembrane domains as well as its C-terminal PDZ binding 
domain required for its interaction with other proteins including Dvl1/2/3, Prickle1/2, 
and p62-SQSTM1 (Nagaoka, Tabuchi, & Kishi, 2015; Puvirajesinghe et al., 2016; Elena 
Torban et al., 2004).  These mice were crossed to create Villin-CreERT VANGL2flox/flox 
mice.  Upon exposure to tamoxifen, Villin-expressing cells will lose both functional 
copies of VANGL2 in intestinal epithelial cells upon exposure to tamoxifen.  Likewise, 
Villin-CreERT VANGL2flox/WT mice were created and lose one functional copy of VANGL2 
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in epithelial cells upon induction.  Villin-CreERT VANGL2WT/WT mice, hereafter known as 
WT for analysis purposes, lose neither copy of the gene upon induction and VANGL2 
remains that of the wild-type (WT).  Given the well-known VANGL2Lp (S464N) mouse 
has a phenotype when a single copy of VANGL2 is mutated, Vangl2 WT mice, with 
VillinCreERT activated, will act as a control for homozygous and heterozygous 
deletion of VANGL2.  
 Initially, the recombination efficiency of our VANGL2 LOF model was assessed.  
The transgenic reporter, RosamT/mG  enables fluorescent detection of Cre activity, with 
red (tdTomato protein) fluorescence in cells which have seen no Cre expression, and 
green (GFP protein) fluorescence in cells which have seen Cre expression and 
therefore recombination activity.  Villin-CreERT RosamT/mG adult mice were induced 
with intra-peritoneal injections of tamoxifen (80 mg per kg of bodyweight) on two 
consecutive days.  On the 5th day following the first injection, animals were culled and 
the colons were prepared for cryo-sectioning.  Sections were prepared and native 
fluorescence observed under a microscope (Figure 4.2.1A).  The number of total and 
GFP+ crypts was counted in ten fields of view (10x magnification) for two different 
mouse colons.  Around 20% of crypts within the colon experienced recombination 
events.  Next, Villin-CreERT VANGL2WT/WT RosamT/mG and Villin-CreERT VANGL2Flox/Flox 
RosamT/mG  adult mice were induced and culled as performed previously.  Epithelial 
cells were isolated as described out in section 4.2.3, and cellular fluorescence was 
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analysed by flow cytometry (Figure 4.2.1B).  GFP+tdTomato-, GFP+tdTomato+, and 
GFP-tdTomato- populations were all identified (Figure 4.2.1B).  Both VANGL2WT/WT 
and VANGL2Flox/Flox genotypes had GFP+ populations of similar size, with 42.55 and 
34.6%, respectively (Figure 4.2.1C) (P = 0.4281) (n = 5).  As the proportion of 
recombined cells in the VANGL2 LOF epithelium is similar to the WT, I can assert that 
loss of VANGL2 does not alter epithelial survival in the adult colon.  As five days 
following induction is quite a short time-frame, analysis of longer-term induction of 
loss of VANGL2 may produce a higher efficiency. 
Villin-CreERT VANGL2WT/WT and Villin-CreERT VANGL2flox/flox adult mice were 
given intra-peritoneal injections of tamoxifen (80 mg per kg of bodyweight) on two 
consecutive days.  On the 5th day following the first injection, animals were culled and 
intestines harvested for subsequent analysis.  During the experiment and at the 
timepoint mice were culled, mice exhibited no altered behaviour or signs of injury 
between genotypes, and intestines and other tissues were macroscopically normal.  
Villin-CreERT VANGL2WT/WT and Villin-CreERT VANGL2flox/flox colons were fixed and 
histologically evaluated with a haematoxylin & eosin (H&E) stain (Figure 4.2.1E).  No 
differences between genotypes were observed in colonic morphology and in 
inflammatory cell infiltrates.   
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4.2.2 Loss of VANGL2 in the colonic epithelium has no effect on 
proliferation 
I then assessed the amount of proliferation within the colon of the Villin-CreERT 
VANGL2WT/WT and Villin-CreERT VANGL2flox/flox mice.  As VANGL2 has previously been 
implicated in regulating proliferation in colonic epithelial cells.  While no obvious 
epithelial thickening was present in either genotype (which would indicate epithelial 
hyperplasia or hypoplasia), a quantitative method is necessary to identify low-level 
proliferative changes or increased proliferation to maintain homeostasis (i.e. from 
decreased epithelial viability).   
Fixed colonic tissue from the genotypes VANGL2WT/WT, VANGL2Flox/WT, and 
VANGL2Flox/Flox was stained for Ki67 or Proliferating cell nuclear antigen (PCNA) (Figure 
4.2.2) to evaluate proliferation in these mutant tissues.  Ki67 is a marker only 
expressed in cycling cells (in G1, S, G2 and M phases).  PCNA is a protein required for 
DNA synthesis expressed in cells in late G1 and S phases.  While both stains routinely 
used for identifying proliferative nuclei, there is some evidence that suggests Ki67 is 
the more specific marker of cellular proliferation (Bologna-Molina, Mosqueda-Taylor, 
Molina-Frechero, Mori-Estevez, & Sánchez-Acuña, 2013).  Using computational 
analysis, the number of positively- and negatively-stained nuclei within the colonic 
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epithelium was quantified and the percentage of positive nuclei was calculated for 
each mouse colon.  I, using Definiens Tissue Studio, trained the software to identify 
haematoxylin-stained nuclei, and DAB-stained nuclei within the epithelium of 
microscopy images.  The trained parameters for nuclei identification was then 
applied to all imaged slides for analysis.  I find that there is no significant change in 
percentage of positive Ki67 or PCNA epithelial nuclei across genotypes.   
Therefore, VANGL2 loss in the colonic epithelium has no effect on 
proliferation.  Previously published work shows an observed decrease in proliferation 
when VANGL2 is knocked down in breast cancer cells (Puvirajesinghe et al., 2016).  In 
contrast, in CRC cells VANGL2 overexpression is shown to decrease proliferation 
(Piazzi et al., 2013).  In the developing lung, VANGL2Lp/Lp lungs have no alteration in 
proliferation, while the same genotype in the developing kidney displays decreased 
proliferation at E18.5 but not at E14.5 (Yates, Papakrivopoulou, et al., 2010; Yates, 
Schnatwinkel, et al., 2010). 
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4.2.3 Isolation of the colonic epithelium 
Given that I was unable to find a proliferative phenotype with regards to VANGL2-
mediated signalling, I decided to evaluate transcriptional changes in epithelial cells 
that are deficient in VANGL2.  Epithelial cells are only a small proportion of the total 
cells in the colon, therefore it was necessary to enrich tissue samples for epithelial 
cells to avoid missing subtle transcriptional changes.  Previously published protocols 
involved a lengthy and/or complicated method, or were found to be ineffective on 
the colonic epithelium (Nik & Carlsson, 2013; Wong et al., 2015).  I therefore decided 
to develop a protocol using Ethylenediaminetetraacetic acid (EDTA) to extract 
epithelial cells from a whole colon.  This is a similar technique to what is used to 
extract intestinal crypts for purposes of intestinal organoid culture (Sato et al., 2009).  
First, colons are harvested, flushed with PBS and cut into small pieces (1-2 mm).  This 
colonic tissue is incubated with 25 mM EDTA for 30 minutes and then the tissue is 
agitated with a pipette in fresh PBS, with the cells collected in the PBS constituting 
one ‘fraction’.  Four fractions are taken in total and contents combined to give 
homogenised epithelium extracted from the colon, which can be subsequently used 
for transcriptional analyses (Figure 4.2.3A).  I validated this protocol for producing 
enriched epithelial fractions by looking at intestinal epithelial and mesenchymal 
marker transcripts.  We can see that the crypt epithelial stem cell marker Lgr5 is 
highly enriched in my epithelial fractions when compared to expression from the 
   
133 
 
whole colon.  We also see moderate Krt19 (pan-epithelial marker) expression across 
epithelial fractions.  Importantly, we see almost no mesenchymal marker expression 
(αSMA) in the epithelial fractions.  These data validate this method for producing 
pure epithelial cell extracts for the purposes of transcriptional analysis. 
 Having developed a reliable method for extracting epithelial cells, I used this 
to isolate epithelial cells from the VANGL2-knockout mouse colon described 
previously, in order to validate loss of functional VANGL2 transcription (Figure 
4.2.3B).  The Villin-CreERT VANGL2WT/WT and Villin-CreERT VANGL2flox/flox mice were 
induced as previously shown and culled after 5 days.  Epithelium was extracted using 
the above method and mRNA was extracted from the pooled fractions.  cDNA 
synthesised from the transcripts were used in a qRT-PCR analysis assaying VANGL2 
expression in the colonic epithelium.  I found that VANGL2 mRNA expression was 
significantly reduced in the Villin-CreERT VANGL2flox/flox epithelium versus the WT 
controls.  While this validates that VANGL2 expression in the colonic epithelium is 
lost, the data also indicates that Cre mediated recombination of VANGL2 is not 100% 
efficient, which has previously been reported (Balzola, Bernstein, Ho, & Lees, 2010).  
Subsequently, data generated from transcriptional analysis should be analysed with 
the caveat that there will also be contaminating epithelial cells which have not lost 
VANGL2.  
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4.2.4 Transcriptome analysis of VANGL2-deficient epithelial cells 
Since previous work has indicated VANGL2 may participate in Wnt/PCP-mediated 
inhibition of canonical Wnt signalling, I analysed canonical Wnt target gene 
expression in WT and in VANGL2-deficient epithelium (Piazzi et al., 2013; Shafer et 
al., 2011).  Transcript expression of five canonical Wnt pathway target genes was 
analysed in WT and Villin VANGL2hom epithelial tissue (Figure 4.2.4): Cyclin D1 
(CCDN1), MYC Proto-Oncogene (cMYC), Lymphoid Enhancer Binding Factor 1 (LEF1), 
Axin 2 (AXIN2), and SRY-Box 9 (SOX9).  No significant changes in canonical target gene 
expression was found in the VANGL2-deficient epithelial cells.  This suggests that 
VANGL2 does not play a role in regulating canonical Wnt signalling in the healthy 
colonic epithelium.   
To identify pathways regulated by VANGL2, a transcriptomic approach was 
utilised.  Villin-CreERT VANGL2WT/WT and Villin-CreERT VANGL2flox/flox epithelial tissue was 
collected as described previously.  This tissue was then used for RNA-Sequencing.  
The datasets from each genotype were compared and genes that were upregulated 
or downregulated in the Villin-CreERT VANGL2flox/flox were identified (Table 4.2.4A) 
compared to VANGL2WT.  38 genes were found to be significantly upregulated in the 
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Villin-CreERT VANGL2flox/flox mouse, while 23 were found to be significantly 
downregulated (q < 0.05). 
In the upregulated gene list, transcript GM22973 is expressed exclusively in 
the VANGL2hom epithelium (Table 4.2.4A).  This is a predicted small nuclear RNA 
(snRNA) of unknown function.  TRPV6, is a multi-pass membrane protein that 
functions as a calcium channel, and is important for Ca2+ ion homeostasis in epithelial 
tissues.  It is also upregulated in some cancers (Al-Ansary, Bogeski, Disteldorf, 
Becherer, & Niemeyer, 2010).  Other Ca2+ signalling-related transcripts upregulated 
are ATP2B1, and CLCA4 (Agnel, Vermat, & Culouscou, 1999; Hilfiker, Strehler-Page, 
Stauffer, Carafoli, & Strehler, 1993; J.-B. Peng et al., 2000).  These could be potential 
targets or regulators of the non-canonical Wnt/Ca2+ signalling pathway.  It is possible 
that Wnt/Ca2+ activity could be upregulated in order to overcome the loss of VANGL2 
in the Wnt/PCP pathway. 
Matrix Metallopeptidase 7 (MMP7) is also upregulated.  MMPs are involved 
in the breakdown of extracellular matrix (ECM), and MMP7 is involved in wound 
healing in intestinal epithelial cells (Puthenedam et al., 2011).  There are also several 
upregulated genes that are involved in the Rho/ROCK signal transduction pathway 
(which is a known downstream target of Wnt/PCP signalling).  Rho GTPase Activating 
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Protein 5 (ARHGAP5), Rho Associated Coiled-Coil Containing Protein Kinase 1 and 2 
(ROCK1 and ROCK2) are all upregulated when VANGL2 is knocked out (Burbelo et al., 
1995; Habas, Dawid, & He, 2003; Ishizaki et al., 1996; Takahashi, Tuiki, Saya, & 
Kaibuchi, 1999). 
 Of the genes significantly downregulated in the VANGL2-deficient epithelium, 
we interestingly see a calcium activated proteinase in CAPN13 (Dear & Boehm, 2001).  
There is also a large representation of ECM proteins downregulated when VANGL2 is 
knocked out.  The type 1 collagen COL1A2, and the type 6 collagen COL6A1 were 
identified, both of which are important for tissue integrity.  Matrix-associated 
proteins Decorin (DCN), and Secreted Protein Acidic and Cysteine Rich (SPARC) have 
been implicated in regulation of tumour development.  Chymase 1 (CMA1) was also 
found, and is produced by mast cells and is thought to be involved in the degradation 
of the ECM (Feng & Tang, 2014; Groulx et al., 2011; A. He & Shi, 2012; Järvinen & 
Prince, 2015; Sampurno et al., 2015).  Two genes which are known to protect the 
intestinal epithelium from insult, Trefoil Factor 2 (TFF2), and Lysozyme 2 (LYZ2), were 
also identified as downregulated (Aamann, Vestergaard, & Grønbæk, 2014; 
Immunologists., Almaghrabi, Leger, & Caspi, 2017).  Interestingly, Growth Arrest 
Specific 1 (GAS1) is known to play a role in growth suppression by blocking entry to 
S-phase, and is a putative tumour suppressor gene is also lost in VANGL2flox/flox 
colonic epithelium versus control (Evdokiou & Cowled, 1998). 
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 To find out which cellular signalling pathways were upregulated or 
downregulated as a result of loss of VANGL2, I performed pathway analysis on the 
significantly changed gene lists identified in Table 4.2.4A.  An over-representation 
analysis (using tools from ConsensusPathDB) was performed on each of the lists, 
which maps genes on the list to a databases of pathway-based gene sets (Kamburov 
et al., 2011; Kamburov, Wierling, Lehrach, & Herwig, 2009).  A minimum of 2 matched 
genes was used for identification of a pathway and only pathways with a significant 
association were used (q < 0.05).  The top 10 significantly over-represented pathways 
from the upregulated and downregulated gene lists are shown (Table 4.2.4B).  
 Pathways identified from genes upregulated in the VANGL2 knockout (KO) 
include the Rho GTPase/ROCK pathway (ROCK1; ROCK2).  The ROCK proteins, which 
control actin polymerisation, are activated by Rho GTPases which are utilised in 
Wnt/PCP signalling.  As the deletion of VANGL2 associates with the upregulation of 
ROCK transcript expression, it may be hypothesised that VANGL2 acts to restrict the 
Rho GTPase/ROCK pathway in the colonic epithelium.  Another pathway upregulated 
which uses the ROCK proteins is the focal adhesion pathway (ARHGAP5; ROCK1; 
ROCK2) which, again, functions through actin polymerisation regulation to control 
cell-ECM adhesion and interaction.  
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Pathways identified from downregulated genes include extracellular matrix 
organisation (DCN; CAPN13; CMA1; SPARC; COL1A2; COL6A1).  The extracellular 
matrix is a network of biomolecules which provide numerous functions including 
protection against physical stress from compression, providing stiffness to tissue, as 
well as having effects on cellular migration, differentiation, and cellular programmes.  
The focal adhesion pathway also has components which are found to be 
downregulated (COL6A1; MYL7; COL1A2).  These are ECM-based components which 
are involved in this process.  Based on the changes seen in these pathways, it may be 
that VANGL2 restricts Rho GTPase/ROCK pathway signalling.  As this signalling 
controls cell-ECM interactions, these changes may explain why we see the reduction 
of expression of several ECM components, including type I Collagen (the most 
abundant in the ECM).  We also see that transcriptional targets of FRA1 and FRA2 are 
also downregulated when VANGL2 is lost (DCN; COL1A2).  FRA1 and FRA2, both 
members of the Fos gene family, are AP-1 transcription factor subunits.  FRA1 has 
been shown to be a regulator of epithelial-to-mesenchymal transition (EMT) in CRC 
cells, and is found at the invasive front in human colorectal cancers (Diesch et al., 
2014).  This suggests that FRA1/FRA2-dependent AP-1 activity is abrogated when 
VANGL2 is lost in the colonic epithelium. 
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4.2.5 Transcriptional investigation of VANGL2-mediated regulation of 
the ECM 
Given the numerous altered genes identified with the pathway in figure 4.2.4, I 
decided to investigate the role VANGL2 plays in regulating the extracellular matrix 
(ECM).  The ECM maintains tissue integrity, regulates cellular differentiation, 
proliferation, and cell migration.  It also contains a host of bound and soluble growth 
factors, such as VEGF, which can be found bound to Fibronectin; while in wound 
repair proinflammatory cytokines, such as IL-6 and IL-8, which are produced in the 
ECM by fibroblasts and macrophages (Hoch, Schraufstätter, & Cochrane, 1996; 
Wijelath et al., 2006).  Changing the ECM is a critical step of tumour progression.  
ECM-regulated signalling pathways can promote cancer cell migration and 
extravasation from the tumour, while the ECM component hyaluronan regulates 
blood vessel endothelium, a critical barrier for cancer cell metastasis.  ECM 
components can also modulate the survival of cancer cells in circulation and at 
secondary sites.   
The importance of ECM components in cancer is evidenced by studies 
showing that DCN mediates the inhibition of colorectal cancer growth in mice, while 
higher expression of SPARC has been shown to suppress colonic tumourigenesis in 
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mice and is associated with better disease-free survival (DFS) (Aoi et al., 2013; Bi et 
al., 2012; Chew et al., 2011).  MMP7, which promotes the turnover of ECM, is a 
negative prognostic marker in CRC patients and has been shown to induce epithelial-
to-mesenchymal transition (EMT) in other cancers (Klupp et al., 2016; Q. Zhang et al., 
2017). 
 Because of the evidence linking these genes to CRC, I decided to look at the 
ECM components DCN, SPARC, and MMP7.  In Figure 4.2.5A, the Log2 fold changes, 
taken from the RNA sequencing analysis, of these genes in the Villin-CreERT 
VANGL2flox/flox mouse (versus the WT) were plotted.  As described in figure 4.2.4, DCN 
and SPARC are both significantly downregulated in the VANGL2-deficient colonic 
epithelium compared to the VANGL2 wild-type.  In addition, MMP7 is significantly 
increased as opposed to the wild-type.  I conducted validation of these three genes 
using qRT-PCR on Villin-CreERT VANGL2WT/WT and   Villin-CreERT VANGL2flox/flox 
epithelium.  We can see that DCN and SPARC are downregulated, while MMP7 is 
upregulated when VANGL2 is lost (Figure 4.2.5B).  However, we do see variable 
efficiency of VANGL2 loss in the colonic epithelium, which gives variable relative 
expression in the VANGL2flox/flox genotype, potentially highlighting the differences in 
efficiency between RNAseq and PCR. 
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 Given the ECM components shown to be altered when VANGL2 is knocked 
out, I decided to assess a further 5 genes which have been shown to be important 
regulators of the ECM.  Epithelial tissue from both genotypes was assessed via qRT-
PCR for transcript expression of MMP2, MMP9, αSMA (α-smooth muscle actin), 
TIMP1 (Tissue inhibitor of Metalloproteinases 1) and TIMP3 (Figure 4.2.5C).  MMP2 
and MMP9, like MMP7, are members of the matrix metalloproteinase family of genes 
(although each member differs in its substrate) and are involved in the turnover of 
the ECM (Said, Raufman, & Xie, 2014).  αSMA is a member of the actin family of 
proteins, and is a marker of mesenchyme (relevant to EMT indication) (X. Y. Han et 
al., 2013).  TIMPs promote ECM stability by inhibition of MMP activity, and while 
TIMP3 has been shown to suppress malignant behaviour of CRC cells, increased 
TIMP1 expression is associated with progression and metastasis in human CRC, 
presenting a mixed picture of TIMPs as a prognostic marker in CRC (H. Lin et al., 2012; 
Song et al., 2016).  In the Villin-CreERT VANGL2flox/flox epithelium, MMP2 is 
downregulated by 38%.  MMP9 expression in the VANGL2-deficient cells is reduced 
by 53%, but this does not reach statistical significance.  This is likely due to the large 
variability in relative expression in the WT samples (n = 3), and a larger dataset may 
find significantly different expression.  In PCR analysis, relative expression of αSMA is 
increased by 142% by the loss of VANGL2.  TIMP1 expression is reduced by 53%, 
whereas TIMP3 expression does not change between genotypes. 
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4.2.6 Histological investigation of VANGL2-mediated regulation of the 
ECM 
Transcriptional changes in extracellular matrix (ECM) components in the colonic 
epithelium, as a result of the loss of VANGL2, does not necessarily mean that the 
composition of the ECM is changes, so I decided to assess ECM protein quantity in 
VANGL2flox mice and control.  Fixed colon from WT and Villin-CreERT VANGL2flox/flox 
was stained for the ECM components DCN, SPARC, and COL1 (type I collagen) (Figure 
4.2.6A).  Type I collagen is the most abundant collagen within the ECM and is 
therefore a good indicator of interstitial integrity of the colon.  Staining of each 
protein was quantified computationally by identifying positive areas of staining and 
stratifying staining into low, moderate, and high expression.  Protein quantity is 
calculated as a ‘quickscore’ (QS), which is a function of staining area and staining 
intensity (Figure 4.2.6B).   
 DCN is expressed highly within the colonic epithelium, while SPARC has a 
lower level of expression.  Villin-CreERT VANGL2flox/flox colons have unchanged 
expression of both these markers when compared to the WT suggesting that there is 
either a lack of concordance between transcript and protein or that the half-lives of 
these ECM proteins is very stable and therefore changes are not seen in the time 
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course examined.  In these genotypes, COL1 protein is significantly decreased in the 
Villin-CreERT VANGL2flox/flox mouse when compared to the WT (Mean QS of 8.68 and 
13.84, respectively). 
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4.2.7 Investigation of ECM-regulating pathways in the Villin-CreERT 
VANGL2flox/flox mouse 
Given the transcriptional changes in extracellular matrix (ECM) components we see 
in the loss of VANGL2 in colonic epithelial cells, as well as the decrease in type I 
collagen we see immunohistochemically, I assayed transcriptional targets of three 
different signalling pathways linked to ECM regulation.   
 It is known that Wnt/PCP signalling leads to activation of c-Jun via c-Jun N-
terminal Kinase (JNK) (Boutros, Paricio, Strutt, & Mlodzik, 1998; Yamanaka et al., 
2002).  C-Jun forms a heterodimer with c-Fos to form the AP-1 (Activator protein-1) 
transcription factor.  Research has shown that type I collagen can be regulated by the 
AP-1 transcription factor (TF) in osteoblasts, and that in cardiac ECM remodelling c-
Jun suppresses the expression of ECM proteins, including type I collagen (other 
proteins suppressed include type III collagen and Fibronectin (FN)) (Windak et al., 
2013; C. C. Wu et al., 2006). Other research shows that the AP-1 and c-Fos mediate 
MMP transcription (Bergman et al., 2003; S. Han, Ritzenthaler, Sitaraman, & Roman, 
2006).  Again, transcript analysis was performed via qRT-PCR and it was found that 
mRNA levels of cJun and Fos1 are suppressed in the Villin-CreERT VANGL2flox/flox 
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epithelium compared to the WT (Figure 4.2.7A), however the data does not meet 
statistical significance. 
The Protein kinase C (PKC) family is a key signalling target of the non-canonical 
Wnt/Ca2+ pathway (Luna-Ulloa, Hernández-Maqueda, Castañeda-Patlán, & Robles-
Flores, 2011).  In a mouse model of muscular dystrophy, it was found that ablation of 
PKCθ reduced the expression of MMP9, a known promoter of fibrosis (e.g. type I 
collagen deposition) (Madaro et al., 2012).  I found that loss of VANGL2 in the mouse 
colonic epithelium leads to a significant reduction of PKCθ expression (Figure 4.2.7B).  
As earlier I found that MMP9 and type I Collagen expression is reduced when VANGL2 
is lost, this would suggest that loss of VANGL2 leads to MMP9-mediated type I 
Collagen deposition, and that this is mediated through PKCθ.  This could be tested 
through the use of PKCθ loss-of-function constructs, as has been used in breast 
cancer both in vivo and in vitro, to evaluate collagen deposition in the VANGL2-
deficient colon (Byerly, Halstead-Nussloch, Ito, Katsyv, & Irie, 2016).  Opposing this 
theory, Paoletti et al showed that PKCθ has been shown to be crucial for maintaining 
normal cardiac ECM homeostasis, and that ablation of the gene leads to an increase 
in fibrosis, including type I collagen (Paoletti et al., 2010).  Therefore, PKCθ may have 
context-dependent roles in fibrosis. 
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One of the most important pathways regulating fibrosis and the ECM is Hippo 
signalling.  This pathway, often transduced by the effector molecules yes-associated 
protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), can 
promote fibrosis (F. Liu et al., 2015).  This is particularly interesting given VANGL2 
carries a c-terminal PDZ-binding domain.  Inhibition of YAP/TAZ signalling has been 
shown to attenuate expression of type I collagen in lung fibroblasts.  Interestingly, 
research has shown that Wnts can activate YAP/TAZ through a non-canonical Wnt 
pathway (H. W. Park et al., 2015).  I conducted qRT-PCR looking at 4 target genes of 
YAP/TAZ signalling: WNT5B, BMP4, CYR61, and IGFPB1 (Figure 4.2.7C).  I found that 




















Knockout of VANGL2 in the mouse adult intestinal epithelium did not affect the 
morphology of the tissue in an H&E stain.  This could be expected as previous 
conditional knockout studies did not find morphogenic changes in tissue but rather 
changes in cell migration/wound healing (Findlay et al., 2016).  In future studies, cell 
migration assays could be carried out in vitro with VANGL2-deficient colorectal cell 
lines.  ‘Scratch’ or ‘wound healing’ assays can be employed to quantify the cellular 
migration/wound healing ability of cells (Justus, Leffler, Ruiz-Echevarria, & Yang, 
2014). 
 It has been indicated that, in CRC cells, VANGL2 constricts proliferation in cells 
(Piazzi et al., 2013).  However, in breast cancer cells VANGL2 promotes proliferation, 
suggesting that VANGL2 supports proliferation (Puvirajesinghe et al., 2016).  I found 
that loss of VANGL2 in the colonic epithelium has no effect on proliferation.  Overall, 
it seems that VANGL2’s role in cellular proliferation acts on a context-dependent 
basis.  For example, VANGL2 function may be affected by the presence of an 
oncogene (such as oncogenic mutations in APC or K-RAS), whereby VANGL2 might 
modify proliferative ability in the context of a tumour.   




Canonical Wnt signalling target expression is not regulated by VANGL2 in 
colonic epithelial cells.  Previous work has shown that VANGL2 can act to activate 
canonical Wnt signalling, or to inhibit it (Dyberg et al., 2016; Shafer et al., 2011).  
While my data indicates that VANGL2 does not affect canonical Wnt signalling, it is 
important to note that many of these pathways are regulated at the protein level, 
and so we may not see signalling changes through transcriptional analysis.  Further 
work examining protein expression (for example, in using western blotting) of 
WNT/β-catenin signalling markers is necessary to define the canonical Wnt signalling 
landscape in our model. 
 I find several indications of perturbation of downstream Wnt/PCP signalling 
in our analysis in the VANGL2 LOF epithelium, including downregulation of AP-1 
subunit transcription.  FRA1 has been shown to be a regulator of epithelial-to-
mesenchymal transition (EMT) in CRC cells, and is found at the invasive front in 
human colorectal cancers (Diesch et al., 2014).  This suggests that FRA1/FRA2-
dependent AP-1 activity is abrogated when VANGL2 is lost in the colonic epithelium.  
This loss of activity may have a suppressive effect on EMT and would, therefore, be 
protective in CRC.  Suppression of EMT can be quantified via examining expression of 
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the epithelial marker E-Cadherin, either at the transcriptional or protein level 
(Zeisberg & Neilson, 2009).  If EMT is suppressed in our VANGL2-deficient epithelial 
cells, we would see increased levels of E-Cadherin over our WT cells. Interestingly, 
there is evidence that cell-ECM interactions can stimulate AP-1 activity, suggesting 
an AP-1-ECM signalling feedback loop (Troussard, Tan, Yoganathan, & Dedhar, 1999).  
I also show that members of the RhoA signalling family are upregulated when 
VANGL2 is lost.  Members of this pathway, including ROCK1 and ROCK2, and been 
shown to have oncogenic roles in CRC (Qiu et al., 2015; Sari et al., 2013; G. Zhang, 
Yang, & Chen, 2016).  Taken together, these data suggest that VANGL2 may be 
suppressing RhoA/ROCK signalling in the intestinal epithelium.  While previous 
evidence has shown that loss of functional VANGL2 in development disrupts RhoA 
and ROCK1 localisation during development, there is no evidence that overall 
expression is altered (Phillips et al., 2005).  VANGL2 may, in fact, act to control 
localisation of RhoA/ROCK1 expression in development and continue to do so in the 
colonic epithelium. 
My transcriptional analysis on VANGL2 LOF epithelial cells show 
downregulation of ECM components DCN and SPARC, as well as the upregulation of 
matrix remodelling protein MMP7.  Both DCN and SPARC have been implicated as a 
tumour suppressors in CRC (Chew et al., 2011; Mlakar et al., 2009).  Higher MMP7 
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expression has been shown to predict poor overall survival (OS) and disease-free 
survival (DFS) in CRC (Sun, Zhang, Qi, Zhou, & Lv, 2015). 
 Further analyses carried out found MMP2 and MMP9 to be downregulated 
when VANGL2 is lost.  These comprise the gelatinase sub-family of MMPs, and 
increased expression of these correlate with worse CRC outcome (Said et al., 2014).  
Mesenchymal marker αSMA is upregulated when VANGL2 is lost.  Increased 
expression of this marker in epithelial cells is an EMT-like phenotype (Valcz et al., 
2012).  Interestingly, inhibition of ROCK has been shown to impede EMT in the human 
cornea.  This suggests that ROCK signalling promotes EMT (Q. Wu, Ouyang, Xie, Ling, 
& Huang, 2017).  My data supports this theory, as in the Villin-CreERT VANGL2flox/flox 
mouse we see increased ROCK expression concurrent with increased expression of 
αSMA.  TIMP-1 is found to downregulated, which, despite being a known inhibitor of 
MMP9, is also associated with poorer prognosis in CRC (Jensen, Vainer, Bartels, 
Brünner, & Sørensen, 2010).  The role of ECM regulators in this context is complex 
with regards to CRC and further work is necessary.  For example, gelatin zymography 
can be utilised to quantify MMP2 and MMP9 activity (as these are gelatinase 
enzymes) (Toth, Sohail, & Fridman, 2012). 
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 In concordance with my transcriptional data, type I collagen is reduced in the 
colonic epithelium when VANGL2 is lost.  Interestingly, in a proteomic analysis type I 
Collagen was identified as being upregulated during tumourigenesis in CRC (Zou et 
al., 2013).  It was also found that a type I collagen degradative telopeptide (CTx) 
correlated with tumour staging and worsened DFS.  Therefore, VANGL2 may help 
promote tumour initiation through increasing expression of type I Collagen. 
The AP-1 transcription factor subunits and two of their targets, DCN and 
COL1A2, are upregulated by VANGL2 in the epithelium.  It has previously been shown 
that a proximal promoter region of the human DCN and COL1A2 genes are bound and 
activated by the AP-1 transcriptional complex (Chung, Agarwal, Uitto, & Mauviel, 
1996; Mauviel et al., 1996).  These data suggest that downstream Wnt/PCP signalling 
mediates ECM components through AP-1 activity, and that VANGL2 promotes this 
activity. 
 The key downstream target of Wnt/Ca2+ signalling, PKCθ, is downregulated in 
the VANGL2 LOF epithelium.  While there are no known interactions between 
VANGL2 and this non-canonical, Calcium dependant, Wnt signalling pathway, it is 
important to note that the non-canonical ligand Wnt5a can activate either Wnt/Ca2+ 
or Wnt/PCP signalling, and that as-yet-unknown cross-talk mechanisms may exist to 
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modulate each other.  Similar to the Wnt/PCP pathway, Wnt/Ca2+ signalling has also 
been shown to be essential for convergent extension during embryogenesis, as well 
as in polarised cell migration (Kinoshita, Iioka, Miyakoshi, & Ueno, 2003; Minami, 
Oishi, Endo, & Nishita, 2010), indicating again that these pathways could be 
integrated.
 
Chapter 5: VANGL2-mediated signalling enhances 
tumourigenesis and regulates the ECM in intestinal 
cancer 
5.1 Introduction 
The data discussed in chapter 4 focussed on the identification of pathways mediated 
by VANGL2 in the adult colon.  This revealed that VANGL2 potentially regulates the 
extracellular matrix (ECM), and further analysis showed that this might be because of 
downstream non-canonical Wnt signalling.  This is in addition to chapter 3 revealing 
that overexpression of VANGL2 in human colorectal cancer (CRC) results in worsened 
disease-free survival (DFS).  In this chapter I will be exploring how VANGL2 mediates 
cancer development, and examining whether these ECM alterations play a part in 
this.  
As previously discussed, VANGL2 upregulation is found in multiple human 
carcinomas (cancers of the epithelium) (Hatakeyama et al., 2014).  As well as this, 
VANGL2 promoter methylation is associated with increased tumour grade and BRAF 
mutations in CRC (both of which are associated with poorer survival) (Piazzi et al., 
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2013).  The evidence around VANGL2s role in CRC (i.e. as a tumour suppressor or as 
an oncogene) is therefore conflicting.  Interestingly, VANGL2 has previously been 
shown to have a role in ECM remodelling in cancer (Cantrell & Jessen, 2010; B. 
Blairanne Williams et al., 2012).  Here, VANGL2 loss in fibrosarcoma cancer cells leads 
to MMP14-dependent ECM invasion and directed migration.  VANGL2 knockdown 
cells show increased activation of MMP2, higher membrane localisation of MMP14 
(a membrane tethered MMP) and decrease in ECM component fibronectin, showing 
that VANGL2 acts to restrict MMP-mediated cleavage of ECM proteins in these cells.  
This suggests that VANGL2 restricts fibrosarcoma invasiveness via ECM turnover. 
Remodelling of the ECM is a well-known and necessary step in colorectal 
cancer progression.  The ECM is composed of the basement membrane (BM), which 
surrounds epithelial cells and acts as a barrier and a regulator of epithelial function; 
and the stromal matrix, which contains a multitude of molecules, which form the bulk 
of the mesenchyme in the intestine.  Found in the BM, laminins are found to be lost 
in colon cancer cells and are a transcriptional target of the tumour suppressor Smad4 
(loss of which is associated with malignancy) (Zapatka et al., 2007).  Type I collagen 
(COL1) is highly expressed at the invasive front of human CRC.  Research has shown 
that type I collagen promotes a stem-like phenotype (indicated by Bmi1 and CD133) 
in human CRC cells (Kirkland, 2009).  Fibronectins (such as FN1) are glycoproteins 
within the ECM and are important for cellular migration through fibronectin-integrin 
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interactions.  As such, colon cancer cell stimulation with fibronectin has been shown 
to increase migration and invasiveness of cancer cells, and patients with high 
expressing FN1 CRC have poorer prognosis (Ding, Li, Wang, Wang, & Wu, 2008; Yi, 
Xiao, Ding, Luo, & Yang, 2016).  Another contributor to the ECM, proteoglycans, are 
also implicated in CRC development.  Loss of syndecan-1 is associated with TNM stage 
and with metastasis (Hashimoto, Skacel, & Adams, 2008).  Decorin is another 
proteoglycan which is present in the stroma and binds to type I collagen.  It has been 
shown to inhibit CRC growth and cancer cell migration via interaction and 
stabilisation of E-cadherin (Bi et al., 2012).  In other cancers, Decorin has been linked 
to tumour development, progression, and angiogenesis (Bi et al., 2008; Davies et al., 
2001; Fiedler et al., 2008; Santra, Eichstetter, & Iozzo, 2000).  Decorin can promote 
angiogenesis in osteosarcoma through facilitating endothelial cell adhesion and 
migration on type I collagen.  This is mediated through binding to α2β1 integrin and 
promoting integrin-collagen interaction.  Integrins are cellular receptors for ECM 
molecules (such as fibronectin, laminin, and collagen) and it has been demonstrated 
that poorly differentiated cancers are characterised by high amounts of integrin-ECM 
interactions.  Furthermore, activation of integrins with collagen in CRC cells activates 
COX-2 signalling, and contributes to cell migration (Broom, Massoumi, & Sjölander, 
2006; Murillo, Rychahou, & Evers, 2004).   
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Conversely, the ECM needs to be turned over and remodelled as well as being 
deposited.  Metalloproteases (or MMPs) are the principal ECM degrading enzymes 
and therefore play a key role in ECM turnover (a crucial step in cancer growth, 
invasion, and metastasis).  MMP1, -2, -3, -7, -9, -13, and -14 (also known as MT1-
MMP) are all known to be elevated in human CRC (Said et al., 2014).  MMP2 and 
MMP9 constitute the gelatinase sub-family of MMPs.  These can be secreted by 
stroma upon induction from CRC cells, and increased levels of MMP9 is associated 
with malignancy (Mook, Frederiks, & Van Noorden, 2004).  Tissue inhibitors of 
metalloproteinases (TIMPs) are also involved in CRC development.  Surprisingly, 
increased plasma levels of TIMP-1 in CRC patients has been shown to be associated 
with worsened overall survival (OS) and time to progression (TTP) of the disease 
(Sørensen et al., 2007).  This surprising paradox between MMPs and TIMPs in CRC 
could be a result of cancer stage or cancer subtype-dependent effects of either 
protein.   
As VANGL2 has an unknown role in CRC, it could potentially regulate the ECM.  
I set out to test the hypothesis that VANGL2 is involved in mediating CRC 
development via ECM regulation. 
 




5.2.1 Long-term epithelial loss of VANGL2 is not sufficient for intestinal 
tumourigenesis 
It is unclear if loss of Vangl2 itself is oncogenic. Therefore, I carried out an experiment 
to find if loss of VANGL2 alone in the healthy epithelium is sufficient for intestinal 
tumourigenesis.  Villin-CreERT VANGL2WT/WT, Villin-CreERT VANGL2Flox/WT, and Villin-
CreERT VANGL2Flox/Flox mice (at ages between 8-12 weeks old, to allow for a fully 
developed adult intestinal tract) were induced with IP injections of tamoxifen aged 
for up to 6 months, before being culled (Figure 5.2.1A).  Over this period, survival of 
each genotype was compared to the VillinCreERT APCflox/WT cancer model.  VANGL2 flox 
genotypes had 100% survival over this period, while the cancer model resulted in only 
53% survival (Figure 5.2.1B).  This suggests that long-term mucosal loss of VANGL2 
does not affect survival.  Intestines from the cancer model and each of the VANGL2flox 
genotypes were assessed for intestinal tumour number.  APCflox/WT mice had an 
average of 45 tumours, while heterozygous and homozygous loss of VANGL2 resulted 
in no observed tumours (Figure 5.2.1C).  Intestines between Villin-CreERT 
VANGL2WT/WT, Villin-CreERT VANGL2Flox/Flox, and Villin-CreERT VANGL2Flox/Flox mice were 
compared histologically, and all were found to be similar and healthy (Figure 5.2.1D).  
This evidence shows that loss of VANGL2 alone is not sufficient for tumourigenesis. 
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5.2.2 Intestinal inactivation of VANGL2 in the VillinCreERT APCflox/WT 
mouse does not alter survival 
To investigate how VANGL2 might mediate colorectal cancer development, I decided 
to look at the loss of the gene in an intestinal tumourigenesis model.  APCflox/WT mice 
lose a functional copy (through creation of a frameshift mutation at AA580) of APC 
when recombination is induced by Cre (Colnot et al., 2004).  Compared to APCMin 
mutant, mice heterozygous for functional APC are prone to a large number of polyps 
in the small intestine, and a small amount in the colon, with  which usually results in 
early mortality due to anaemia (Johnson & Fleet, 2013).  Spontaneous loss of 
heterozygosity by mutation of the remaining APCWT allele causes tumour initiation in 
this model, which leads to constitutive WNT/β-catenin signalling and uncontrolled 
proliferation. 
By crossing APCflox/WT mice with our VANGL2 deletion model used in chapter 
4, I created the Villin-CreERT APCflox/WT VANGL2flox/flox model.  This allowed me to induce 
intestinal epithelial-specific loss-of-function (LOF) of VANGL2 to assess its effect on 
intestinal tumourigenesis in the mouse.  APCflox/WT mice had loxP sites targeted to 
each side of APC exon 14 that was lost upon induction with Cre (Figure 5.2.2A).  I 
induced VillinCreERT expression via intraperitoneal injection of tamoxifen, which led 
   
166 
 
to subsequent intestinal tumourigenesis (Figure 5.2.2B).  All three genotypes 
(VillinCreERT APCflox/WT VANGL2WT/WT or VANGL2Flox/WT or VANGL2Flox/Flox) were initially 
healthy, and experienced symptoms from intestinal tumourigenesis from around 50 
days onwards.  Symptoms (which progressed over the duration of the experiment) 
include hunching, rectal bleeding, and anaemia.  These expected symptoms were 
seen in all genotypes.  Mice were sacrifice when scored disease severity reached 
endpoint status, typified by pale feet (caused by anaemia) and hunching (up to 300 
days following induction).  Survival between genotypes was not significantly different 
(Figure 5.2.2C).  The median lifespan of VANGL2WT/WT mice was 182 days, while 
VANGL2Flox/WT was 168 days, and VANGL2Flox/Flox was 167 days (Log-rank p = 0.8723).  
Therefore, partial, or full loss of functioning VANGL2 in the intestine does not alter 
the survival rate of VillinCreERT APCflox/WT mice following intiation of CRC. 
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5.2.3 Loss of VANGL2 ameliorates tumour formation in inactivated APC-
driven intestinal tumourigenesis 
Tumours were examined microscopically and were deemed to be histologically 
similar across genotypes, in tumour differentiation and grade (Figure 5.2.3A).  Upon 
inspection by a histopathologist, tumours from both genotypes were classified as 
tubular adenomas with low grade dysplasia, with no evidence of invasion.  No 
evidence of mucosal invasion or metastasis was found with mice up to 300 days 
following induction.   
Tumour number within the small intestine and colon of each genotype was 
quantified (Figure 5.2.3B).  All visible polyps were included in counts (with small and 
large polyps being counted equally), and tumour diameter was measured in mm.  
Changes in number of tumours can indicate an alteration in tumour initiation rates.  
APCflox/WT VANGL2Flox/Flox mice developed significantly fewer colonic tumours 
compared to both the APCflox/WT VANGL2Flox/WT and the APCflox/WT (average of 9.2 
tumours versus 16.5 and 17.1, p < 0.05).  No change in number of colonic tumours 
was found between APCflox/WT and APCflox/WT VANGL2Flox/WT mice.  Number of tumours 
was also assayed within the small intestine and across the whole intestine, and no 
significant alteration in tumour number was found when VANGL2 is lost.   
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Next, I looked at colonic burden to assess total polyp growth between 
genotypes (Figure 5.2.3C).  Tumour burden was calculated as the sum of all tumour 
diameters within the colon, small intestine, or whole intestine.  Changes in this 
measure could indicate alterations in tumour initiation and/or growth.  I found that 
APCflox/WT VANGL2Flox/Flox mice developed significantly less colonic tumour burden 
compared to both the APCflox/WT VANGL2Flox/WT and the APCflox/WT (average of 21.6 cm 
versus 40.6 and 41.8, p < 0.05).  Again, no change in colonic tumour burden was found 
between APCflox/WT and APCflox/WT VANGL2Flox/WT mice, and no significant alteration of 
tumour burden was found in the small intestine or whole intestine, indicating that 
VANGL2 plays a specific role in the formation of colonic tumours.   
Finally, average tumour diameter was measured to assay tumour growth 
within each genotype (Figure 5.2.3D).  Changes in this measure would indicate 
alteration to tumour growth rates within the intestine.  I found that there was no 
alteration in average tumour diameter between genotypes in the colon, small 
intestine, or whole intestine.  Therefore, as the homozygous loss of VANGL2 results 
in an decrease in colonic tumour number, but not diameter, I can conclude that this 
is a tumour initiation phenotype and not tumour growth. 
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5.2.4 ECM component expression in VANGL2-deficient intestinal 
tumours 
As we see reduced tumour formation in the colon VANGL2 deletion, I decided to 
investigate cellular pathways which may be regulated by VANGL2 to mediate tumour 
development.  This was informed by my previous observation that in pre-malignant 
tissue VANGL2 regulates the colonic ECM. 
First, I looked at VANGL2 expression in APCflox/WT and APCflox/WT VANGL2Flox/Flox 
tumours (Figure 5.2.4A).  Tumours were isolated from the colon and qRT-PCR analysis 
performed.  As expected, VANGL2 expression is lost in the VANGL2Flox/Flox tumours.  
Relative expression was reduced to 2% of VANGL2WT/WT tumours, however this loss 
of transcript was not statistically significant due to variability in VANGL2 expression 
in murine WT epithelium.  Guided by the data found in chapter 4, I analysed ECM 
component expression within tumours from both genotypes (Figure 5.2.4B).  I found 
an upregulation in Decorin, SPARC and TIMP1 mRNA expression in VANGL2-deficient 
tumours, while MMP9 expression is unchanged in wild-type tumours compared to 
those lacking VANGL2.  Interestingly, I found in chapter 4 that each of these 
components are downregulated in VANGL2-deficient epithelium.  It may be that in 
normal epithelial conditions the loss of VANGL2 reduces ECM component deposition, 
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whereas in the highly altered state of the intestinal adenoma, cells may behave 
differently with the upregulation of the gene.  Connective tissue growth factor (CTGF, 
or CCN2), is one of the most well documented proteins involved in ECM remodelling 
and colorectal cancer.  In pancreatic cancer, upregulation has been found to correlate 
with early stages of tumour development, while upregulation has also been found to 
inhibit invasion and metastasis of CRC.  Bennewith et al found that CTGF inhibition of 
xenografted CRC cells dramatically reduced tumour growth.  This was found to be 
mediated by CTGF protection of CRC cells from hypoxia-mediated apoptosis 
(Bennewith et al., 2009).   In a report from Lin et al, patients with stage II and stage 
III CRC with high CTGF tumour expression had both better overall and disease-free 
survival than patients with low CTGF expression (Been-Ren Lin et al., 2005).  
Reduction of CTGF levels in CRC cells implanted in BALB/c mice resulted in increased 
liver metastasis.  In later work, it was revealed that lower CTGF levels in CRC patients 
was associated with higher peritoneal disease recurrence, and that CTGF decreases 
CRC cell adhesion ability in CRC cells (B.-R. Lin et al., 2011).  Loss of VANGL2 leads to 
an increase in expression levels of CTGF in tumours (Figure 5.2.4C).  CTGF is a 
transcriptional target of Hippo (or YAP/TAZ) signalling and, interestingly, studies have 
shown that deregulation of Wnt/PCP signalling results in the activation of this 
pathway (Cordenonsi et al., 2011; Gujral et al., 2014).   
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5.2.5 Immunohistological analysis of ECM-regulation by VANGL2 within 
the colonic tumour environment 
Given the upregulation of ECM transcripts observed in APCflox/WT VANGL2Flox/Flox 
tumours, I sought to look at the regulation of ECM components known to be 
important CRC histologically and determine whether these ECM proteins are 
differentially expressed in VANGL2 WT vs floxed tumours. 
Staining, using immunohistochemistry for the ECM components DCN, SPARC, 
type I Collagen (Col1), and Laminin was performed on fixed colon from APCflox/WT 
VANGL2WT/WT and APCflox/WT VANGL2Flox/Flox mice.  I computationally quantified 
expression within tumours and presented the data as a quickscore (QS) (Figure 5.2.5).  
QS is used for IHC semi-quantitation and is calculated as QS = staining intensity x 
proportion of positively-stained tissue.  While transcription of Decorin and SPARC is 
upregulated in tumours, I find that protein expression is unchanged when VANGL2 is 
lost.  However, the expression of type I collagen is significantly increased in 
VANGL2Flox/Flox tumours over VANGL2WT/WT.  This represents another contradiction 
from chapter 4’s expression analysis in in VANGL2Flox/Flox epithelial tissue, where I 
found type I collagen is significantly decreased in the healthy colonic epithelium.  
Additionally, laminin is significantly increased in VANGL2Flox/Flox tumours.  I also found 
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that CTGF expression is increased when VANGL2 is lost, which is in line with the mRNA 
expression data. 
Furthermore, I also analysed the expression of downstream Wnt/PCP target 
c-Jun and its biologically active form phospho-c-Jun (Serine 73).  It has previously 
been shown that inactivation of c-Jun reduces tumour number and size in the APCmin 
mouse model (Nateri, Spencer-Dene, & Behrens, 2005).  I found no significant change 
in c-Jun or phospho-c-Jun expression in APCflox/WT VANGL2Flox/Flox tumours. 
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5.2.6 Intestinal organoids as an ex vivo tool for investigating VANGL2-
mediated signalling 
While the in vivo studies so far present an ideal representation of the epithelial 
phenotype in functional loss of VANGL2, it comes with common issues such as the 
time taken to generate adult mice and intestinal tumours, as well as issues with the 
presence of cell types in the stroma and inflammatory processes which can confound 
data in evaluating epithelial phenotypes.  Traditionally human CRC cell lines (such as 
HCT 116 or DLD1 cells) have been used as in vitro models.  However, these cells do 
not typically reflect the cell-type of the tissue from which they were derived.  They 
have often undergone a vast number of passages resulting in adaptations to culture.  
There are also limitations in the amount of pathological data for each of the cell lines 
available.  Therefore, I decided to develop a more physiological epithelial culture 
system. 
 Epithelial organoid culture allows recapitulation of tissues into models of 
epithelial homeostasis or disease.  It was found that epithelial stem cells (within 
intestinal crypts) can undergo long-term culture when dissociated from tissue and 
placed in Matrigel (a laminin-rich basement membrane replacement (Sato et al., 
2009).  It was later found that adenoma/adenocarcinoma tissue could also be 
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cultured in this way (Sato, Stange, et al., 2011).  I decided, therefore, to utilise 
adenoma organoid culturing to investigate pathways altered by loss of VANGL2 in 
colonic adenomas. 
Intestinal organoid cultures were first prepared from healthy epithelial crypts from 
WT mice (Figure 5.2.6A).  Dissected colonic tissue was agitated for 30 minutes in 25 
mM EDTA at 4C.  Extracted crypts were plated in Matrigel with growth factors 
necessary for colonic organoid growth (EGF, Noggin, R-Spondin1, and Wnt3a).  Self-
organising intestinal crypt structures are formed within a week.  Intestinal adenoma 
organoid culture was performed by extraction of tumours from VillinCreERT APCflox/WT 
mice three months after induction with tamoxifen (Figure 5.2.6B).   Tumours were 
isolated and digested into single cells using TrypLE Express (Gibco).  Single cells are 
plated in Matrigel.  Organoids were cultured without R-spondin1 growth factor or 
Wnt ligand, required in colonic crypt organoid culture, to select for cancer cells 
(which have constitutive β-catenin stabilisation due to loss of APC, which typically 
acts to turn over b-catenin).  After a week, organoids form into large 
hyperproliferative cysts. 
Adenomas from VillinCreERT APCflox/WT VANGL2WT/WT and VillinCreERT APCflox/WT 
VANGL2flox/flox mice were collected and cultured as organoids in Matrigel (Figure 
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5.2.6C).    There was no observed difference in viability or architecture in the VANGL2-
deficient organoids.  This could be explained by the loss of APC, which results in the 
elevation of canonical Wnt signalling.  Established organoids were collected and 
consequently used in qRT-PCR analysis of gene expression.  As expected, 
VANGL2flox/flox organoids had ablated VANGL2 expression (p = 0.040) (Figure 5.2.6D).  
Expression of canonical Wnt signalling targets was analysed (Figure 5.2.6E ).  No 
significant change in mRNA expression was found in the VANGL2flox/flox organoids.  
This is as anticipated, due to the Wnt/B-catenin signalling hyperactivation from APC 
loss.  Next, I assayed targets of non-canonical Wnt signalling: SPARC, Decorin, Fos1, 
and PKCθ (Figure 5.2.6F).  No significant changes in expression were found in these 
targets, suggesting that VANGL2 may not be regulating the non-canonical pathways 
in murine adenomas.  Finally, the expression common targets of Hippo (YAP/TAZ) 
signalling, which require non-canonical Wnt activation, were quantified: comprised 
of WNT5B, BMP4, CYR61, IGFPB4, and CTGF (Figure 5.2.6G).  I found that BMP4 
expression was significantly downregulated in the VANGL2flox/flox organoids (p = 
0.033).  As with the in vitro tumour analyses, CTGF was found to be upregulated when 
VANGL2 expression is lost. 
























As previously discussed, Piazzi et al found that VANGL2 overexpression in CRC cells 
decreased proliferation and colony formation (Piazzi et al., 2013).  This data would 
suggest, therefore, that VANGL2 plays a role in restricting tumour initiation in CRC.  
In breast cancer, VANGL2 was shown to be overexpressed in tumour over non-
tumour samples.  It was also shown that in breast cancer cell xenografts that VANGL2-
overexpressing cells causes a dramatic reduction in time for tumour development, 
suggesting that VANGL2 plays a role in promoting tumour initiation.  It was found that 
this effect could be ameliorated by disrupting JNK signalling (Puvirajesinghe et al., 
2016).  Given that from TCGA data we can see VANGL2 expression is associated with 
DFS in CRC patients, it may be that JNK signalling also plays a part CRC progression.  
This is significant as it suggests that VANGL2 can function as a prognostic marker in 
breast cancer, while VANGL2-mediated JNK signalling could be a therapeutic target 
in the future.   
In chronic lymphoid leukaemia (CLL), VANGL2 is overexpressed, and it is 
shown that PCP pathway components are required for migration and cellular 
invasiveness (Kaucká et al., 2013).  As well as this, high expression of PCP genes FZD3, 
FZD7, and PRICKLE1 (but not VANGL2) is associated with worsened CLL survival.  In 
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2010, it was shown that loss of VANGL2 in cancer cells promotes ECM invasion, and 
this increased invasion was a result of directed migration, and that this cancer 
progression was MMP-dependent (Cantrell & Jessen, 2010).  In other research it was 
shown that VANGL2 regulates degradation of the ECM in human fibrosarcoma cells 
(B. Blairanne Williams et al., 2012). 
Overall, the role of VANGL2 (and PCP signalling) in tumour development 
appears highly context dependent.  Within the limited in vitro analyses on VANGL2 in 
CRC published so far, it seems that VANGL2 plays a role in tumour initiation.  This 
shows, therefore, that in vivo analyses of VANGL2 are needed for elucidating its role 
within the colorectal cancer context.  My observations suggest that VANGL2 mediates 
colonic tumour initiation. 
I created a VANGL2 loss-of-function (LOF) intestinal cancer model, and found 
that mice with partial or full VANGL2 LOF did not have altered survival when 
compared to the WT animals.  This is the first time that an inducible knockout of 
VANGL2 has been used to look at cancer development in vivo.  Previous work looking 
at survival in breast cancer found VANGL2 is associated with poorer prognosis 
(Puvirajesinghe et al., 2016). 
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The fact that VANGL2 LOF mice develop significantly less colonic tumours 
compared to WT mice suggests that VANGL2 mediates tumour initiation.  This is in 
contrast from the work by Piazzi et al, where they found VANGL2 expression inversely 
correlated with CRC cell proliferation and colony formation in vitro (Piazzi et al., 
2013).  However, in using an in vivo model of breast cancer, it has been found that 
VANGL2 acts as an activator of tumour development, in agreement with my data 
(Puvirajesinghe et al., 2016).  Cancer models can recapitulate some of the aspects 
seen during tumour growth including metastasis, invasion, and angiogenesis, which 
are typically lost when working with cell lines.  Given that loss of VANGL2 is associated 
with tumour promotion in both my cancer model and in the previously mentioned 
research in breast cancer, we can be confident that VANGL2 is worthy of investigation 
as a mediator of tumour development in other cancer models.  However, the lack of 
tumour progression to invasion or metastasis does not preclude VANGL2 from 
regulating these processes.  Using more models of CRC which recreate more 
advanced tumours, I could analyse how VANGL2 impacts the invasiveness and/or 
metastatic potential of intestinal tumours (Marsh et al., 2008). 
The restriction of colonic tumour number was not observed in the 
heterozygous LOF VANGL2 mice.  This is similar to data showing VANGL2 acts 
genetically dominant in development (E. Torban et al., 2008).  In development, both 
copies of VANGL2 must be inactivated for a phenotype to occur, and my data suggests 
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that VANGL2 displays a similar dominance in the context of colonic adenoma 
development. 
Interestingly, the VANGL2 LOF tumour initiation phenotype found in the colon 
was not seen in the small intestine.  Colon-specific tumour regulation has been found 
in APCmin mice before; it is likely that, in mice, a different set of genetic alterations 
are needed for small intestinal tumour development compared to the colon (Lefebvre 
et al., 1998; Wheeler, 2002).  The lack of a small-intestinal phenotype in this model 
could be as a result of the absence of prominent VANGL2 and PTK7 co-localisation in 
the small intestine.  This data may, therefore, signal that VANGL2 is a colon-specific 
promoter of tumour development.  Interestingly, a Wnt/PCP factor downstream of 
VANGL2 had a contrasting effect.  In another intestinal cancer mouse model, RhoA 
was inactivated within the intestinal epithelium, leading to an increase in small 
intestinal tumours but no effect on colonic tumours (Rodrigues et al., 2014).  As the 
phenotype observed here is specific to colonic tumour initiation, we could use a 
colonic-specific tumour model by inducing colitis-associated dysplasia in APC mutant 
mice by treating with dextran-sodium sulphate (DSS), or by treatment with the 
carcinogen azoxymethane (AOM) (Cooper et al., 2001; Schwitalla et al., 2013). 
   
192 
 
It may be that VANGL2 is only a promoter of tumour development in the 
colon.  It was also found that colonic tumour burden was significantly decreased in 
the APCflox/WT VANGL2Flox/Flox mice.  However, as average tumour size was found to be 
unchanged, this effect is a result of increased tumour number.  This implies that 
VANGL2 deficiency modifies adenoma initiation, but is not a modifier of adenoma 
growth.  In contrast, the aforementioned paper examining VANGL2 in breast cancer 
found that suppressed expression of VANGL2 abrogated tumour growth 
(Puvirajesinghe et al., 2016).  These data, therefore, supports the theory that VANGL2 
functions as an oncogene in colonic tumour initiation. 
As previously mentioned, the ECM component Decorin was found to have 
increased expression in VANGL2 LOF colonic tumours.  As Decorin has previously 
been shown to act as a suppressor of intestinal tumour initiation in vivo, upregulation 
of Decorin in the intestinal tumours following VANGL2 loss may be the reason I have 
observed abrogated tumour initiation in my model (Bi et al., 2008).  Fellow ECM 
protein SPARC was upregulated in VANGL2 LOF tumours, but has previously been 
shown to be pro-tumourigenic in murine intestinal cancer model (Sansom, Mansergh, 
Evans, Wilkins, & Clarke, 2007).  This is in contrast to what is expected, as we see that 
loss of VANGL2 in my intestinal tumour model reduces tumourigenesis.  I have found 
TIMP1 expression is increased in VANGL2 LOF tumours.  TIMP1 has been found to 
suppress angiogenesis in fibrosarcoma cells, suggesting that VANGL2 deficient CRC 
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may be more resistant to angiogenesis (Ardi, Kupriyanova, Deryugina, & Quigley, 
2007).  This would support data I presented earlier showing that CRC patients with 
high VANGL2 expression have faster disease recurrence (a phenotype which could be 
caused by angiogenesis).  The increases in ECM components found here contrasts 
with the expression levels found in VANGL2 LOF epithelium, where they are 
decreased.  This suggests that these ECM components may act as tumour markers of 
improved DFS, if indeed these changes are as a result of VANGL2-deficiency.  CTGF 
transcripts and protein expression are increased in tumours when VANGL2 is lost, 
and this transcriptional change is replicated in tumour organoids.  This is a strongly 
indicative finding, as it has previously reported effects in inhibiting CRC metastasis 
and high expression correlating with higher disease-free survival (Bi et al., 2008).  This 
correlates with my finding that patients with high VANGL2 expression experience 
higher disease-free survival.  It may be that the epithelial ‘niche’ in tumours with high 
VANGL2 expression may be primed for invasiveness/metastasis through reduction in 
CTGF levels.  In addition, I observe increased deposition of type I collagen, the most 
abundant interstitial protein of the ECM, in VANGL2 LOF tumours.  Accumulation of 
type I collagen is associated with a fibrotic phenotype, as Kauppila et al found in 
breast cancer that malignant breast cancer tumours display increased expression of 
type I procollagen mRNA in the fibroblastic cells of the stroma (Pathol, Stenback, 
Risteli, Jukkola, & Risteli, 1998). 
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While my analyses looking at c-Jun and phospho-c-Jun (Serine 73) found no 
significant change was found when VANGL2 is lost, suggesting VANGL2 does not 
regulate downstream JNK activity in tumour development, Wnt/PCP signalling can 
function through RhoA/ROCK signalling and has been implicated in the 
invasiveness/migratory ability of CRC cells (Bi et al., 2008). 
I have also established intestinal organoid culture as a tool for investigating 
VANGL2-mediated signalling.  This allows me to utilise the VANGL2 LOF tissue to 
assess tumour-regulating signalling pathways without the lengthy process of 
obtaining animal tissue.  This ex vivo technique will allow close to physiological CRC 
conditions.  However, limitations apply to this method as organoid cultures only 
represent the epithelial cell population of an intestine, while the basement 
membrane matrix is provided by Matrigel (Corning).  It has been shown that matrix-
organoid interactions can alter cellular behaviour, so advancements in technology to 
allow as close to physiological conditions as possible in the matrix would be welcome 
(Pastuła et al., 2016).  From assays looking at Hippo (YAP/TAZ) target gene 
transcription, I found that BMP4 and WNT5B were downregulated in VANGL2 LOF 
tumour organoids.  BMP4 has been shown to promote terminal differentiation and 
apoptosis in CRC stem cells, while also increasing chemosensitivity (Lombardo et al., 
2011).  Downregulation of tumour BMP4 expression, therefore, does not 
immediately explain why we see reduced colonic tumour initiation in the VANGL2 
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LOF intestinal cancer model.  However, the evidence for the effect of BMP4 in CRC 
development is conflicting.  BMP4 expression is seen to be highly enriched at the 
invasive fronts of human CRCs, suggesting a role played by BMP4 in invasion 
(Voorneveld et al., 2015).  As well as this, BMP4 is reported to support lung cancer 
tumourigenesis and metastasis in murein allograft models (J. S. Kim, Kurie, & Ahn, 
2015).  I also see downregulation of WNT5B, implicated in CRC migration and invasion 
through JNK signalling, in VANGL2 LOF tumours (Y. Zhang et al., 2016).  This would 
suggest that VANGL2 could be again responsible for maintaining an epithelial niche 
primed for invasiveness, giving a possible explanation why CRC patients with high 
VANGL2 expression are associated with reduced DFS.  In the future, this organoid 
culture system will allow further analysis of VANGL2-mediated signalling and binding 
partners in colonic tumourigenesis.  It would also be interesting to investigate gene 
targets upstream of the genes assessed here, such as those involved in Wnt/PCP 
signalling.   
Overall, these data indicate that VANGL2 is an important factor in colonic 
tumour development.  I found that VANGL2 in the mouse colon promotes tumour 
initiation in the APCflox/WT model.  ECM components key to CRC development were 
found to be upregulated when VANGL2 is lost, including type I Collagen, Laminin, and 
CTGF.  This suggests that VANGL2 is involved in regulating levels of these proteins in 
tumours.  Alternatively, loss of VANGL2 may result in more indirect changes to ECM 
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component stability.  VANGL2 LOF tumour organoids also showed upregulation of 
CTGF, and interestingly, downregulation of BMP4.  VANGL2 is involved in promoting 
colon tumour development and this is may be via regulation of the ECM and 
modulation of CTGF and BMP4.  This theory could be tested by analysing BMP4 
secretion and activation within WT and VANGL2-deficient tumours. 
  
 
Chapter 6: Discussion  
VANGL2 is a critical mediator of development through its role in morphogenic 
Wnt/PCP signalling.  This key regulator is important in a number of different 
functions, from its role in proper neural tube closure, to eye development (Y.-P. Lei 
et al., 2010; Leung et al., 2016).  Often, key developmental signals are utilised in adult 
tissues to maintain homeostasis.  However, when these key signals are aberrantly 
activated/repressed they can lead to the development of disease.  One of the best 
characterised morphogenesis pathways is canonical Wnt signalling, where it is 
required for maintenance of many adult tissues, and perturbations in this signalling 
cause many human diseases including cancer (Nusse, 2005).  While the canonical Wnt 
signalling pathway is a key activator of colorectal cancer (CRC), there is limited 
research around the non-canonical pathways (such as Wnt/PCP signalling) within this 
context.  While maintenance of proper polarity has been implicated in protecting 
against CRC progression (as Langlois and colleagues found with PTEN phosphatase), 
no such evidence exists for the planar cell polarity pathway (Langlois et al., 2010). 
Current literature provides little insight as to how VANGL2 functions in the 
context of the adult intestine, with the majority of recent studies examining the role 
of VANGL2 in mammalian tissue morphogenesis during embryonic development 
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(Findlay et al., 2016; L. Li et al., 2017; Obara, Suzuki, Irie, & Shibata, 2017; Yang et al., 
2017).  There are, however, some reports indicating that VANGL2 plays important 
roles in both lung and kidney podocyte homeostasis, in which it is indicated that 
VANGL2 is necessary for proper tissue growth in the adult and could be critical for 
tissue repair in human adults (Poobalasingam et al., 2017; Rocque et al., 2015). 
In this thesis, I have defined the role VANGL2 plays in intestinal homeostatic 
mechanisms and in cancer using human CRC patient transcriptomic databases, 
patient tumour samples, murine intestinal VANGL2 loss-of-function, intestinal cancer 
models, and colonic adenoma organoids.  This body of work consists of 2 major 
themes; the first investigates the role of VANGL2 in the healthy intestinal epithelium 









6.1 VANGL2 as a regulator of intestinal epithelial homeostasis 
VANGL2 plays a critical role in mammalian development through establishment of 
planar cell polarity (PCP).  It is essential for proper morphogenesis of various 
epithelial structures including the neuroepithelium, where loss-of-function (LOF) 
mutations in VANGL2 have been identified in humans with neural tube defects (NTDs) 
(Kibar, Vogan, et al., 2001; Y.-P. Lei et al., 2010; van Abeelen & Raven, 1968).  VANGL2 
is required for proper fore-stomach morphogenesis and it is also expressed in the 
intestinal tube during development (Cervantes et al., 2009; Satoh et al., 2008; Elena 
Torban et al., 2007).  Pathways essential during embryonic development of tissue are 
often key regulators of that tissue in the adult, be it regulating cellular behaviour or 
regenerative activation in response to tissue insult.  However, there has been limited 
research conducted on VANGL2 in mediating healthy adult tissue.  Poobalasingam et 
al found that heterozygous loss-of-function of VANGL2 results in impaired lung 
function, as well as markers of lung epithelial tissue damage.  An interaction between 
VANGL2 and lung function was also found in smokers.  The implication of this study 
is that VANGL2 is required for lung homeostasis (Poobalasingam et al., 2017).  
Looking at the adult corneal epithelium, Findlay et al showed that knockdown of 
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VANGL2 disrupted cellular migration in cells and in vivo through loss of planar 
alignment (Findlay et al., 2016).  These studies again suggest that VANGL2 plays a role 
in supporting tissue homeostasis in the adult. 
In examining VANGL2 in the adult mouse colonic epithelium for the first time, 
I found that VANGL2 is expressed along with Wnt/PCP ligand WNT5A.  In the 
developing limb bud, it has been shown that WNT5A can induce VANGL2 
phosphorylation of serine/threonine residues, and that this phosphorylation can 
regulate VANGL2’s PCP activity (B. Gao et al., 2011).  WNT5A has been reported to be 
essential for regeneration of colonic crypts by, paradoxically, inhibiting crypt SC 
proliferation.  This is caused by WNT5A activation of transforming growth factor-β 
(TGF- β) signalling, thereby establishing the importance of WNT5A in intestinal 
homeostasis (Miyoshi, Ajima, Luo, Yamaguchi, & Stappenbeck, 2012).  I also showed 
that VANGL2 co-localises with PTK7 within the colon.  VANGL2 and PTK7 have been 
previously shown to genetically interact in vertebrate development as well as display 
similar abnormal PCP phenotypes when either is overexpressed (Hayes et al., 2013; 
Lu et al., 2004).  Martinez et al showed that PTK7 and ROR2 physically interact to 
activate JNK and cellular migration, and that this is potentiated by WNT5A (Martinez 
et al., 2015).  The presence of this Wnt/PCP ‘signalling hub’ within the murine colon 
supports the theory that VANGL2 participates in homeostatic signalling within this 
tissue.  Furthermore, I describe for the first time that VANGL2 is also expressed within 
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the healthy human colon, and co-localises with PTK7.  PTK7 has been shown to 
promote Wnt/PCP signalling in vertebrate development (Hayes et al., 2013).  Finding 
similar component arrangement within murine and human epithelium suggests that 
Wnt/PCP signalling is comparable between species.  While murine models are 
regularly used to investigate Wnt signalling, the highly tissue-dependant effects of 
Wnt/PCP signalling may limit comparisons across species. 
 When VANGL2 is functionally lost from the murine colonic epithelium, I found 
no architectural disorganisation or alteration to proliferation.  This suggests that 
VANGL2 does not play an essential role in intestinal integrity or mucosal turnover in 
the adult.  However, VANGL2 may be required for homeostatic mechanisms not 
tested within this thesis.  For example, VANGL2 may modulate regeneration or injury 
response in the intestine.  This is similar to what is observed in lung epithelial damage 
previously mentioned and in podocytes where deletion of VANGL2 leads to an 
exacerbation of the damage response (Rocque et al., 2015).  Inducing colitis using 
DSS in my VANGL2 LOF mouse model and assessing regenerative capacity would 
allow interrogation of how VANGL2 mediates response to mucosal damage in the 
colon (Chassaing, Aitken, Malleshappa, & Vijay-Kumar, 2014).   
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 Wnt/PCP signalling is typically represented by two downstream pathways.  
The first, activation of RhoA which leads to ROCK activation, resulting in cytoskeletal 
rearrangements.  The second, activation of JNK and subsequent activation of c-Jun, 
part of the AP-1 transcription factor complex.  I demonstrate that ROCK1 and ROCK2 
are upregulated in the murine colonic epithelium when VANGL2 is lost, suggesting 
that VANGL2 may act to restrict RhoA/ROCK signalling or that downstream 
components of the pathway are over expressed to compensate for VANGL2 loss.  I 
also found that AP-1 subunits FRA1 and FRA2 are downregulated when VANGL2 is 
lost.  Further to this, I showed that AP-1 subunits c-Jun and Fos1 are also 
downregulated when VANGL2 is lost.  This suggests that VANGL2 acts to promote the 
AP-1 transcription factor complex through Wnt/PCP signalling, potentially acting as a 
point of positive autoregulation.  There may also be a signalling equilibrium where 
VANGL2 mediates Wnt/PCP/AP-1 signalling over Wnt/PCP/ROCK signalling.  
Supporting this theory, I found that AP-1 transcriptional targets Decorin and COL1A2 
are downregulated when VANGL2 is lost.  However, further work is necessary to 
evaluate RhoA activity and its downstream effects on cytoskeletal rearrangement.  
Downstream Wnt/PCP signal activation in my VANGL2 LOF model could be further 
measured by looking at activation of JNK/cJun and RhoA/ROCK signalling.  
Examination of JNK phosphorylation is one of the most well used readouts of 
Wnt/PCP signalling and has previously been used to show that JNK activation is 
reduced when VANGL2 is knocked down in breast cancer cells, while cJun 
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phosphorylation, at Serine 63 and Serine 73, has also been used as a readout for PCP 
signalling (Puvirajesinghe et al., 2016; Shafer et al., 2011).  Active-RhoA specific 
pulldowns have also been used to quantify RhoA activity in cells (for example in 
examining the PCP component RYK), however this has never been applied to look at 
VANGL2 modulation of RhoA activity (Macheda et al., 2012).  However, VANGL2 has 
been found to control the localisation of RhoA and ROCK1 in the developing 
myocardium, while phosphorylation of downstream targets of RhoA/ROCK such as 
MYPT696 has been used as an indicator of activity. MYPT696 localisation was also 
found to be under the control of VANGL2 in the developing myocardium (Phillips et 
al., 2008, 2005).   
 Another non-canonical Wnt signalling pathway is implicated in my VANGL2 
LOF model.  Wnt/Ca2+ signalling (involved in cellular behaviours such as proliferation 
and migration) controls intracellular Ca2+ levels, which can activate the Protein Kinase 
C (PKC) family of proteins.  I discovered that one these proteins, PKCθ, is 
downregulated when VANGL2 is lost in the colonic epithelium, and other Ca2+ 
signalling transcripts are also altered.  No knowledge exists on interactions between 
VANGL2 and Wnt/Ca2+ signalling, however, given the shared Wnt/Fzd interaction that 
is seen in both pathways, as well as the crosstalk that already exists between 
canonical and non-canonical signalling, it seems likely that Wnt/PCP and Wnt/Ca2+ 
signalling intersect (Grumolato et al., 2010; Hayes et al., 2013). 
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Interestingly, one of the transcription factors PKCθ is thought to activate is 
AP-1, in CD4+ T cells (Chirmule, Goonewardena, Pahwa, Pasieka, & Kalyanaraman, 
1995).  The contribution CD4+ T cells to the pathogenesis of inflammatory bowel 
diseases (IBD) is currently the focus of a large body of research, and this may provide 
insight into future intestinal damage models looking at VANGL2 (Brasseit et al., 2016; 
Eri, McGuckin, & Wadley, 2012).  Further studies should examine Wnt/Ca2+ signalling 
activation to assess VANGL2-mediated control of the pathway. 
In my VANGL2 models, I also found several extracellular matrix (ECM) 
components that are regulated by VANGL2 in the healthy colonic epithelium.  Matrix 
metalloproteinases (MMPs) are calcium-dependent endopeptidases, which are 
capable of degrading ECM proteins.  MMP2 and MMP9 are both found to be 
downregulated when VANGL2 is lost in the epithelium.  MMP2 and MMP9 comprise 
the gelatinase family of MMPs.  They are capable of degradation of both gelatin and 
type IV collagen.    Studies show that MMP9 and MMP2 are required for proper 
remodelling of the ECM at the epithelial basement membrane in the human colon (Z. 
S. Zeng, Cohen, & Guillem, 1999).  This evidence suggests that VANGL2 promotes the 
expression of the gelatinase family of MMPs in the colonic epithelium, and that this 
may act to promote remodelling in the epithelial basement membrane.  In human 
colorectal tumourigenesis, loss of key basement membrane protein type IV collagen 
is associated with increased expression of both MMP2 and MMP9 (Z. S. Zeng et al., 
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1999).  Increased expression of MMP2 and MMP9 have also been seen in patients 
with IBD, and this is also seen in a DSS mouse model of colitis (Lakatos et al., 2012; 
Sim et al., 2012; Suzuki et al., 2011).  Therefore, VANGL2 may act to predispose the 
colonic mucosa to disease through gelatinase-MMP basement membrane 
remodelling.  MMP7 is a membrane associated MMP which is known to use laminin, 
fibronectin, type IV collagen, and gelatin as substrates.  It is found to be strongly 
expressed in areas of mucosal insult (i.e. colitis).  Epithelial cells which express MMP7 
had disrupted basement membrane, shown by loss of laminin and fibronectin 
expression (Saarialho-Kere et al., 1996).  I revealed that MMP7 expression is 
upregulated in loss of VANGL2, suggesting that VANGL2 may act to inhibit MMP7 
expression in colonic epithelial homeostasis.  Tissue inhibitor matrix 
metalloproteinase 1 (TIMP1) was found to be downregulated when VANGL2 is lost.  
In nerve repair, TIMP1 has been shown to be expressed in areas of injury and protects 
type IV collagen from MMP9-mediated degradation (Fleur, 1996).  This suggests that 
VANGL2 helps protect areas of injury from ECM breakdown via promotion of TIMP1 
expression.  If VANGL2 does indeed protect areas of injury from ECM breakdown, it 
may play a key role in limiting fibrosis in chronic mucosal injury (e.g. IBD). 
The changes in ECM regulators also simultaneously result in changes in the 
structural components of the ECM, when VANGL2 is lost in the murine colonic 
epithelium, such as Proteoglycans (PGs) that fill the interstitial space beneath the 
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basement membrane.  One of these, Decorin, is found to be downregulated in the 
colonic epithelium when VANGL2 is lost.  SPARC (secreted protein acidic and rich in 
cysteine) is a glycoprotein that is also downregulated when VANGL2 is lost.  SPARC 
has previously been implicated in assisting ECM remodelling through promoting 
collagenase expression (Tremble, Lane, Sage, & Werb, 1993).  I showed that a type I 
collagen precursor, COL1A2, is downregulated when VANGL2 is lost in the epithelium.  
COL1A2 is an AP-1 transcription factor target and this reduction may be as a result of 
the downregulation of various AP-1 components seen in the VANGL2 LOF epithelium 
(Chung et al., 1996).  This reduction in type I collagen was also observed histologically 
in VANGL2-deficient epithelium, suggesting VANGL2 has an influential role to play in 
regulation of the ECM.  In future studies, more work could be completed to provide 
a full picture of the changes to the structural proteins of the ECM, as well as exploring 
MMP activity changes when VANGL2 is functionally lost.  It would also be of interest 
to look at later timepoints following gene inactivation to see if the observed changes 
in the ECM accumulate, and if these changes drive phenotypic changes in colonic 
epithelial homeostasis. 
It may be that this VANGL2-mediated ECM turnover results in more profound 
changes in epithelial tissue.  Extracellular matrix (ECM) proteins have been implicated 
in regulating epithelial-mesenchymal transition (EMT), and I found that EMT marker 
α-SMA is upregulated in VANGL2-deficient epithelial cells (Q. K. Chen, Lee, Radisky, 
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& Nelson, 2013).  As previously discussed, I revealed that ROCK1 and ROCK2 were 
upregulated in the epithelium when VANGL2 is lost.  Both proteins have previously 
been shown to promote EMT, suggesting that VANGL2 may act to restrict EMT via 
suppression of Wnt/PCP ROCK signalling (H. Peng et al., 2016; Ye et al., 2016; X. Zhang 
et al., 2016).  Coyle et al postulated that, having found that VANGL2 interacts with 
MMP14 localisation in human fibrosarcoma cells, pathways mediating ECM 
proteolysis and cell polarity converge to conduct cellular migration (and therefore, 
could also regulate EMT) (Coyle, Latimer, & Jessen, 2008).  The data here suggests 
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6.2 VANGL2 as a mediator of colorectal cancer 
Using human colorectal cancer (CRC) datasets, murine model of intestinal cancer, and 
adenoma-derived organoid culture, I have identified VANGL2 as a putative oncogene 
in CRC.  Previously, VANGL2 has been shown to influence progression of other 
cancers, such as overexpression indicating poorer prognosis in breast cancer 
(Puvirajesinghe et al., 2016).  It was also shown that VANGL2 overexpression 
increases tumour growth, but this can be restricted by inhibition of JNK signalling.  
This suggests that VANGL2 supports JNK/cJun signalling to promote tumour 
development.  In CRC cell lines, overexpression of VANGL2 has been shown to be 
associated with reduction in proliferation, colony formation, and Wnt/β-catenin 
signalling, and in humans methylation of VANGL2 is associated with pro-tumourigenic 
markers such as higher tumour grade, MSI status, and BRAF mutation (Piazzi et al., 
2013).  While this represents a discrepancy with the results presented in this thesis, 
it may be that VANGL2 has a wide range of effects on CRC progression depending on 
cancer sub-type. 
 I identified a subset of colorectal cancer patients with high VANGL2 tumour 
expression.  While these patients do not experience worsened overall survival (OS), 
they have a significantly reduced disease-free survival (DFS).  Following primary CRC 
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treatment (such as surgical resection of the adenocarcinoma), VANGL2-high patients 
experience quicker time-to-relapse than those patients without high VANGL2 
expression.  Typically, colorectal cancers with reduced time-to-relapse typically have 
higher invasiveness (as tumour spread decreases the effectiveness of surgical 
resection) and/or metastatic activity (as the cancer is no longer merely locoregional) 
(Tougeron et al., 2015).  I found that higher VANGL2 expression in patient tumours is 
associated with grade II tumours (showing poorer differentiation of tumours) over 
grade I tumours, while it is also associated with lower invasiveness (associated with 
T1 over T2).  Given the results from our cancer mouse model, it appears initially that 
VANGL2 has an effect on initiation, and investigation of VANGL2’s effects on colonic 
epithelial invasiveness and metastasis is needed.  In other cancers VANGL2 promotes 
the degradation of the ECM via MMP14 to promote invasion (B. B. Williams et al., 
2012; B. Blairanne Williams et al., 2012). 
 In concordance with what is seen in human CRC, I revealed that my murine 
intestinal cancer model had no reduction in survival when VANGL2 is lost.  With any 
loss of an oncogene it may be expected that CRC survival is improved, however it is 
important to stress that the APC-deficient murine model does not model advanced 
cancer and is limited in duration by anaemia from small intestinal bleeding.  I 
observed that loss of VANGL2 leads to a significant reduction in colonic tumours; and 
can, therefore, conclude that VANGL2 is oncogenic in the context of hyperactivated 
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Wnt signalling through APC loss.  However, loss of VANGL2 does not affect growth 
rate of tumours in this model.  The evidence found here is interesting as this is the 
first time VANGL2 has been implicated in tumour initiation, with previous research 
implicating VANGL2 in the progression of CRC  (Piazzi et al., 2013).  The regulation of 
the ECM by VANGL2 may offer answers as to how VANGL2 modifies tumour initiation.  
The ECM is involved in the modulation of CRC in early stages (i.e. tumour 
initiation/growth), as well as in progression of the disease (i.e. invasion/metastasis) 
(Pickup, Mouw, & Weaver, 2014).  VANGL2 may, therefore, act to drive changes in 
the ECM to promote tumour initiation while at the same time predispose the colonic 
ECM to invasion and cancer progression.  While my APC-deficient mouse model of 
intestinal cancer is commonly used to investigate tumourigenic mechanisms, it has 
some limitations.  Intestinal tumourigenesis is not a faithful reproduction from the 
human due to the prevalence of small intestinal tumours in the mouse, whereas in 
humans there is predominance of colorectal tumours and small intestinal cancer is 
comparatively rare (Huels et al., 2015).  Also, this model is limited to investigation of 
tumour initiation as mice succumb to anaemia before tumour progression-related 
pathology can occur; therefore, this study is limited to understanding the role of 
VANGL2 in early tumours.  As mentioned previously, examining the role of VANGL2 
in models which recreate more advanced tumour stages would help us to define how 
VANGL2 regulates the invasive or metastatic properties of CRC.  For example, loss of 
the PI3K/AKT regulator PTEN in the APC-deficient context leads to rapid development 
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of early and advanced invasive adenocarcinomas (Marsh et al., 2008).  Examination 
of the current cancer model with the addition of PTEN loss would allow me to assay 
the effects of VANGL2-deficiency in the invading intestinal adenocarcinoma. 
 Previous studies looking at VANGL2 in human fibrosarcoma cells found that 
VANGL2 restricts cellular migration and ECM invasion (via MMPs) (Cantrell & Jessen, 
2010).  This suggests that VANGL2 influences invasion, and therefore possibly 
metastasis, in cancer.  In my murine intestinal cancer model, I showed that VANGL2-
deficient colonic tumours have moderate increases in the ECM components DCN, 
SPARC, and TIMP1.  This upregulation is in contrast with normal colonic epithelium, 
where I find that the loss of VANGL2 downregulates the expression of these genes, 
suggesting that VANGL2’s ECM-related activity may be modulated by the tumour 
context.  Decorin has been shown suppress tumour initiation, growth and migration 
(Bi et al., 2008, 2012).  SPARC has also been shown to promote tumour initiation, but 
restrict enterocyte migration (Sansom et al., 2007).  While these proteins may seem 
to have contrasting roles in CRC, this by no means a complete picture of the ECM, 
and further depiction of the regulation of the ECM by VANGL2 is needed.  In 
particular, a longer-term analysis would be beneficial due the long half-lives of ECM 
proteins.  Overexpression of TIMP1 has been shown to increase proliferation, 
metastasis and restrict apoptosis in colon cancer cells (Song et al., 2016).  Given the 
current knowledge, it may be that VANGL2 promotes tumour initiation via restriction 
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of SPARC expression, while VANGL2 may restrict progression of CRC through 
promotion of Decorin expression.  Contrasting again with what is found in healthy 
epithelium, I found that type I collagen is increased in VANGL2-deficient colonic 
tumours, while another component of the ECM, laminin, is also increased.  Type I 
collagen has a positive association with the stem-ness of human CRC cells, while 
laminin expression can be lost in malignant cancer cells (Kirkland, 2009; Zapatka et 
al., 2007).  Interestingly, I found that CTGF is upregulated in VANGL2-deficient 
tumours and tumour-derived organoids.  CTGF upregulation seems to be a mediator 
of early tumour development, while also being an inhibitor of invasion and metastasis 
of CRC (Jacobson & Cunningham, 2012; B.-R. Lin et al., 2011; Been-Ren Lin et al., 
2005).  The evidence I have accumulated seems to point towards VANGL2 as a 
promoter of tumour initiation, but potentially acting as an inhibitor of malignant 
features of CRC such as invasion and metastasis.  It would be possible to determine 
if VANGL2 mediates any effects on intestinal cancer progression in vivo however for 
this we would need to develop a model of invasive cancer which invades and is 
metastatic.  A key basement membrane protein not examined in this work the 
glycoprotein Fibronectin.  Quantification of Fibronectin regulation in the VANGL2 LOF 
models used here could yield further insight into changes seen in the ECM.  By use of 
in vitro cell culture or ex vivo organoid assays, future work could focus on assays 
examining migration and the breakdown of the ECM. 
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Using colonic adenoma organoid culture, I showed that YAP/TAZ (Hippo) 
signalling targets BMP4 and WNT5B are down regulated in VANGL2-deficient 
organoids.  Studies have shown that WNT5B promotes proliferation and migration, 
as well as promoting an EMT phenotype in human lung carcinoma cells (Harada et 
al., 2017; Kato, Hayakawa, Sakurai, Saiki, & Yokoyama, 2014).  This technique could 
also be used to explore downstream Wnt/PCP signalling.  Moreover, the intestinal 
organoid culture system provides an excellent physiological representation of the 
intestinal epithelium and, in the case of colonic adenoma organoids, of colorectal 
cancer.  There are, however, limitations to the intestinal organoid model.  As this is 
an epithelial culture the cells lack their native microenvironment.  This is an issue 
concerning cellular response to ECM changes induced by VANGL2.  Interestingly, co-
culture with stromal cells has been performed in organoids and could potentially be 
used here with intestinal organoids (Mondrinos, Jones, Finck, & Lelkes, 2014).  
Another issue with organoid culture is the absence of immune cells.  This is, again, a 
particularly important problem for examining the ECM as immune cells are important 
for ECM regulation.  A final issue with organoid culture in relation to the ECM is 
problems with mimicking the in vivo biomechanical forces that are exerted upon cells 
by the ECM, which is important due to the many cellular response that are created 
from epithelial cells to their microenvironment.  However, this can be overcome by 
engineering the microenvironment with ECM factors to reproduce what is observed 
in vivo (Soen, Mori, Palmer, & Brown, 2006).  Intestinal organoid culture offers novel 
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ways of examining human CRC in culture.  For example, human colonic tumour 
resections could be cultured; both from VANGL2 high expression and VANGL2 low 
expression tumours, and downstream Wnt/PCP signalling could be assayed, as well 
as experiments defining migratory phenotypes.  One could also transplant human 
tumour organoids onto mice in order to model malignancy of human CRC with 
differential VANGL2 expression (Boj et al., 2015).  Colorectal cancer-derived organoid 
biobanks offer an exciting method to bridge the gap between cancer genetics and 
clinical trials (Van De Wetering et al., 2015).  Patient derived organoids with varying 
VANGL2 expression status could be investigated for malignant potential using the 
above methods looking at migration, invasion, and metastasis.  CRC patients within 
the VANGL2-high subclass (as identified in chapter 3) experience worsened DFS, 
could have adenoma resections cultured as organoids and compared to organoids 
derived from patients with normal VANGL2 expression.  Migration/invasiveness of 
the organoids can be analysed by measuring the protrusions of the organoids into 
the basement membrane matrix (e.g. Matrigel or collagen), while investigating 
metastatic ability of VANGL2-high and VANGL2-normal tumours via xenograft of 
patient-derived organoids into mice may explain why we see differences in disease-
free survival (X. Li et al., 2014; Nguyen-Ngoc et al., 2014; Shamir, Coutinho, Georgess, 
Auer, & Ewald, 2016). 
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6.3 Future Directions 
Given the limited amount of studies into the function of VANGL2 and indeed 
Wnt/PCP signalling within the context of the intestine, there are several areas still to 
be investigated.  Although some analysis has been carried out in this thesis studying 
downstream non-canonical Wnt signalling transcriptional targets, more direct 
quantification of these pathways, looking at Wnt/PCP mediator phosphorylation, is 
needed to define VANGL2s role within the intestinal epithelium and cancer.  We can 
examine activation the JNK pathway through analysis of the active JNK protein, 
phospho-JNK, which would allow quantification of JNK activation from western 
blotting.  Similarly, the phospho-active form of cJun (downstream target of JNK 
signalling) could be analysed in this manner.  The RhoA signalling molecule could be 
analysed for activation by utilising a method for precipitating the active form, RhoA-
GTP before western blotting for RhoA (Guilluy, Dubash, & García-Mata, 2011).  ROCK 
activity could be measured by measuring the amount of active phosphorylated form 
of myosin-binding subunit (p-MBS) over total myosin-binding subunit (t-MBS) (Hata 
et al., 2011).  RhoA can also be inhibited by Rhosin, while Y-27632 is a well-known 
inhibitor of ROCK (Ishizaki et al., 2000; Shang et al., 2012).  It would be useful to assess 
activation of both the RhoA/ROCK and the JNK/cJun pathways in both VANGL2 WT 
and LOF WNT5A-treated organoids to elucidate the role VANGL2 plays in Wnt/PCP 
signalling.  WNT5A treated organoids have been utilised before to assess its effects 
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on crypt stem cell homeostasis (Miyoshi et al., 2012).  Given the interesting results 
showing that loss of functioning VANGL2 results in changes to Wnt/Ca2+ signalling 
targets, in the future we could analyse the activity of this pathway through analysis 
of the activated form of CaMKII (calcium/calmodulin-dependent protein kinase II), p-
CaMKII (Y. Li, Ahrens, Wu, Liu, & Dudley, 2011).  CaMKII is a key downstream 
transducer of the Wnt/Ca2+ pathway and has been shown to regulate colon cancer 
proliferation and migration via ERK1/2 and p38 signalling (W. Chen et al., 2017). 
 As VANGL2 loss has been implicated here with many changes to the ECM 
which are associated with invasiveness and metastasis, future work could focus on 
one the cellular driver of these processes: migration.  VANGL2 has previously been 
shown to regulate migration in fibrosarcoma cells (Cantrell & Jessen, 2010).  
Transient knock down using shRNA targeted towards VANGL2 could be used in 
human cancer cell lines to assess the impact the gene has on migratory capacity.  
Migration can be measured by using a wound healing, or ‘scratch’ assay.  A scratch is 
created on a cell monolayer and migratory cell intrusion into the scratched area is 
observed over time, replicating cellular migration in wound healing (C.-C. Liang, Park, 
& Guan, 2007).  If these studies prove that VANGL2 may direct cancer cell migration, 
in vivo analyses could then be utilised to analyse VANGL2 as a regulator of metastasis.  
One method that could be used would be performing implantation of either (A) CRC 
cell lines (pre-treated for knockdown or overexpression of VANGL2) cells or (B) 
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VANGL2 WT or VANGL2 LOF adenomas derived from my mouse models into the 
colonic submucosa of mice (Bettenworth et al., 2016).  Tumour growth is followed by 
metastases to the liver and/or peritoneum in this model. 
Further work should be done looking at the ECM.  Fibronectin is a very 
important protein in the basement membrane (like laminin), which was not 
examined in this thesis.  It was previously found that high expression of fibronectin 
in CRC tissues positively correlated with distant metastasis and poorer prognosis in 
patients, while knockdown in cells restricted cellular proliferation, migration and 
invasion (Yi et al., 2016).  In future studies, the expression levels of fibronectin in 
VANGL2 LOF adenomas could be assayed to support the theory that key basement 
membrane proteins (including laminin) promoting metastasis are upregulated in 
VANGL2 LOF tumours.  
Diseases other than cancer are affected by ECM composition.  Therefore, if 
VANGL2 regulates ECM changes in the intestine, it may also regulate other intestinal 
diseases.  Intestinal fibrosis is a common complication of intestinal diseases such as 
inflammatory bowel disease (IBD) and colitis.  Fibrogenesis is triggered by 
inflammation and results in ECM protein production by intestinal mesenchymal cells, 
and fibrosis is the aberrant production of these proteins (Ueha, Shand, & 
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Matsushima, 2012).  One of the pro-fibrogenic signals is CTGF, which was revealed to 
be upregulated in VANGL2 deficient adenoma organoids.  Considering I also identified 
pro-fibrotic markers (CTGF and type I Collagen) my IHC quantifications, assessment 
of this factor and other ECM factors in our V2 LOF model in healthy colonic epithelium 
and colitis would help define how VANGL2 might be involved in intestinal fibrosis and 
wound repair.   
Upregulation of the markers indicative of epithelial-to-mesenchymal 
transition (EMT) was also seen in both the VANGL LOF epithelium and VANGL2 LOF 
adenoma organoids.  Loss of the cell adhesion molecule E-Cadherin loss is considered 
one of the most fundamental events of EMT (Serrano-Gomez, Maziveyi, & Alahari, 
2016).  Also, VANGL2 has been found to regulate E-Cadherin in epithelial cells through 
internalisation (Nagaoka, Inutsuka, Begum, hafiz, & Kishi, 2015).  This suggests that 
VANGL2 may act to regulate entry into the EMT developmental programme through 
control of E-Cadherin.  This could be validated by analysing if VANGL2 LOF organoids 
lose E-Cadherin expression (when compared to VANGL2 WT organoids). 






• I have localised VANGL2 and other key regulators of Wnt/PCP signalling within 
the murine colon. 
• I have identified cellular activities mediated by VANGL2 in the colon, including 
non-canonical signalling networks, and the deposition of extracellular matrix 
(ECM) proteins. 
• I have identified VANGL2 as a modulator of intestinal tumourigenesis in mice, 
and found that it also is associated with disease-free survival in human 
colorectal cancer (CRC). 
My results offer insight towards the role of VANGL2 and Wnt/PCP signalling 
within the mammalian intestinal epithelium in homeostasis and in cancer.  It is 
established that VANGL2 is an influential factor in intestinal tumourigenesis and 
human cancer progression and raises questions as to which of the mechanisms 
VANGL2 mediates regulates tumour initiation.  The interactions shown between 
VANGL2 signalling and intra- or extra-cellular changes establish an important 
framework for future study.  By investigating the mechanisms downstream of 
VANGL2 signalling (which control such changes), we will be able to reveal 
opportunities to interfere with colorectal cancer and other intestinal pathologies. 
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